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Abstract
Albumin provides the vital scaffolding for growth and tissue repair and supports oncotic
blood pressure and hemodynamics. In hemodialysis patients, albumin aids with fluid
removal by drawing excess fluid from edematous tissues back into the blood where it can
then be removed by a dialyzer. The hyperglycemia seen in dialysis patients with Type II
diabetes progressively damages kidney glomeruli, which permits albumin seepage into
the urine, thus lowering serum albumin. The conceptual framework underpinning this
research is the van’t Hoff theory of osmotic pressure. Under this framework, the solutesolvent relationship largely contributes to the osmotic movement of fluid. The purpose of
this study was to determine if albumin levels differed in Hispanics on dialysis with and
without diabetes and if potential differences existed over time. Differences in diabetes
incidence in Hispanics suggest albumin levels may be dissimilar. Albumin physiology is
abundant in the literature; how and to what magnitude albumin levels are affected in
patients with diabetes is unclear. This quantitative, retrospective cohort study employed
ANOVA, Repeated Measures t tests, Spearman Correlation, and regression analysis to
evaluate potential associations between the research variables. Data were extracted from
CMS-2728 forms to amass the final cohort (N = 827). Differences in albumin levels at
the first 2 intervals were observed (Baseline 1.29 ± 0.49 mg/dL, F = 2.28, p < .032; 3
months 0.47 ±0.41 mg/dL, F = 1.62, p < .004). Covariables (hypertension, peripheral
vascular disease, and infections) were controlled for but showed inconclusive results.
Lower serum albumin in Hispanic dialysis patients with diabetes provides the impetus for
developing ethnic-specific albumin therapies, thus promoting positive social change.
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Chapter 1: Introduction to the Study
Background
Albumin is a ubiquitous protein found in blood plasma. Its ubiquity readily
provides the body with the protein necessary for growth maintenance and tissue repair
and supports oncotic blood pressure and hemodynamics (Brin & Christensen, 2006). For
patients undergoing hemodialysis treatments, albumin found in the blood aids with fluid
removal by drawing excess fluid from edematous tissues back into the blood, where it
can then be removed by a dialyzer (Fresenius Medical Care, 2013). As a consequence of
their disease, patients with a Type II diabetes mellitus diagnosis suffer from renal
dysfunctions ranging from renal insufficiencies to chronic renal failure (CRF) due to the
kidney’s compromised ability to filter albumin. The greater the severity of the renal
disease, the greater the decreases in albumin levels found in the blood plasma and hence
the greater the degree of albuminuria (Haller, 2006; Stoian, Stoica, & Radulian, 2012).
As the most abundant plasma protein, albumin is largely responsible for colloid
osmotic pressure. From a physiological perspective, this pulls water into the circulatory
system through the capillaries, maintaining homeostatic blood pressure. A reduction of
albumin in plasma, therefore, can cause a decrease in colloid osmotic pressure and
subsequently tissue edema (Ahren & Burke, 2012). The physiological functions of
albumin, including blood pressure regulation is abundant in the literature; what are not
clear is how and to what degree albumin levels are affected in patients with a Type II
diabetes diagnosis and how these potential differences might influence blood pressure
and renal disease. It has not been ascertained how and to what magnitude albumin levels
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are affected in patients with Type II diabetes undergoing hemodialysis therapy compared
to patients with an alternative diagnosis. I aimed to pursue this research gap.
According to Chukwueke and Cordero-MacIntyre (2010), an estimated 17.5
million people in the United States were diagnosed with either Type I or Type II diabetes
in 2007. In that year, it was the leading cause of blindness in people between the ages 20
and 74 years and of end-stage renal disease (ESRD) in Hispanic Americans (Chukwueke
& Cordero-MacIntyre, 2010). The financial burden of diabetes is high and increasing
every year.
The reasons for this burden have largely been attributed to people with diabetes
having a predisposition for disease sequelae, including cardiovascular and renal disease.
It is true that, while people without diabetes may never visit the hospital in a given year,
people with diabetes are more likely to consult their doctor for regular diabetes check-ups
(Chukwueke & Cordero-MacIntyre, 2010). These statistics establish the significance of
the study and also provide the impetus and urgency to conduct the study, analyze the
results and disseminate the research outcomes. The primary objective was to narrow the
research gap by determining the relationship between albumin levels in Hispanic
hemodialysis patients with and without Type II diabetes mellitus. Although the
relationship between the dependent variable, albumin, and the independent variable, type
II diabetes mellitus is well established in the literature, potential albumin level
differences in these patients has not been studied to date.

3
Problem Statement
Decreased serum albumin levels are most notable in Hispanic American patients
with diabetes. Type II diabetes prevalence is 14% in the Hispanic population (Black,
2002). This group suffers a higher risk of mortality and microvascular complications
including renal disease. Albuminuria is often seen in Hispanic patients with diabetes and
is strongly associated when kidney disease as a comorbidity (Choi et al., 2011;
Yokoyama et al., 2011; Zakerkish et al., 2013). Albumin levels are lower in this group
since the incidence of diabetes is higher in this population. The higher occurrence of
renal failure and hence improper renal filtration lowers albumin levels markedly in
Hispanic patients on maintenance hemodialysis (Black, 2002; Lorenzo et al., 2009;
Yokoyama et al., 2011; Zakerkish et al., 2013). Consequently, the number of Hispanics
requiring hemodialysis rose by 70% between 1996 and 2001 (Lash, Vijil, Gerber, & Go,
2005), correlating with observations that this population is the fastest growing
demographic in the U.S. (Kanna, Fersobe, Soni, & Michelen, 2007).
Given these current statistics, which disproportionately affect this ethnic
population and considering the potential long-term and sometimes catastrophic sequelae
which may ensue from fluctuations in albumin levels in patients undergoing maintenance
hemodialysis, there is a need to investigate if albumin level differences exist in both
diabetic and non-diabetic patients undergoing maintenance hemodialysis and whether
disparate patterns persist through the course of their treatment, which could incur
additional risk to their maladies or even premature mortality. Although uncertain, the data
on this relationship might reveal nutritional policies for dieticians and may help inform
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clinical staff to design clinical therapeutic interventions regarding albumin
supplementation that is tailored for Hispanic patients with a Type II diabetes diagnosis on
maintenance hemodialysis.
Purpose Statement
There is a paucity of literature on differences in albumin levels of Hispanic
patients with and without Type II diabetes, undergoing maintenance hemodialysis. The
differences in diabetes incidence in the Hispanic population suggest albumin levels may
also be different in this population. I aimed to narrow this literature paucity. The
objective of this quantitative study was to examine the relationship of serum albumin
levels in Hispanic patients initiating hemodialysis treatment due to renal disease
associated with a Type II diabetes diagnosis and those without the disease after
controlling for gender, hypertension and other covariables.
A retrospective examination of the medical records of these patients was
conducted to determine if albumin levels differed in a population of adult Hispanic
hemodialysis patients with and without a Type II diabetes diagnosis. I aimed to ascertain
if albumin levels continued to follow trends observed from hemodialysis treatment onset.
Patient medical records were analyzed at baseline, 0, 3, and 6 months post baseline to
ascertain possible differences in albumin levels between those with and without Type II
diabetes. According to the Kidney Disease Outcome Quality Initiative (KDOQI)
guidelines, an acceptable albumin clinical goal for patients on hemodialysis is ≥4.0g/dL
(American Journal of Kidney Disease, 2007; National Kidney Foundation, 2002;
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National Kidney Foundation, 2013). This was the clinical standard to which collected
patient albumin values were compared to in this study.
This study entailed collecting and analyzing data on the health status and renal
measures from medical records of Hispanic dialysis patients seen at Fresenius Medical
Care-North America’s designated renal dialysis clinics in San Antonio, Texas. These
records are maintained on all patients admitted to these facilities. With appropriate
permission from Fresenius’ research department (Frenova Renal Research), and
Walden’s Institutional Review Board (Approval # 12-17-14-0298443), data were
collected from Center for Medicare and Medicaid Services (CMS)-2728 forms. These
forms have clinical data collected by nursing personnel, including anthropometric
measures, as well as renal parameters such as BUN-serum creatinine ratios, hemoglobin
A1c, lipid profiles, and serum albumin documented at the onset of treatment. Subsequent
blood draws are done weekly for Hemoglobin A1c and pre and post BUN-creatinine
ratios and potassium if deemed necessary by the nephrologist. Calcium, phosphorus, and
albumin levels are collected monthly, peritreatment. Both weekly and monthly lab tests
are documented in the patient’s medical records. The primary cause of renal failure and
ICD-9 codes for associated comorbidities are documented on the patient’s medical
records. Routine lab testing and reporting of monthly albumin levels through Spectra
Laboratories were reviewed from the patient’s treatment records.
Research Questions
Research Question 1. Is there a difference in serum albumin levels between
Hispanics with and without Type II diabetes initiating hemodialysis treatment?
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HO1: There is no difference in serum albumin levels between Hispanics with and
without Type II diabetes initiating hemodialysis treatment.
HA1: Differences in serum albumin levels are observed between Hispanics with
and without Type II diabetes initiating hemodialysis treatment, (HO is false).
Research Question 2. Is there a difference in serum albumin levels over time
(baseline, 3 months, and 6 months post baseline) between Hispanics with and
without Type II diabetes following hemodialysis treatment?
HO2: No albumin level differences are observed over time (baseline, 3 months,
and 6 months post baseline) between Hispanics with and without Type II diabetes
following hemodialysis treatment.
HA2: Albumin level differences are observed over time (baseline, 3 months, and 6
months) between Hispanics with and without Type II diabetes following hemodialysis
treatment.
Research Question 3. Is there a relationship between serum albumin, Type II
diabetes, and known predictors (e.g., hypertension, peripheral vascular disease,
and infection/inflammation) that may modulate albumin levels in Hispanic
dialysis patients?
HO3: There is no relationship between serum albumin, Type II diabetes, and
known predictors (e.g., hypertension, peripheral vascular disease, and
infection/inflammation) that may modulate albumin levels in Hispanic dialysis patients.
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HA3: There is a relationship between serum albumin, Type II diabetes and known
predictors (e.g., hypertension, peripheral vascular disease, and infection/inflammation)
that may modulate albumin levels in Hispanic dialysis patients.
Conceptual Framework
This research study was framed by long-standing physiological concepts that
inform and guide this inquiry. The osmosis phenomenon and the van’t Hoff theory of
osmotic pressure provide the pillars that ground and support this study. Osmosis is the
flow of a solvent through a semi-permeable membrane that separates two volumes of
liquid and disallows the passage of solute particles (Lachish, 1999; Marieb & Hoehn,
2007; Villani, Dunlop, & Damitz, 2007). The solvent flows from the volume of higher
solvent concentration to the volume of lower solvent concentration. Correspondingly,
when solute particles are present only in one volume, the osmotic pressure is the pressure
on the solution that ceases the solvent flow (Lachish, 1999). The formula for osmotic
pressure was derived by van't Hoff. The van’t Hoff theory of osmotic pressure posits that
π is proportional to the molar concentration (c), the absolute temperature of the system
(˚K), and the gas constant (R). The van’t Hoff formula π = c R T is derived by the
comparison of the pressure of an ideal gas of the same concentration and temperature.
The molar concentration of solute particles c is proportional to the gas constant R (0.0821
L *ATM/mole*K), and the absolute temperature T in degrees Kelvin (Lachish, 2007).
This study is grounded by these two concepts; both the osmotic pressure
phenomenon and the van’t Hoff theory of osmotic pressure have a direct correlation to
this study in that albumin is the circulating solute in blood plasma. As the osmotic
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pressure theory posits, the protein is unable to cross the semipermeable plasma
membrane of cells; but, the solvent or fluid can cross freely. This osmotic movement of
fluids draws fluid from the plasma into the capillaries to maintain homeostatic blood
pressure. These physiological concepts are well understood and described in the literature
and applicable to this study.
Dialyzing patients can therefore be approached through the lens of these two
axiomatic physiological concepts. The osmosis phenomenon and the van’t Hoff theory of
osmotic pressure are exploited in patients undergoing maintenance hemodialysis, which
by the nature of their renal disease are unable to remove excess fluid from their bodies.
Specifically, in hemodialysis patients the excess fluid in edematous tissues, collected
during the interdialytic period, is drawn into the capillaries by osmosis and then filtered
through a dialyzer using a prepared dialysate solution that can readily remove excess
fluids from the patient (Fresenius Medical Care, 2013). To remove the excess fluids, an
extracorporeal dialyzer is used, utilizing a dialysate solution that flows in a
countercurrent direction of blood flow. This flow allows for the exchange between
important electrolytes found in the dialysate and toxins that accumulate in the blood. The
prescription of a certain dialysate composition is modified in order to obtain not only
adequate blood purification but also optimal treatment tolerability (Fresenius Medical
Care, 2013).
In hemodialysis patients, dialysate composition can be tailored in terms of the
sodium, potassium, calcium and bicarbonate content; these represent the solutes (ions) in
the dialysate that are essential for electrolyte balances in the body. Sodium balance
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represents the cornerstone of cardiovascular stability and blood pressure control
(Fresenius Medical Care, 2013). The vasoactivity of potassium increases blood flow
when it is infused into the arterial supply of a vascular bed. Potassium levels can be
manipulated by supplementation or during hemodialysis treatments, which can assist in
regulating blood pressure (Haddy, Vanhoutte, & Feletou, 2006). Calcium is used to
maintain bone density. Because patients on hemodialysis have dysfunctional kidneys,
they are unable to convert vitamin D into the hormone Calcitrol. This hormone facilitates
calcium absorption from the intestines into the blood. Consequently, low blood calcium
levels cause calcium to be pulled from bone tissue, leading to a plethora of
osteodystrophies (Davita, 2013). Lastly, bicarbonate in dialysate is personalized in order
to avoid acidosis and post-dialysis alkalosis (Vigano, DiFilippo, Manzoni, & Locatelli,
2008).
The primary goal of hemodialysis for patients with chronic renal failure is to
restore the composition of the body’s hemodynamic environment. This is accomplished
principally by formulating a dialysate whose constituent concentrations are set to
approximate homeostatic values in the body (Fresenius Medical Care, 2013). Over time,
by diffusional transfer and by obeying fundamental physiological osmotic principles, the
concentrations of solutes that were initially increased or decreased are effectively
corrected (Fresenius Medical Care, 2013). When an abnormal electrolyte concentration
poses immediate adverse hemodynamic effects, the dialysate concentration of that
electrolyte can be set at a nonhomeostatic level to achieve a more rapid electrolyte
hemodynamic correction (Fresenius Medical Care, 2013). For chronic renal disease
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patients, the composition of the dialysate can be individually adjusted in order to satisfy
the specific electrolyte balances of each patient (Fresenius Medical Care, 2013). This
electrolyte-blood toxin exchange between the prescribed dialysate and the bloodstream
aligns with the principles of osmosis, osmotic pressure, and membrane permeability.
The intricate hemodialysis process discussed in this study is grounded by
fundamental physiological principles. Both the osmotic pressure phenomenon and the
van’t Hoff theory of osmotic pressure provide a suitable conceptual framework for this
inquiry. These concepts provide a reasonable explanation for why patients with a Type II
diabetes diagnosis, receiving hemodialysis treatments show aberrant levels of albumin in
their blood. The theories reflect the filtering capacity of the kidneys. In patients with a
diabetes Type II diagnosis, undergoing hemodialysis because of renal disease, this
filtering capacity has been compromised, therefore disobeying fundamental osmotic
pressure principles.
Nature of the Study
The research design for this quantitative investigation was retrospective in nature.
After receiving permission from Frenova Renal Research, the research department of
Fresenius Medical Care - North America (FMC-NA), CMS-2728 forms and medical
records of patients that underwent hemodialysis at designated clinics in San Antonio,
Texas were examined. Patients admitted to these facilities have their blood drawn and
serum albumin levels are documented on CMS-2728 forms. The records of Hispanic
patients receiving hemodialysis treatments with and without a type II diabetes diagnosis
on maintenance hemodialysis were examined at treatment onset, baseline (CMS), 0, 3,
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and 6 months post onset. Since this was a retrospective analysis of data, a complete case
analysis was conducted. A listwise deletion of patients that did not meet inclusion criteria
was conducted. These criteria included hemodialysis patients with and without a type II
diabetes diagnosis that remained in the dialysis facilities for at least six months and who
had full hematology profiles documented on CMS-2728 forms and treatment records for
that time period. Those patients who moved away, received a transplant, changed dialysis
modalities, made the decision to discontinue treatment, passed away, or transferred
before the six-month period were excluded from the study.
To ensure statistical power, G*Power 3 software was used to determine an
appropriate sample size. SPSS analysis software was used to collect and then quantify
albumin levels in this sample population to ascertain possible albumin trends and to
identify if hemodialysis patients with a Type II diabetes diagnosis evidenced differences
in albumin levels and hence decreased renal function compared to hemodialysis patients
with a different etiologic diagnosis. Studies confirm that 3 and 6 month checks are
appropriate intervals to monitor albumin levels (Black, 2002; In Control, 2007).
Researchers who have collected data at 3 months, after regular hemodialysis treatments
and albumin supplementation have shown significant increases in serum albumin levels
from an average of 2.9± 0.4 mg/dL to 3.45 ± 0.4 mg/dL (Dalrymple et al., 2013; In
Control, 2007). Higher albumin levels were maintained during this period and persisted 3
months after hemodialysis treatments and albumin supplementation. Studies showing
albumin differences or improvement patterns in Hispanic, hemodialysis patients with a
Type II diabetes diagnosis are nonexistent.
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I aimed to identify improvement trends from hemodialysis patient schedules, from
treatment onset to 6 months into the patients’ treatment. The independent variable is Type
II diabetes in hemodialysis patients, and the dependent variable is albumin levels in blood
plasma in these patients. The null hypothesis is that no differences in albumin levels will
be observed between the diabetic and nondiabetic groups and no apparent albumin level
trends will be noted from treatment onset and at 3 and 6 months into the course of their
treatments in both groups. Chapter 3 will present a more expansive description of the
study design.
Definitions
Type II diabetes mellitus: A metabolic disorder that is characterized by
hyperglycemia in the context of insulin resistance and relative lack of insulin (Mahler &
Adler, 1999).
Albumin: A simple and ubiquitous form of protein that is soluble in water and
coagulable by heat, such as that found in egg white, milk, and blood serum (Alpern et al.,
2013; Rozga et al., 2013).
Ultrafiltration: The process by which a pressure gradient is utilized to force fluid
through a membrane (Fresenius Medical Care, 2013).
Hemodialysis: The clinical process used to achieve the extracorporeal removal of
uremic wastes such as creatinine and urea and to remove fluid from the blood when the
kidneys are in renal failure status (Davita, 2014; Fresenius Medical Care, 2013).
Dialyzer: A 30 centimeter long plastic device through which blood flows through
a cluster of 20,000 extremely fine fibers used in hemodialysis that acts as an artificial
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kidney and replaces vital functions of the natural organ (Davita, 2014; Fresenius Medical
Care, 2013).
Dialysate: A chemical bath utilized in hemodialysis to draw fluids and toxins out
of the bloodstream and supply electrolytes and other chemicals to the bloodstream
(Davita, 2014; Fresenius Medical Care, 2013).
Countercurrent flow (exchange): The mechanism occurring in nature and
mimicked in industry and engineering, in which there is a crossover of some property,
usually heat or some component, between two flowing bodies flowing in opposite
directions to each other. The flowing bodies can be liquids, gases, or even solid powders,
or any combination of those. In hemodialysis counter current flow is used where the
dialysate is flowing in the opposite direction to blood flow in the extracorporeal circuit or
dialyzer. Counter-current flow maintains the concentration gradient across the membrane
at a maximum and increases the efficiency of the dialysis (Davita, 2014; Fresenius
Medical Care, 2013).
Selectively Permeable: The term used to describe a membrane that will allow
certain molecules or ions to pass through it by diffusion (Marieb & Hoehn, 2007).
Interdialytic Period: The period between dialysis treatments, typically 1 or 2
days, during which fluid and uremic waste products accumulate; this fluid is removed by
hemodialysis.
Assumptions
There exist some factors that can potentially influence a research study.
Assumptions, for example, can be made for this study for which there is no hard data
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available, a researcher might not ever satisfactorily know, and for which there is no intent
to or feasibly not be able to control. The first assumption made is that the cohort of
patients selected for this study was correctly diagnosed with Type II diabetes according
to ICD-9 codes 25040 and 25000A by clinic nephrologists. The diagnosis assignment is
assumed to be accurate and distinguishable from Type I diabetes, as this disease is not
reviewed in this study. A second assumption made is that the data documented in the
patient records with respect to anthropometric measurements, hematology profiles,
associated comorbidities, dialysis treatment dose and modality, and dialysate prescription
were correct and accurately recorded by clinical staff. It was also assumed that patients
correctly self-identified themselves of Hispanic ethnicity.
Scope and Delimitations
This study was focused on determining whether albumin differences exist in
Hispanic patients on maintenance hemodialysis with and without a type II diabetes
diagnosis. Studies in the literature present information on albumin levels in different
populations with other chronic diseases such as Type I diabetes or coronary artery
disease. The studies also presented several study design models, including observational,
prospective, and retrospective studies as well as case control designs. However, albumin
level differences in a Hispanic population, undergoing maintenance hemodialysis have
not been studied using a retrospective model.
Since medical records were examined, this study undertook a retrospective
approach. Compared to a prospective model, a retrospective analysis of medical records
provides readily available data, shortening the time for data collection and analysis. The
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selected study population may not be generalizable to other ethnic populations; however,
future research studies can expand on the population to include other ethnicities.
Limitations
As this is a records-based study, a significant limitation lies in the quality of
clinical records by the dialysis facilities and the degree of thoroughness with which
information was collected. Missing data on CMS-2728 forms due to hospitalization,
patient transfers, noncompliance, treatment absenteeism, transplantation, allograft
rejection, or death may have potentially limited data collection and analysis. In such
instances, patients were excluded from the study population sample.
Generalizability to other ethnic populations may have also limited this study. The
study population was Hispanics undergoing maintenance hemodialysis with and without
a Type II diabetes diagnosis exclusively, and therefore may not be generalizable to other
ethnic populations. The study population is restricted to patients attending weekly
dialysis treatments at local dialysis clinics, and so excludes patients undergoing home
hemodialysis, in-patient hospital hemodialysis, or those electing a dialysis modality not
available at these clinics such as peritoneal dialysis.
Other important considerations that may have limited this study include patient
phobias and demographics. Patients that for lack of insurance or that simply refuse
dialysis treatment either because of disease denial or because of physician, needle, or
blood phobias may not be included in the sample population. The population sample may
be capturing only those that are sick that are actually attending the dialysis clinics and
excluding those that are sick and not receiving necessary treatments. The clinics from
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which the data were collected may represent a demographic limitation in that the
community in which the clinic is located may have a higher or lower Hispanic
representation than do other similar clinics in other regions of the city.
Although challenging, there are some measures that can be employed to
reasonably overcome potential limitations. Secondary data, although readily available,
should be reviewed to ensure instrumentation and data collection and documentation was
thorough, consistent, and streamlined by trained professionals. Future studies conducted
using other ethnic populations, encompassing a broader population of patients in homehealth and in-patient hemodialysis venues may help control the generalizability. Selecting
clinics with similar demographics may help streamline the sample population. Although
limitations confer shortcomings, conditions, or influences that can be challenging to
control, measures can be taken to minimize them to avoid methodological and study
conclusion aberrations.
Significance
The scarcity of studies and dearth of information about albumin levels in this
population opens the opportunity to make a contribution to positive social change.
Because of the high incidence of Type II diabetes in the Hispanic population and
considering the demographics in south central Texas, the population in this region suffers
a disproportionate burden of Type II diabetes mellitus. Examinations and comparisons of
albumin levels in Hispanic patients with and without a Type II diabetes diagnosis in this
region may reveal information about specific albumin trends that may exist in one group
and not the other. These examinations may help reveal possible albumin improvement
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trends that can inform healthcare professionals about ethnic-specific nutritional
supplementation or therapeutic interventions. With these supplementations and/or
interventions, healthcare professionals can enhance albumin levels to achieve dialysis
goals and improve overall health.
Some studies in the literature, where albumin levels have shown a significant
increase with hemodialysis and albumin supplementation (In Control, 2002), provide a
good basis for further investigating albumin levels in hemodialysis patients with and
without a Type II diabetes diagnosis. Since there is a reasonable expectation that higher
albumin levels should improve health in patients with Type II diabetes, the outcome of
this study may elucidate specific trends that would inform and direct disease-specific
efforts to increase albumin levels in this group. Not only does the identification of
potentially modifiable factors associated with albumin levels have the potential for
translational therapeutic implications, the outcomes from this study can be useful for
clinical risk stratification. This study confers a clear contribution to positive social
change.
This research study provides the positive social change necessary in terms of
improving public health by identifying disease-specific albumin trends that could
influence the course of diseases such as diabetes and renal disease so that ethnic-specific
and disease-specific care can be developed for these patients. Should the albumin levels
show any disparate patterns in this study population, hemodialysis patients with Type II
diabetes may benefit from this research by its potential to inform and empower dialysis
clinical care professionals to devote concerted efforts towards raising albumin levels in
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these patients, which would help maximize their muscle mass, grip strength, and leg
power (Snyder et al., 2012), thus improving the quality of life of patients afflicted with
Type II diabetes and renal disease. The study’s research findings can contribute to the
scarce body of literature and help address diabetes health and renal disease to potentially
improve diabetic and renal health outcomes in this population. The social change
implications from this project are impactful, beneficial, definitive and long-term.
Summary
This chapter includes the salient features of this proposed study. Hemodialysis
patients endure a rigorous treatment regimen to remove toxins from their blood and
excess fluid that accumulates due to a decrease in the filtering capacity of the kidney
(Fresenius Medical Care, 2013; Yokoyama et al., 2011). The gravity of this kidney
filtration insufficiency may result in significant morbidity and mortality. The literature
provides a robust association between albumin levels and chronic kidney disease. It is
well established in the literature that patients with lower albumin clinical values
correlates with poorer clinical prognoses, most notably in patients with a Type II diabetes
diagnosis. There is evidence that increased albumin levels improves hemodialysis clinical
outcomes and mediates overall patient health status.
Chapter 2 includes an exploration of the current literature relevant to the
dependent and independent variables of this proposed study. The chapter includes an
expansive discussion on the osmosis and osmotic pressure theory, seminal literature,
membrane filtration and permeability, the hemodialysis process, patient fluid overload,
the epidemiology, pathophysiology, and endocrinology axis of Type II diabetes, and the
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salient relationships between the dependent and independent variables. Chapter 2
includes an introduction to potential confounders and limitations for this study that may
influence the study outcomes. Finally, a review of the literature relevant to the
epidemiological studies, which were employed to conduct this observational research,
will be presented.
Chapter 3 will detail the rationale and construct of the study design. A discussion
of the construct for the retrospective analysis of medical records for a population of
Hispanic patients on maintenance hemodialysis with and without a Type II diabetes
diagnosis will be presented. Chapter 3 will provide an explanation of the sample size,
inclusion and exclusion criteria, and rationale for these criteria. An elaboration on
confounding variables involved and the methods employed to control for them during the
analysis phase will be presented. The data collection strategy, and the statistical methods
used in the analysis will be described. The results of this study as well as an elaborative
discussion, interpretation, and recommendations for dissemination and future research
will be detailed in Chapters 4 and 5.
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Chapter 2: Literature Review
Albumin level differences in maintenance hemodialysis patients are
fundamentally based on long-standing physiological theories and concepts. The
differences in diabetes incidence in the Hispanic population suggest serum albumin levels
may also be different in this population (Black, 2002; McBean et al., 2005). The literature
supports associations between albumin and kidney disease. However, the literature is
scarce on associations between albumin and a Type II diabetes diagnosis and whether
albumin level differences exist among this hemodialysis population. This literature
review will present the salient facts, theories, and physiological constructs that proffer
support for the hypothesis that differences in albumin levels may exist in a population of
Hispanic, dialysis patients. Specifically, the relationship between serum albumin levels in
Hispanic patients receiving maintenance hemodialysis due to renal disease associated
with a Type II diabetes mellitus diagnosis and those without the disease were examined
My primary objective was to fill this literature gap.
This literature review begins with a review of the physiological constructs,
formulae, and theories guiding this study. This section includes a didactical narrative
about physiological concepts, pioneering research, and historical figures and perspectives
that provide the foundation for this inquiry. In the next section, the study’s dependent
variable will be introduced, reviewing current literature on what is known about the
protein albumin found in blood plasma. This will include a summation of what is
understood about albumin, its current associations, and physiological characteristics that
provide the framework for the course and direction of this inquiry. The presentation of
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the dependent variable will include a biological description, chemical characterization,
and physiological albumin review, including its major functions, importance, and utility
in the human body. Given known normoalbuminemic levels, the epidemiology and
pathophysiology of albumin will be reviewed and its relationship to kidney filtration and
colloid osmotic blood pressure. Specifically, this relationship will be examined in
patients undergoing maintenance hemodialysis. The third section is an examination of the
independent variable, Type II diabetes mellitus. I reviewed the epidemiology,
pathophysiology, endocrinology axis, and its relationship to the study’s dependent
variable through the presentation of current research in the literature. The presentation of
the independent variable will provide the rationale for possible differences in albumin
levels in Hispanic patients receiving hemodialysis with a Type II diabetes diagnosis and
those without one.
Literature Search Strategy
To conduct the literature search, I employed a series of key words, word
combinations, and phrases related to this discipline. These included: albumin,
albuminuria, serumalbumin, albumin physiology, hypoalbuminemia, albumin
pathophysiology, albumin epidemiology, biology and chemistry of albumin, van’t Hoff
and osmotic pressure theory, Type II diabetes mellitus, Type II diabetes and
hemodialysis, Type II diabetes in Hispanics, Type II diabetes in Hispanic hemodialysis
patients, hemodialysis process, albumin in hemodialysis patients, albumin in
hemodialysis diabetic patients, renal failure, hemodialysis fluid overload, renal disease,
chronic kidney disease, diabetic nephropathy, hemodialysis patients with diabetes,
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epidemiology of Type II diabetes, Hispanic culture and traditions, Hispanic religion,
Hispanic behaviors, and epidemiology of Type II diabetes in Hispanics. These key words
and word combinations were used to maximize response hits. I searched and obtained
information from peer-reviewed journal articles from several institutions, including the
Walden University Library, the John Peace Library at The University of Texas at San
Antonio, the Driscoe Library at The University of Texas Health Science Center at San
Antonio and the Jones Medical Library at Baylor College of Medicine in Houston, Texas.
I performed searches for pertinent literature from several databases, including PubMed,
MEDLINE, Science Direct and Google Scholar. Leading, reputable dialysis company
websites were visited such as Fresenius Medical Care and Davita, Inc. to discuss the
intricate hemodialysis process. I researched information from biology, physiology,
endocrinology, and nephrology textbooks to provide a foundation for the pertinent
research variables.
The references used for this study span from 1947-2015. Some references,
particularly those used to present the conceptual framework, the population
characterization, and the historical perspectives are considerably older; these older
references, however, illustrate the long-standing constructs used to frame this study and
are timeless concepts whose applicability and relevancy to this study and discipline
remain unaltered through the course of time. These older references, in addition, will help
underscore the deep-rooted customs and traditions that have enriched the Hispanic
culture for centuries.
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Conceptual Framework
The Osmosis and Osmotic Pressure Phenomena
Osmosis is defined as the diffusion of a solvent across a semipermeable
membrane (Marieb & Hoehn, 2007; Villani, Dunlop, & Damitz, 2007). Lachish (1999)
described the processes as the movement of solvent through a semipermeable membrane
that separates two volumes of liquid and disallows the passage of solute particles. The
solvent flow, according to this principle, is from a higher solvent concentration to lower
solvent concentration. When solute particles are present only in one volume, the osmotic
pressure is then the pressure on the solution that ceases the solvent flow (Lachish, 1999).
Marieb and Hoehn (2007) proffered a concise description of this phenomenon from a
solute perspective; osmosis is a process by which dissolved chemicals will move from an
area of high concentration to a lower concentration area. Dissolved compounds or solutes
in solution will randomly spread out until there is an equal concentration of solutes
throughout the specified area.
Osmosis can describe the movement of solutes until the concentration is evenly
distributed throughout the solution and it can also describe the movement of the
dissolving liquid, referred to as the solvent, moving to an area of higher solute
concentration, which would essentially dilute the solute. The latter description allows for
an equilibration of the concentration of dissolved solutes (Marieb & Hoehn, 2010; Villani
et al., 2007). Historically, this phenomenon has been conceptualized, studied, improved,
and applied to a plethora of scientific inquiries and provides a suitable framework for this
study and discipline.
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Historical Perspective
Nollet and Dutrochet were two seminal pioneers that demonstrated the concept of
osmosis and osmotic pressure. Nollet was the first to demonstrate the process by which a
solvent passed selectively through a membrane. Dutrochet is credited with later coining
this process osmosis. Both men made important contributions to science, which laid the
groundwork for future cell theories, the elucidation of membrane structure and function,
and vital physiological processes such as kidney function.
From Electrical Flow to Water Flow. In the 1750s, Nollet applied his interest in
physics (Mason, 1991). Specifically, Nollet used his knowledge about electrical flow and
applied it to crude experimentation in biological systems. Early experiments by Nollet
entailed covering a glass tube containing sugar water with a piece of ordinary paper. He
submerged the tube, paper end down, into a receptacle of water. Nollet observed that the
level of liquid in the tube rose with time. The pure water crossed through the paper faster
than the sugar water did. Being aware of the German experiments that observed the
effects of electricity on the flow of water, where water in a thin capillary tube would
simply drip from the open end, he sought to expand on that body of knowledge and
investigate what would occur if electricity were applied to that tube. Nollet noted that the
water in the capillary tube would flow in a constant stream instead of the continuous drip
noted by his German colleagues. Armed with this new research lead, Nollet began a
series of experiments in which he measured the rate of water transpiration in plants and
animals both in the presence and absence of electricity, noting an increase in flow rate

25
when the organism was electrified (Mason, 1991). His early research opened avenues of
research not yet explored in the scientific community at that time.
Nollet then carried out the first of a series experiments in which the principle of
osmosis was discovered. He prepared a vessel containing alcohol, (he used "spirits of
wine”) and enclosed the vessel within a harvested pig bladder (Mason, 1991). Upon
placing the covered vessel into a larger receptacle filled with water, Nollet observed that
only the water would cross the bladder membrane. For some of his experiments, the
bladder would expand until it actually ruptured. The alcohol in the vessel, however, did
not cross the pig bladder membrane, suggesting that the membrane was only permeable
to the solvent. In addition to this early principle of what would eventually be referred to
as osmosis, Nollet had also demonstrated the semi or selective permeability properties of
the bladder wall. The term semipermeable itself, however, would not be applied to this
principle for another 150 years.
Dutrochet and Cell Membranes. Although Nollet utilized a biological
membrane layer, namely a pig bladder, the conceptual discovery would not be
immediately applied to cell membrane theory (Nezelof, 2003; Pickstone, 1994; Wilson,
1947). In the early 19th century, after learning about Nollet’s previous success with
bladder experiments, Dutrochet attempted to apply the same principle to movement of
fluids across cellular membranes. Dutrochet’s microscopic work with both plant and
animal membranes revealed the movement of solvent (water) through the cell
membranes, a process he coined osmosis. Dutrochet’s studies further revealed that the
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membrane itself did not determine the direction of solvent flow, but rather the nature of
the solvent.
Two of Detrochet’s early experiments used snails and chickens as research
models. The first experiment entailed placing a snail sperm sac into water in order to
examine it microscopically (Pickstone, 1977). His microscopic observations revealed that
the contents were extruded from the open tip of the horn. The movement he observed was
easily visible because the turbid contents (solutes) contrasted with the water (solvent)
outside the snail sperm sac. Detrochet noted that the fluid movement ceased when the
turbidity was observed on both sides of the snail membrane. The second early experiment
by Detrochet involved constructing a sac from a portion of chicken gut. After filling the
sac with milk, he immersed it in a receptacle of water and as expected the sac swelled,
illustrating the osmotic movement of water into a membrane containing a lower solvent
concentration (Pickstone, 1977).
To further test his ideas, Dutrochet invented an endosmometer, an early version of
the osmometer, which is an instrument built in the form of a U, designed to measure the
movement of water across an artificial barrier. Dutrochet described the movement of
water across the barrier as endosmosis, and the reverse solvent movement exosmosis
(Nezelof, 2003; Pickstone, 1977; Pickstone, 1994 Wilson, 1947). Detrochet’s fascination
with force vitale, the driving force that leads to tissue composition and decomposition in
the chemie vivante, and the dynamic exchanges between fluids responsible for these
physiological processes Detrochet described, propelled the discussion and research to
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further explicate and clarify the concept of osmosis into the next century (Nezelof, 2003;
Wilson, 1947).
In the mid 1800s, Graham and von Liebig sought to extend the research on
osmosis commenced by their pioneering predecessors (Wisniak, 2013). Despite their
efforts, Graham and von Liebig were unable to develop a suitable theory to conceptualize
this phenomenon. Graham did, however, distinguished between those substances that
could cross through parchment paper and those that could not; these were termed
crystalloids and colloids, respectively. Graham's additional research provided the impetus
for the application of the concept of osmosis principles to the process of dialysis, which is
used today in dialyzers and artificial kidney machines (Wisniak, 2013). Both Graham and
von Liebig set the foundation for the next series of advances towards conceptualizing
osmosis principles.
The next important advance in the discipline came in 1877 when a German
botanist Pfeffer studied osmotic pressure (Borg, 2003). Like Nollet, for his experiments
the test protocol was also sugar water. This time, though, the sugar solution was placed in
a porous clay vessel, which was submerged in a receptacle filled with pure water. Using a
manometer, Pfeffer measured the osmotic pressure of the system and discovered that it
was inversely proportional to the volume of a solution and directly proportional to
absolute temperature or PV = kT, where P is pressure, V is volume, and T is absolute
temperature (Borg, 2003). The constant k was subsequently used to define the universal
gas constant by van't Hoff and other gas laws. van’t Hoff determined that the osmotic
pressure a solute exerts is the same it would exert as a gas at the same volume and
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temperature (Lachish, 2007). The formula for osmotic pressure was derived by Jacobus
van't Hoff. The van’t Hoff theory of osmotic pressure states that π is proportional to the
molar concentration (c), the absolute temperature of the system (˚K), and the gas constant
(R). The formula π = c R T, is derived by the comparison of the pressure of an ideal gas
of the same concentration and temperature. c in the equation is the molar concentration of
solute particles, R is the gas constant (0.0821L *ATM/mole*K), and T is the absolute
temperature in degrees Kelvin (Lachish, 2007). The elucidation and derivation of this
osmotic pressure law was fundamental to the advancement of the concept.
Another German botanist, van Mohl further advanced Pfeffer's research. In
addition to describing cell division, he provided a lucid explanation for osmosis, which
was the first of its kind (Ing, Rahman, & Kjellstrand, 2012). His description about the
membrane having an inner protoplasm, a term used to describe the living contents of a
cell surrounded by a cell membrane, provided an anatomical basis for the osmotic process
in biological cells. Pfeffer's clay pot was a semipermeable membrane, which accurately
represented the membranes surrounding most animal and plant cells. Mohl’s research that
described the protoplasm applied this concept of osmosis to living cells. These historic
osmosis studies have inspired studies in various disciplines such as cell physiology, cell
molecular biology, biochemistry, and further scientific inquiries investigating solution
purification strategies and chemistry analysis. Nephrology studies about the hemodialysis
process and application are fundamentally based on these revolutionizing concepts and
are the basis for this dissertation inquiry.
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The osmosis and osmotic pressure phenomena have been applied to research
studies for many years. The seminal research conducted by these pioneers is didactic to
numerous fields in academia as well as to healthcare protocols like the hemodialysis
process used to remove blood toxins from patients with renal failure. Both the osmotic
pressure theory and the van’t Hoff theory describe the solute-solvent relationship. The
phenomenon is based on the concentration of solute on two sides of a semipermeable
membrane, which will allow for the solvent to move towards the side that is less
concentrated (Lachish, 1999; 2007). In hemodialysis, the albumin protein is the primary
circulating protein solute in blood plasma. As the osmotic pressure theory posits, the
protein is unable to cross the semipermeable plasma membrane of cells, but the solvent,
however, can cross freely. This osmotic movement of fluids draws fluid from the plasma
into the capillaries to maintain homeostatic blood pressure. This concept is applied to
hemodialysis treatments in which patients, by the nature of their renal disease, are unable
to remove excess fluid from their tissues. Specifically, in hemodialysis patients the excess
fluid in edematous tissues, collected during the interdialytic period, is drawn into the
capillaries by osmosis and then filtered through a dialyzer using a prepared dialysate
solution that can readily remove the excess fluids from the patient via a countercurrent
flow (Fresenius Medical Care, 2013). The prescription of a certain dialysate composition
changes in order to obtain not only adequate blood purification, but also optimal
treatment tolerability. Dialysate composition can be tailored in terms of the sodium,
potassium, calcium and bicarbonate content; these represent the solutes (ions) in the
dialysate.
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The specific ionic components of the dialysate prescribed by the nephrologist are
vital to the osmotic movement of fluids and therefore patient clearances (Ing, Rahman, &
Kjellstrand, 2012). These four ions are sodium, potassium, calcium, and bicarbonate.
Sodium balance represents the cornerstone of cardiovascular stability and blood pressure
control (Fresenius Medical Care, 2013). Potassium increases vasoactivity when it is
infused into the arterial supply of a vascular bed. Potassium levels can be manipulated by
supplementation or during hemodialysis treatments, which can assist in regulating blood
pressure (Haddy, Vanhoutte, & Feletou, 2006; Ing et al., 2012). Calcium is used to
maintain bone density. Because patients on hemodialysis have dysfunctional kidneys,
they are unable to convert vitamin D into the hormone Calcitrol. This hormone is used to
facilitate calcium absorption from the intestines into the blood. Consequently,
hypocalcemic levels cause calcium to be pulled from bone tissue, which may lead to
renal osteodystrophies (Davita, 2013; Ing et al., 2012). Bicarbonate concentration in
dialysate is tailored to avoid acidosis and post-dialysis alkalosis (Ing et al.,2012; Vigano,
DiFilippo, Manzoni, & Locatelli, 2008).
This intricate hemodialysis process is grounded by fundamental physiological
concepts and theories. Both the osmotic pressure theory and the van’t Hoff theory of
osmotic pressure provide a suitable conceptual framework for this study. These theories
provide a plausible mechanism by which patients with Type II diabetes receiving
hemodialysis treatments show lower levels of albumin in their blood and consequently
albuminuria. The theories, physiological concepts, and dialyzer membranes used for
maintenance hemodialysis reflect the filtering capacity of the kidneys. In patients with
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Type II diabetes and renal disease, this filtering capacity has been compromised,
therefore disobeying fundamental osmotic pressure principles and membrane filtration
processes.
At that time, the novel concept of the cell membrane as a barrier capable of
regulating osmosis was initially inimical to cell theory and thus beyond immediate
application by Nollet (Mason, 1991). Nollet's discovery nevertheless represented one of
the first of its kind in the developing discipline of experimental physics and physiology.
Furthermore, when a similar phenomenon was found to occur in biological membranes,
the inception of several scientific disciplines began to arise. Pfeffer, for example,
explained a role for osmotic pressure in the action of fluids within plant vessels (Borg,
2003). The significant contribution to the mathematics of osmosis and chemical
equilibrium was derived by van't Hoff. van't Hoff is credited with referring to the
principle behind Nollet's pig bladder membrane as semipermeable, which was the first
use of that term in describing cellular membrane physiology. The salient history behind
the fundamental principles of osmosis and osmotic pressure theories provides the
foundation for the intricate hemodialysis process that patients with renal failure endure to
filter their blood.
The Hemodialysis Process
The Dialysis Machine
The first dialysis machine was constructed by Dutch physician, Dr. Willem Kolff,
in 1941 (Fresenius Medical Care, n. d.; Ing, et al., 2012; Kidney Dialysis Information
Centre, n. d.). His crude machine was constructed from the cooling system of an old
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Ford, cellophane wrapped sausage skin, parts from an old downed German airplane and a
porcelain bathtub. Kolff's early work on dialysis machine construction was seemingly a
junkyard challenge. Modern kidney dialysis machines, however, are much more
sophisticated, with digital displays and state-of-the-art dialyzers and web-based
monitoring and data storage systems. The basic principle behind Kolff’s original
machines, however, still remains today; the machines remove a small amount of blood
from the body at a time and filter out waste products from the blood through fundamental
osmotic principles. Today's machines and dialyzers, though, are capable of removing a
broader range of uremic wastes products from the blood and can effectively balance
essential ion concentrations (Fresenius Medical Care, n. d.; Ing, et al., 2012; Kidney
Dialysis Information Centre, n. d.).
Kidney Function
When the kidneys have become damaged and are no longer functioning properly,
kidney dialysis is used to replace normal kidney function (Davita, 2014). Physiologically,
the kidneys aid in controlling the levels of dissolved minerals called electrolytes and filter
out waste products or metabolites created by cells using energy. These functions help in
the maintenance of homeostatic amounts of compounds such as sodium, potassium and
calcium in the blood as well as the removal of potentially toxic compounds. These toxic
compounds are filtered, concentrated and collected by the kidneys into urine, which
allows them to be excreted from the body. When the kidneys fail, the dialysis process can
be used to take over that function (Davita, 2014).
The hemodialysis process aligns with the principles of osmosis, solution
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permeability, and membrane structure and function (Fresenius Medical Care, 2013). The
process involves removing blood from the body via an access, usually an arteriovenous
graft in the forearm, and circulated and filtered through an extracorporeal fluid circuit,
then returned to the patient through the same access. The circuit includes a hemodialyzer,
which is a device that is used to filter the blood. The hemodialyzer contains a selectively
permeable membrane, similar to the membranes that Nollet, Dutrochet, Pfeffer and Kolff
used, with a filtration capacity that allows fluids and uremic waste products to cross
through, but prevents the exchange of blood components and proteins such as albumin.
The countercurrent movement of the dialysate fluid that is used to clean and detoxify the
blood, flows on the opposite side of the dialyzer membrane and draws waste and extra
fluid from the blood, which can then be discarded (Fresenius Medical Care, 2013).
Osmosis and Hemodialysis
Kidney dialysis machines exploit osmotic principles to take over the filtering
capacity of the kidneys (Sakai, 2000). Like those original membranes first introduced by
Nollet and Detrochet capable of filtering substances from a given solution, dialysis
machines employ a sophisticated semipermeable membrane, which is capable of allowing
small molecules, such as water, salts, and metabolites to pass, but disallows larger
components such as proteins (albumin) and blood cells from filtering through. Dialysis
machines direct the blood alongside a semi-permeable membrane while circulating a
large volume of a liquid called the dialysate along the opposite side of the membrane.
The countercurrent flow between the blood and the dialysate causes the metabolites to
flow out of the blood, through the membrane, and into the dialysate via osmosis. The
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membrane, furthermore, also allows electrolytes to seep through the membrane as well so
that the blood can remove electrolytes that are in excess, thereby maintaining electrolyte
homeostasis. It is through the principles of osmosis that dialysis machines and dialyzers
effectively remove toxins from the blood and essentially take over the filtration function
from the kidneys (Ing et al., 2012; Sakai, 2000).
Diffusion, Osmosis, and Ultrafiltration
Three fundamental concepts frame the elaborate hemodialysis process. The
process by which the albumin protein provides the mechanism by which colloid pressure
is maintained is due in large part to these physiological processes. These three processes
are: (a) diffusion; (b) osmosis; and (c) ultrafiltration. Each process plays a vital role in
human physiology and is directly related to the process by which homeostatic blood
pressure is maintained in order to dialyze patients suffering from renal failure. The
dialysis process and the effective filtration of metabolites and other toxins from albumin
protein in the circulatory system to hemodialyze patients is a direct application of these
concepts. Furthermore, as discussed by Iseki et al. (1993), albumin levels in patients with
a type II diabetes mellitus diagnosis serve as predictors for death, providing the reasoning
and justification for this research inquiry.
Diffusion. Diffusion is a fundamental driving force in many biological processes,
and is an example describing how the living world is regulated by the same physical laws
as the nonliving world (Villani, Dunlop, & Damitz, 2007). Diffusion, therefore, applies to
the process of hemodialysis. Diffusion is defined as the exchange of solutes dissolved in
fluid across a semipermeable membrane because of differences in the concentration
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gradient on both sides of the membrane (Fresenius Medical Care, 2013). When there is a
higher concentration of a given solute on one side of a membrane relative to the other, the
diffusion randomly occurs to try and achieve equal solute concentrations on both sides of
the membrane. In hemodialysis, the dialysis machine controls this transfer of solutes by
controlling the chemicals in the dialysate according to the doctor's prescription.
Hemodialysis machines control the chemicals in the dialysate by mixing dialysis fluid
concentrates such as acetate or sodium bicarbonate plus acetic acid based solutions with
purified water. Each of the solutes in the dialysate can be manipulated to improve the
amount of solute removed by diffusion to adequately dialyze patients (Fresenius Medical
Care, 2013).
Osmosis. Whereas diffusion describes the random movement of solutes across
membranes, osmosis describes the diffusion of a solvent, usually water, across a
biological membrane from areas of high to low concentration (Villani et al., 2007). This
phenomenon is the net movement of the solvent across a semipermeable membrane
driven by a difference in the amounts of solute on the two sides of the membrane
(Fresenius Medical Care, 2013). In hemodialysis, this refers to the movement of a solvent
across cell membranes within the body such as the movement of solvent within
erythrocytes to the blood plasma, or from within cells of the various tissues in the body to
interstitial fluid, and not to water movement across the hemodialyzer membrane.
Manipulating sodium, referred to as sodium profiling, can be used to increase the rate of
osmosis early in the hemodialysis treatment by increasing the sodium concentration of
the plasma (Fresenius Medical Care, 2013).
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Ultrafiltration. Lastly, ultrafiltration utilizes a pressure gradient to force fluid
through a membrane (Fresenius Medical Care, 2013). This phenomenon is useful because
it controls the patient’s weight loss over the course of the treatment. Modern dialysis
machines are referred to as volumetric, which means they control the volume of fluid
removed from the patient directly, allowing dialysate pressure to change naturally in
order to achieve the prescribed fluid removal goal. To achieve volumetric control, the
flow rate of dialysate into and out of the dialyzer is controlled using two flow controllers,
or by having equal dialysate flow rates into and out of the dialyzer and removing fluid
between these two equal flows. Employing volumetric control allows the physician to
exploit the effective "high flux" dialyzers, which allow a great deal of fluid movement
with minimal pressure differences (Fresenius Medical Care, 2013; Ing et al., 2012).
Fluid Overload and Ultrafiltration
There exists a wide array of current studies that are a direct application of the
principles of osmosis, membrane function, fluid movement, and filtration. These concepts
are common denominators that guide and inform this study’s research questions. When
any of these processes go awry, it illustrates the pathophysiology of kidney function and
filtering capacity. As a consequence, hemodialysis patients experience fluid overload.
Patients with end-stage renal disease are exposed to extreme shifts in body volume and
thereby cardiovascular strain as a result of interdialytic weight gain, fluid removal during
hemodialysis, and also chronic fluid overload (Ismael et al., 2014). Fluid overload, either
because the semipermeable membranes of nephron glomeruli are compromised or
because of inadequate dialyzer and/or dialysate prescription, may lead to abnormal

37
hemodynamic conditions and higher risk for cardiovascular morbidity. Even subtle
fluctuations in fluid balances may have dire clinical outcomes and poor prognoses
(Antlanger et al., 2013; Kim et al., 2012), underscoring the importance of and the direct
application to the principles of osmosis, membrane filtration, and the intricate
hemodialysis process.
It is well understood that fluid accumulation in hemodialysis patients is associated
with adverse outcomes in critically ill patients. Bouchard et al. (2009) sought to ascertain
if fluid accumulation is associated with mortality and non-recovery of kidney function in
critically ill adults with acute kidney failure. The authors defined fluid overload as having
more than a 10% increase in body weight relative to normal baseline weight recordings.
Of the 618 patients enrolled in their prospective, multicenter observational study, the
authors found that patients with fluid overload experienced significantly higher mortality
within 60 days of maintenance hemodialysis. Among patients that were dialyzed,
survivors had significantly lower fluid accumulation at the start of dialysis treatment
compared to non-survivors. The authors also noted that 31% of the population selected
for their study had Type II diabetes as a comorbidity; this may or may not have
influenced fluid accumulation in their study, but is a noteworthy factor to consider when
making conclusive assessments about fluid accumulation in this population (Bouchard et
al., 2009).
Fluid accumulation and overload was also investigated by Hecking et al. (2012).
In their prospective, multicenter, randomized, controlled clinical trial, the authors
recruited 60 hemodialysis patients with fluid overload and sought to determine if
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ultrafiltration was the superior method to control fluid overload over conventional
hemodialysis. The patients were randomized into three groups: (a) an ultrafiltration and
dialysate conductivity group; (b) an ultrafiltration and temperature regulation group; and
(c) a conventional hemodialysis group. The authors found that the ultrafiltration and
dialysate conductivity group showed significantly fewer intra and post dialytic
complications. The prescribed dialysate recipe has shown to improve the diffusion of
toxins from the blood into the dialysate and osmotically draws fluids from the
extracellular spaces into the circulatory system, while simultaneously ridding of excess
fluid accumulation for cardiovascular fluid homeostasis. The ultrafiltration process
utilizes a pressure gradient to force fluid through the dialyzer membrane (Fresenius
Medical Care, 2013). This hemodialysis strategy is useful because it controls the patient’s
weight loss over the course of the treatment, which can translate into improved dialysis
clearances and better overall dialysis hemodynamic outcomes (Hecking et al., 2012).
Fluid overload was further investigated by Antlanger et al. (2013). Like previous
studies, the authors assert that chronic fluid overload is closely associated with higher
mortality (Antlanger et al., 2013; Bouchard et al., 2009; Hecking et al., 2012). For their
prospective study, 144 hemodialysis patients at three Fresenius dialysis facilities in
Austria were recruited. The authors found that of the recruited population, 39% had
predialysis fluid overload. Those patients with higher BMI’s had lower fluid overload,
suggesting that patient dry weights were inadequately prescribed and/or difficult to
achieve when they were overweight (Antlanger et al., 2013). Additionally, and perhaps
correspondingly, the albumin levels in the fluid overloaded patients were significantly
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lower. The authors concluded that cardiovascular parameters and volume measurements,
including albumin levels, when compromised or abnormal, might suggest that fluid
overload is a biomarker for cardiovascular risk (Antlanger et al., 2013). Bouchard et al.
(2009), Hecking et al. (2012), and Antlanger et al. (2013) shared an important
methodological population recruitment strategy. The population for these studies was
recruited from multiple dialysis centers with a wide ethnic representation of hemodialysis
patients, proffering increased generalizability of study outcomes to populations beyond
Hispanic Americans.
Lindberg, Prutz, Lindberg and Wikstrom (2009) agree with Bouchard et al.
(2009), Hecking et al. (2012), and Antlanger et al. (2013) that excessive interdialyitc
weight gain and ultrafiltration rates above 10ml/h/kg body weight suggest higher
morbidity and mortality. In their study, the authors retrospectively examined cohorts of
patients on maintenance hemodialysis from The Swedish Dialysis DataBase and The
Swedish Renal Registry of Active Treatment of Uremia from 2002-2006. A cohort of
9,693 hemodialysis sessions in 4,498 patients were examined. The study aimed to
estimate the prevalence of fluid consumers, identify ultrafiltration patterns, and attempt to
explicate interdialytic weight gain. The authors concluded that there are potentials for
continuing improvements in the care of hemodialysis patients with fluid overload,
including more frequent dialysis, such as nocturnal or daily dialysis to all patients
(Lindberg et al., 2009). This study’s design was a retrospective analysis of both a
Swedish database and registry, which qualifies as secondary data analysis. This study
aimed to utilize a similar data analysis strategy to elucidate the albumin levels of patients
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on hemodialysis in the selected population. This study also provided a model option for
possible population size requirements that would satisfy statistical power during data
analysis.
A multicenter, interventional trial that was based on several observational studies
was conducted by Kim et al. (2012) to determine hemodynamic and biochemical benefits
of measuring fluid status is hemodialysis patients. The authors enrolled 120 patients and
divided them into two groups: (a) the hyperhydrated group, and (b) the dehydrated group.
After reducing the patients body weight in the hyperhydrated group and raising the body
weight in the dehydrated group for sixteen weeks, the results showed that despite
enrolling all euvolemic patients for their study, the hyperhydrated patients contributed
over one-third of the participants. Of the 120 enrollees, 44 were in the hyperhydrated
group and 18 were in the dehydrated group. Furthermore, the authors found that after
sixteen weeks systolic blood pressure and pulse pressure decreased in the hyperhydrated
group, while there was no change in blood pressure in the dehydrated group post
intervention. The study underscored the importance of accurately assessing fluid status in
hemodialysis patients so as to regulate blood pressure (Cigarran et al., 2007; Kim et al.,
2012). Since blood pressure is largely maintained by albumin levels, the authors
measured albumin levels at week 0, 8, and 16 and found that compared to the dehydrated
group, the hyperhydrated group showed an albumin drop from 3.89mg/dL, 3.89mg/dL,
3.79mg/dL in weeks 0, 8, and 16, respectively. These results correlate with an expected
reduction in kidney filtering capacity. Additionally, the results align with osmotic
pressure principles. Since some albumin is lost during the filtration process, a
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hemodynamic change occurs whereby the fluid moves from the capillary lumen through
the selectively permeable membranes into the interstitial fluids, causing fluid overload
tissue edema.
Cigarron et al. (2007) followed suit with a cross-sectional study that aimed to
evaluate the relationship between serum albumin concentration and hydration state. The
study investigated 108 non-selected patients that were put into three groups based on
their serum albumin levels. Seventy-five healthy individuals comprised the control group
for comparisons. The authors concluded that hypoalbuminemia is a marker of fluid
overload (Artlanger et al., 2013; Cigarran et al., 2007). There exists a direct relationship
between albumin levels and fluid excess as a consequence of albumin level differences in
patients on maintenance hemodialysis (Cigarran et al, 2007; Kim et al., 2012). The
physiological importance and clinical significance of albumin in patients undergoing
maintenance hemodialysis is formidable and worthy of further exploration.
Hispanic Population
Minority populations are rapidly growing in the United States. This is especially
evident in the Hispanic population (Lopez, 2008). In 2002, Hispanics became the largest
minority group in this country, accounting for 14.5% of the U.S. population by 2005.
Consequently, the demand for health care among this population is growing as well.
According to Lopez et al. (2008), Hispanic individuals in the U.S. have a high prevalence
of Type II diabetes mellitus, which is a known risk factor for the development of chronic
kidney disease. This, in turn, places the Hispanic population at high risk to develop stage
5 chronic kidney disease, which often requires maintenance hemodialysis. Therefore, the
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importance of recognizing the needs of this growing population segment by health care
providers, including physicians, nurses, social workers and dieticians is imperative. For
this research, a retrospective examination of the treatment records of a sample Hispanic
population that received hemodialysis at local dialysis clinics in San Antonio, Texas was
conducted. Both diabetic and nondiabetic patients on maintenance hemodialysis that
received treatments at these clinics were reviewed to determine if albumin level
differences existed between hemodialysis patients with a Type II diabetes mellitus
diagnosis and those without one. The medical records were analyzed at baseline, 0, 3, and
6 months post baseline. An acceptable goal level for albumin, according to the Kidney
Disease Outcome Quality Initiative (KDOQI) guidelines is ≥4.0g/dL (American Journal
of Kidney Disease, 2007; National Kidney Foundation, 2002; National Kidney
Foundation, 2013). This level was also used in this research as the acceptable level for
comparing albumin levels in the sample population.
The study consisted of collecting and analyzing data on the health status and renal
measures from medical records of Hispanic dialysis patients seen at Fresenius Medical
Care-NA’s designated renal dialysis clinics in San Antonio, Texas. These records are
maintained on all patients admitted to these facilities. After obtaining permission from
Frenova Renal Research and Walden’s Institutional Review Board (Approval # 12-17-140298443), data were collected from Centers for Medicare and Medicaid Services (CMS)2728 forms. The CMS-2728 government form is a validated data collection instrument
that is completed for all new patients who are initiated on dialysis (Appendix A). Data
arising from this form have been published in numerous studies. It records data on
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sociodemographic characteristics and captures information on a many comorbidities,
hematology profiles, and clinical indicators (Murthy, Malony, & Stack, 2005). The
clinical data are collected by nursing personnel, including anthropometric measurements
of age, weight, and height, as well as renal parameters such as BUN-serum creatinine
ratios, hemoglobin A1C, lipid profiles, and serum albumin documented at the onset of
treatment. Subsequent blood draws are done weekly for Hemoglobin A1C and pre and
post BUN-creatinine ratios and potassium if deemed necessary by the nephrologist.
Calcium, phosphorus, and albumin levels are collected monthly peritreatment. Both
weekly and monthly lab tests are documented in the patient’s medical records.
Additionally, the primary cause of renal failure and ICD-9 codes for associated
comorbidities are documented on the patient’s medical records. Routine lab testing and
reporting of monthly albumin levels through Spectra Laboratories were reviewed from
the patient’s medical records.
Retrospective analysis of medical records in end-state renal disease (ESRD)
patients who underwent maintenance hemodialysis were examined by Ricks et al. (2012).
The authors reviewed records in any 1 of the 580 outpatient dialysis facilities of Davita,
Inc. from July 2001 through June 2006. Cohort inclusion criteria consisted of patients
that were on dialysis for at least 90 days, were being treated with maintenance
hemodialysis at study onset, had a history of diabetes, and had at least one A1C
measurement. Medical Evidence CMS-2728 forms of the U.S. Renal Data System were
examined for preexisting comorbid conditions. The patient records were reviewed from
July 2001 to June 2006 and followed up for one year. Over the five-year period, 164,789
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adult subjects received dialysis treatment in Davita clinics. Of these, 141,762 patients
were undergoing maintenance hemodialysis at the time of entry into the cohort. 54,757
diabetic, maintenance hemodialysis were identified. The authors aimed to determine
mortality predictability of A1C and random serum glucose over time. Cox proportional
hazards regression were used to examine whether glycemic control predicted survival for
up to 6 years of follow up. Exploratory analysis among patient subgroups, including a
serum albumin based subgroup was conducted. Logistic regression was performed to
analyze the predictive value of A1C and to assess the association between different
laboratory and clinical parameters and A1C levels. The authors found that poor glycemic
control appeared to be associated with decreased survival in the general population of
diabetic, maintenance hemodialysis patients. In the serum albumin subgroup in particular,
the results showed that even with moderate glycemic increases, this group revealed a
marked increase risk for all-cause or cardiovascular mortality (Ricks et al., 2012).
A retrospective, secondary data analysis from 2000 through 2008 on a multiethnic
group of participants (N = 122,716) from the Kidney Early Evaluation Program (KEEP)
was also conducted by Jolly et al. (2011). KEEP is a free, community-based voluntary
screening program designed to detect chronic kidney disease, aimed at identifying
individuals with risk of kidney disease. Participants were screened based on blood and
urine specimen to assess serum creatinine, fasting blood glucose, and urine albumin
levels. The authors included patients with a known diabetes diagnosis, hypertension,
kidney disease, and a family history of diabetes. For this study, patients that were on
hemodialysis or had undergone a kidney transplant were excluded from the study. After
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exclusionary criteria, n = 19,205 constituted the final population for this study. The
authors divided the population into five groups based on ethnicity: (a) Non-Hispanic
White, (b) African American, (c) Asian, (d) American Indian/Alaska Native, and (e)
Hispanic. The authors conducted multivariate Cox proportional hazards regression
analyses to determine the association of race/ethnicity with all-cause mortality among all
participants with chronic kidney disease. The authors showed that the risk was similar
among African Americans, higher for American Indian/Alaska Natives, and lower in
Hispanics compared to their White counterparts. The latter result is consistent with the
literature on the existence of the “Hispanic Paradox,” describing a high chronic disease
risk factor profile with a lower mortality compared to their white counterparts. The
authors concluded that significant differences in mortality exist among persons with
chronic kidney disease (Jolly et al., 2011).
The Hispanic Paradox was further confirmed in another study conducted by Ricks
et al. (2011). For their retrospective, cohort study, the authors examined a 6-year cohort
of N = 109,605 maintenance hemodialysis patients including n = 39,090 Blacks, n =
17,417 Hispanics, and n = 53,098 non-Hispanic white outpatients from DaVita dialysis
clinics between 2001 and 2007. Cox proportional hazards models and Kaplan-Meier logrank tests examined the association between BMI and the six-year survival among these
race/ethnic groups. Of the 109,605 patients selected for the study, 45% of the population
was diagnosed with Type II diabetes. The authors reviewed the Davita database and
Medical Evidence Form CMS-2728 to determine presence or absence of diabetes and
associated comorbidities. The authors showed that a higher BMI had a protective quality
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and therefore higher survival rate among African Americans and Hispanics compared to
their white counterparts. Although obesity is associated with deleterious outcomes in the
general population, in maintenance hemodialysis patients this association is reversed,
confirming the “reverse epidemiology” phenomenon. For the Rick’s et al. (2011) study,
both the reverse epidemiology phenomenon and the Hispanic paradox were important
population considerations (Ricks et al., 2011) and were equally important considerations
for this investigation.
Hispanic, hemodialysis population studies were also conducted by Yan et al.
(2013). A retrospective analysis of a cohort of Caucasian, Black and Hispanic patients
from the United States Renal Data System was identified. A cohort of N = 1,282,201
patients were included in the study. Medical Evidence Forms CMS-2728 were reviewed
to ascertain patient ethnicities and specific patient comorbidities. The authors sought to
investigate if survival in hemodialysis patients is modified by age, ethnicity, and race.
Cox regression analysis was used to determine survival differences for the entire study
cohort. The authors found that mortality risk was lowest in Hispanics, intermediate in
non-Hispanic Blacks, and highest in non-Hispanic Whites. This trend held true for the
overall dialysis population and most age groups (Yan et al., 2013).
Murthy et al. (2005) confirmed this survival advantage in Hispanic patients on
maintenance hemodialysis. In their historical, prospective cohort study of new ESRD
patients, the authors identified N = 158,685 adult patients who initiated hemodialysis
between 1995 and 1997. Patients were identified from the Medical Evidence Form CMS2728. Descriptive statistics of patient characteristics were performed for the entire cohort
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and for the six combined race subgroups. Chi square tests were used to compare
categorical variables and means of variables were compared using ANOVA. Multivariate
logistic regression was performed to examine the association of ethnicity and race with
three comorbid indicators, including diabetes and hypoalbuminemia. Additionally,
multivariate Cox regression models examined the relationship of ethnicity-race with
mortality risk in new ESRD patients. After exclusion criteria, the study cohort consisted
of n = 100,618 patients. 10,393 (10.3%) were identified as Hispanic. The authors
concluded that survival of new ESRD Hispanic dialysis patients was significantly higher,
with a 17% lower adjusted mortality risk among those without diabetes and 30% lower
adjusted mortality risk among those with a diabetes diagnosis (Murthy et al., 2005).
To further assess patterns and predictors of mortality in hemodialysis patients,
Lukowsky et al. (2012) examined a large (N = 82,566) cohort of incident hemodialysis
patients from Davita clinics from 2001 to 2006. After exclusion criteria, n = 18,707
incident dialysis patients constituted the study population. Descriptive analysis was
performed on the population. Kaplan-Meier estimation, mortality ratios, and survival
curves were produced. Multivariate logistic regression models were conducted to
estimate standardized mortality ratios. Cox proportional hazard models were used to
calculate hazard ratios for the 5-year survival for the patient characteristics such as
demographics, comorbidities, and laboratory values. The patients were selected from The
United States Renal Data System databases. The authors divided the cohort into a priori
groups to estimate survival at 3, 6, 12, and 24 months. Serum albumin as well as other
clinical values were collected at treatment onset and documented on CMS-2728 forms
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and subsequently during treatments. The authors found that incident hemodialysis
patients exhibit the highest mortality during the first six months of dialysis treatment,
particularly in the first two months. Of these, hypoalbuminemia accounted for one third
of all deaths in the first 90 days (Lukowsky et al., 2012).
Dalrymple et al. (2013) sought to measure serum albumin and prealbumin
concentrations in incident dialysis patients to evaluate protein-energy wasting (PEW).
The authors reported that low albumin and prealbumin levels are important biochemical
indicators of PEW and are powerful predictors of mortality risk in patients undergoing
maintenance hemodialysis (Dalrymple et al., 2013). The authors recruited participants
from the Comprehensive Dialysis Study (CDS) for a prospective cohort study of adults
with end-stage renal disease (ESRD) in whom maintenance hemodialysis was newly
initiated. Participants were enrolled between 2005 and 2007. A cohort of N = 1,678
incident dialysis patients from 297 facilities consented to participate in the surveys and/or
laboratory component of the CDS. Of these, 35 patients donated serum for the laboratory
research component.
The authors collected baseline data from the Medical Evidence Form from the
Department of Health and Human Services and the Centers for Medicare and Medicaid
Services (CMS 2728 Form). They classified participants as having diabetes if diabetes
was the primary cause of ESRD or if diabetes was listed among the comorbidities. For
the laboratory chemistry, blood was drawn at enrollment and thereafter every three
months for the first year of the study by participating dialysis units. The authors
measured albumin and prealbumin twice on each serum sample and used the mean
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concentration of the duplicate serum albumin and prealbumin values in the statistical
analyses.
For their study, the dependent variables of interest were longitudinal changes in
serum albumin and prealbumin levels, measured at 0, 3, 6, 9, and 12 months. A total of n
= 266 CDS Nutrition substudy participants with laboratory measures were included in the
study of which 35 enrolled in the laboratory research component. These participants were
from 56 participating dialysis facilities. The mean age of the participants was 62 years.
55% were male, 71% were white, 68% were on hemodialysis, and 8% were on peritoneal
dialysis. The study cohort was characterized by a high prevalence of Type II diabetes.
The authors found that serum albumin concentration increased, whereas prealbumin
concentration remained relatively stable over time. After testing individually for diabetes,
atherosclerotic vascular disease, heart failure, and higher C-reactive protein, the
concentrations were associated with lower serum prealbumin concentrations. From their
results, the authors concluded that further understanding of the mechanisms underlying
differences between albumin and prealbumin kinetics in dialysis patients may lead to
improved approaches to the management of PEW.
This study aimed to employ a similar study design as Dalrymple et al. (2013). The
study intended to examine albumin levels at baseline, 0, 3 and 6 months from CMS-2728
forms and patient records to ascertain possible differences in serum albumin levels.
Whereas Dalrymple et al. (2013) measured albumin levels in a large multi-ethnic cohort
of hemodialysis patients, most with a diabetes diagnosis, this study aimed to evaluate
albumin levels in a cohort of Hispanic hemodialysis patients with the same chronic
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disease diagnosis.
Numerous studies have investigated large cohorts of hemodialysis patients to
address a myriad of research questions regarding treatment outcomes, albumin
improvement patterns, mortality, as well as comorbidity comparisons among various
ethnicities. Some studies have examined hematology profiles of specific ethnic
populations receiving maintenance hemodialysis treatments. As discussed above, several
have reviewed and compared Hispanic survival analysis, dialysis modalities,
glycemic/A1C control, race/ethnicity and age, renal disease risk, and associations between
dialysis outcomes with a Type II diabetes mellitus diagnosis. None, however, have
investigated if a Type II diabetes diagnosis in dialysis patients might influence albumin
levels or whether albumin level differences or improvement patterns exist from treatment
onset through the course of their dialysis treatments. It is apparent from the studies
presented in this literature review that the protein albumin is a key research indicator
from which to monitor dialysis treatment progress and to gauge patient prognosis.
Albumin Characterization and Physiological Roles
Albumin is characterized as a globular protein with a molecular weight of 69,000
daltons (Alpern, Caplan, & Moe, 2013). It has a negative charge at physiological pH, is
synthesized in the rough endoplasmic reticulum in liver hepatocytes, and catabolized by
all metabolically active tissues (Alpern et al., 2013; Rozga et al., 2013). The molecule is a
single peptide chain composed of 585 amino acids with a polypeptide arrangement in
folded alpha helices, held together by disulfide bridges. Because of this flexible
arrangement, albumin may change shape, facilitating its ability to bind many endogenous
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and exogenous ligands (Rozga et al., 2013).
This ubiquitous plasma protein largely contributes to plasma colloid osmotic
pressure (COP) due to both its small size and abundance. Compared to other globular
proteins in the blood, albumin accounts for 55-60% of total plasma proteins by weight,
which is why it plays such a significant role in blood pressure regulation (Rozga et al.,
2013). Its synthesis is regulated primarily by a change in interstitial colloid osmotic
pressure. The normal range of human serum albumin in adults is 3.5–5.0 g/dL. In tissue
spaces, however, the concentration is much lower at 1.4 g/dL. In addition to this major
physiological function, albumin also serves as a carrier protein for many insoluble
organic substances, is recruited for binding and transporting drugs, is a prolific free
radical scavenger, is useful in acid-base balances, plays a major role in anticoagulatory
and antithrombotic regulation, and is vital for vascular permeability (Alpern et al., 2013;
Rozga et al., 2013). Considering these vital roles in the human body and because albumin
protein levels have shown to fluctuate in pathomechanistic incidences, each of these roles
are explicated further to provide a comprehensive characterization of the protein’s
physiological utility and therefore relevance to this study.
Colloid Osmotic Pressure
Colloid osmotic pressure (COP) is the force opposing hydrostatic pressure (Rozga
et al., 2013). It is created by the presence of large non-diffusible molecules, such as
plasma proteins, which cannot cross the capillary wall. These molecules draw water to
themselves because the water concentration in their immediate surroundings is lower than
it is on the opposite side of the capillary wall (Marieb, & Hoehn, 2010). According to
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Alpern et al. (2013), hydrostatic pressure that is created by the presence of albumin
accounts for 75 - 80% of the COP. Blood pressure regulation can be explicated by the
Starling’s equation as well as fundamental osmotic pressure theories and principles
(Alpern et al., 2013). According to the equation, the flow of fluid out of capillaries is
determined by a filtration constant multiplied by the net force driving fluid out of the
capillary (hydrostatic pressure minus oncotic pressure) minus the osmotic gradient
pulling the fluid out. Altogether, the Starling's equation for blood pressure regulation can
be quantified using the equation: Transcapillary Flow = k [(Pcap + Pi) - (Pi + Pcap )]
(Janecek & Sigler, 1996; Rozga et al., 2013).
The salient concepts of blood pressure maintenance and regulation are
fundamentally based on the principles of osmosis and the osmotic pressure theory.
According to these principles, the movement of water draws fluid into the cells away
from the tissues to maintain homeostatic blood pressure, accurately reflecting the process
of osmosis by which solvent moves down its concentration gradient (Fresenius Medical
Care, 2013; Lachish, 2007). Each cell membrane serves as the semipermeable membrane
that will allow for this osmotic fluid movement that regulates COP.
Binding and Transport
Albumin possesses binding and transport properties (Alpern et al., 2013; Roszga
et al., 2013). The binding and transport functions include circulating ligands, metabolite
and drug delivery to tissue sites, detoxification, drug inactivation, various molecule
stabilization, metabolism of endogenous and exogenous substances, and antioxidant
protection. The protein is capable of binding drugs and other ligands, therefore reducing
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the circulating serum concentration of these compounds. Albumin’s morphology consists
of four binding sites with varying specificity for different compounds. Because of this
unique structure, competitive binding of drugs may occur at either the same or entirely
different structural sites. For instance, the drugs that are important for albumin binding
include Warfarin (Coumadin), Digoxin, NSAIDS, Midazolam, and Thiopental. Some of
these, like Warfarin and Diazepam, compete for the same binding site. It is therefore
important to consider that hypoalbuminemia is related to higher free drug levels and vice
versa (Alpern et al., 2013; Rozga et al., 2013).
Free Radical Scavenging
Albumin contributes to antioxidant and free radical scavenging (Alpern et al.,
2013; Rozga et al., 2013). Albumin is a major source of sulphydryl groups; these "thiols"
scavenge free radicals, specifically those with a nitrogen and oxygen species, whose
cumulative effects wreak havoc on tissues and overall physiological function (Alpern et
al., 2013; Rozga et al., 2013). Albumin is known to inhibit oxygen free radical production
by polymorphonuclear leukocytes. It is capable of binding iron and copper, making them
less likely to form reactive oxygen species. The protein’s antioxidant properties are
demonstrated in the inflammatory response, carbon tetrachloride poisoning, and uremia
(Rozga et al., 2013).
Acid-Base Homeostasis
Albumin is known to play a role in plasma buffering due to the presence of many
positively and negatively charged residues on the albumin molecule (Rozga et al., 2013).
Chemically, albumin is a negatively charged protein, contributing heavily to the “anion
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gap.” This concept posits that the concentration of anions and cations in plasma should be
equal. The anion gap is calculated as AG = (Na + K)- (Cl) in (mEq/l). The remaining
anions that are added to this equation come mostly from albumin, inorganic phosphate
and hemoglobin. Therefore, in hypoalbuminemic states, the anion gap is narrowed
(Alpern et al., 2013).
Anticoagulant and Antithrombotic Effects
Although the anticoagulant and antithrombotic effects of albumin are poorly
understood, it does play a role in preventing coagulation and dissolving existing
coagulants in a Heparin-like manner by binding nitric oxide radicals, inhibiting
inactivation, and permitting a more prolonged antiaggregatory effect (Alpern et al., 2013;
Rozga et al., 2013). Additionally, albumin may inhibit platelet function through platelet
activating factor and the cyclo-oxygenase pathway. In diabetes specifically, glycosylated
albumin may increase thrombotic event and atherosclerosis incidences (Alpern, et al.,
2013; Rozga et al., 2013).
Vascular Permeability
Evidence shows that albumin may play a role in limiting the capillary bed leakage
during stress-induced increases in capillary permeability (Alpern et al., 2013; Rozga et
al., 2013). This is directly related to endothelial cell’s ability to control the permeability
of their walls and to the interstitial spaces between them. Albumin is thought to play a
role in plugging this gap or may have a repelling effect because of its overall net negative
charge (Alpern et al., 2013; Rozga et al., 2013). Rozga et al. listed albumin’s vascular
permeability functions as increasing microvascular permeability during inflammation,
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sepsis, and trauma, minimizing microvascular permeability to large molecules by
repelling negatively charged molecules or by narrowing the channels by binding to the
endothelial cells, and reducing vascular permeability by exploiting its antioxidant and
anti-inflammatory properties.
There is a marked relationship between albumin and patients with a Type II
diabetes diagnosis. Folsom, Eckfeldt, Nieto, Metcalf, & Barnes (1995) confirm this
assertion. In their study, the authors reviewed data from the Atherosclerosis Risk in
Communities Study to determine if there was a relationship between Type II diabetes
mellitus and albumin levels. The authors found that of the adult population recruited for
their study, the mean albumin concentration was .04 to .12 g/L lower in participants with
a Type II diabetes diagnosis compared to those without the disease (Folsom et al., 1995).
What is not known, however, is if similar decreases in albumin is seen in adult, Hispanic
patients on maintenance hemodialysis with the same chronic disease diagnosis.
Considering the prevalence of Type II diabetes in this population, and the number of
Hispanics that are currently receiving maintenance hemodialysis treatments due to renal
failure, a study to ascertain if a Type II diabetes diagnosis influences albumin levels in
this hemodialysis population provokes intrigue and warrants further investigation.
Type II Diabetes Mellitus
The study investigated albumin levels in the Hispanic population with a Type II
diabetes diagnosis undergoing maintenance hemodialysis. This section will briefly
describe the epidemiology, pathophysiology and endocrinology implications of this
disease to highlight the role it plays in its relationship to albumin levels and to provide
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justification for the population selected for this study. Additionally, this section will
elaborate on the population used for this study. Because the Hispanic population is deeprooted in long-standing culture and customs, behavioral, cultural, religious, and
psychosocial dimensions will be briefly presented to provide a comprehensive profile of
the Hispanic community, its culture, influences, customs, and traditions which can
broaden the understanding of and provide ample evidence for the higher prevalence of
this disease in this population.
Type II diabetes mellitus has become a serious public health epidemic in the
United States and across the globe. According to Rosal et al. (2009), by 2050
approximately 29 million Americans will be diagnosed with Type II diabetes mellitus.
The evidence exists of the impact this disease will have on population health. This
disease is especially prevalent in the Hispanic community. It is estimated that more than
20% of the U.S. Hispanic population will develop Type II diabetes by 2030 (Rosal et al.,
2009). The diabetes health issue in the Hispanic community is serious and omnipresent.
The prevalence rates of Hispanic adults with diabetes are about twice that of their white
counterparts (Centers for Disease Control and Prevention, 2005) and rapidly growing
with every passing decade. In fact, this population suffers higher rates of morbidity and
mortality related to diabetes than any other ethnicity. The unique social determinants of
health that are significant factors in the health status of this community, including
behavioral, psychosocial, and cultural aspects, are, for the most part, the underlying
culprit for this serious health issue in this community. Additionally, the strong religious
traditions, rooted in Mexican influences exacerbate this health dilemma.
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Type II Diabetes Endocrinology and Pathophysiology
Type II diabetes is a chronic metabolic disease characterized by high glucose
levels in the blood (Mahler & Adler, 1999). This occurs because of impaired regulation
of liver glucose synthesis and β-cell dysfunction and failure. The primary etiology of
diabetes is an initial deficit in insulin secretion by the pancreatic β islets of Langerhans
and insulin deficiency associated with peripheral insulin resistance. In patients with
diabetes, the absence or insufficient secretion of insulin causes hyperglycemia, which
causes numerous abnormal physiological effects and disease sequelae (Campbell, 2000;
Mahler & Adler, 1999).
A person with diabetes is defined as someone with a fasting blood sugar of
140mg/dL or higher (Mahler & Adler, 1999). Typical signs and symptoms of this disease
include polydipsia and polyuria. As excess sugar accumulates in the bloodstream, fluid is
pulled from the tissues, which can cause dehydration and producing an unusual thirst. As
a result of the increased fluid intake, urine synthesis increases and polyruria subsequently
occurs. Diabetes mellitus also triggers polyphagia since a depletion of insulin prevents
sugars from being adequately transported into cells. This endocytotic dysfunction causes
muscular and organ energy depletion, triggering the insatiable appetite. Despite eating
more than usual to try and satiate hunger, people who suffer from diabetes may lose
weight and may experience cachexia. Without the ability to metabolize glucose, the body
uses alternative fuels stored in muscle and fat (lipolysis) instead. The inordinate glucose
concentration that accumulates in the blood, therefore, exhausts and eventually
compromises glomerular filtration capacity, which allows excess glucose to seep into the
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urine. Glucosuria, therefore, is common in patients with a Type II diabetes diagnosis
(Figure 1). Additional symptoms typically seen in these patients include chronic fatigue,
irritability, frequent infections, retarded wound healing, blurred vision, retinopathy,
neuropathy, and scleroderma diabeticorum (Campbell, 2000; Mahler & Adler, 1999).

Albumin and Type II Diabetes
Global prevalence of Type II diabetes mellitus has increased dramatically over the
past two decades. According to Zakerkish, Shahbazian, Shahbazian, Latifi and Aleali
(2013), the prevalence grew from about 30 million cases in 1985 to 177 million in 2000
and 285 million in 2010. If this trend continues, by 2030 more than 360 million people
will be diagnosed with Type II diabetes mellitus. In the U.S., Type II diabetes is the
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primary cause of end-stage renal disease, non-traumatic limb amputations, and blindness
in adults. With the increasing prevalence of Type II diabetes worldwide, it is expected
that this chronic disease will remain among the primary causes of human mortality
(Zakerkish et al., 2013).
Uncontrolled Type II diabetes may gradually progress towards renal failure. One
of the first clinical symptoms of diabetic nephropathy is microalbuminuria, which
progresses to macroalbuminuria soon thereafter. This continual loss of albumin in the
urine due to kidney dysfunction is noted by a progressive loss in glomerular filtration
rate. The loss of filtration rate finally leads to end-stage renal disease, requiring
hemodialysis (Yokoyama et al., 2011; Zakerkish et al., 2013). The relationship between
albumin and Type II diabetes is clear and finite and warrants further exploration.
Zakerkish et al. (2013) sought to investigate the correlation between urine
albumin and a Type II diabetes diagnosis in a sample population (N = 350) of patients in
Iran. In their cross-sectional study, the authors examined diabetic patients attending the
Diabetes Clinic at Golestan Hospital from 2010 to 2011. Chi Square, 1-way ANOVA,
multiple logistic regression, t tests, and linear regression analyses were conducting on
study variables. The authors found that of the 350 participants, n = 72 patients (20.6%)
had microalbuminemia and n = 18 (5.1%) had macroalbuminemia and hence
albuminuria, suggesting that diabetic patients had higher prevalence rates of renal failure.
Additionally, the authors found that duration of diabetes mellitus was extended with
albuminuria (Zakerkish et al., 2013).
Hsu et al. (2011) enrolled N = 738 normoalbuminuric Type II diabetic subjects for
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a prospective cohort study. The authors aimed to reassess the association between insulin
resistance and microalbuminuria in these patients by following the patients from 20052009. Kaplan-Meier analyses and univariate Cox proportional hazards models were used
to explore associations between insulin resistance. The authors found that insulin
resistance is a strong predictor in determining the development of microalbuminuria
within 5 years for Type II diabetic patients (Hsu et al., 2011). The study demonstrates the
intimate relationship between albumin levels and type II diabetes mellitus.
Locatelli, Cavalli, Manzoni, and Pontoriero, (2011) investigated the impact of
membrane permeability on survival in incident hemodialysis patients who were
hypoalbuminemic (≤4 g/dL) and normoalbuminemic (>4 g/dL) as separate randomization
groups. In their prospective, randomized Membrane Permeability Outcome (MPO) study
the authors enrolled N = 738 hemodialysis patients from 59 European countries.
Hypoalbuminemic patients accounted for n = 567 of the study population and 171
enrollees had albumin levels greater that 4 g/dL. Statistical analyses included Kaplan
Meier and Cox proportional hazards models. After exclusion criteria, n = 647 patients
were included in the survival analysis. Patients in both groups had similar baseline
characteristics. The authors found that patients with serum albumin ≤4 g/dL had
significantly better survival rates in the high-flux membrane permeability group
compared with the low-flux group. The authors additionally considered the diabetic
patients in their population (n = 157). A post-hoc secondary analysis of the diabetic
subpopulation showed that high-flux membranes might significantly improve survival in
diabetic patients. A relative risk reduction in mortality in patients with albumin levels ≤4
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g/dL was 18.9% and 53.3% in diabetic and non-diabetic patients, respectively with high
flux membrane use. No difference was found in patients with normal albumin levels
(Locatelli et al., 2011). The comparative analysis between diabetic and nondiabetic
groups based on baseline albumin levels informed the study design for this investigation.
Yokoyama et al. (2011) conducted an observational four-year cohort study to
investigate the annual rate of glomerular filtration rate decline in association with
albuminuria progression in Type II diabetes. The authors enrolled N = 1002 subjects of
whom 699 were normoalbuminuric between 2004 and 2006. Inclusion criteria consisted
of those patients that had been treated for diabetes or hypertension. Patients who visited
the Jiyugaoka Internal Medicine clinic for at least 1 year, had more than three
measurements of serum creatinine after 2004, and who had three measurements of
urinary albumin to creatinine ratio at baseline and at follow up were eligible for
inclusion. Patients with a serum concentration of greater than 132.6 µmol/L were
excluded. Statistical analyses included linear regression model of time on glomerular
filtration rate, chi square tests to determine significance of differences between groups,
and multiple linear regression for the analysis of associations of variables with
glomerular filtration slope values. The authors reported that patients with a Type II
diabetes diagnosis and normoalbuminruria exhibited a steeper slope decline in glomerular
filtration rate compared to those without Type II diabetes (Yokoyama et al., 2011). The
methodology employed by Yokoyama et al. (2011) is noteworthy. The authors compared
diabetic and nondiabetic patients to ascertain possible glomerular filtration rate declines
and albuminuria in a Japanese population. This study similarly examined patient records

62
with and without a Type II diabetes diagnosis to identify possible albumin level
differences but in a different population.
Lorenzo et al. (2009) also examined a cohort of 333 patients with chronic kidney
disease of which 46% were diabetic. In their retrospective, longitudinal, observational
study, patients that were referred to a nephrology clinic at the University Hospital of
Canary Islands were examined for 7.5 years to clarify whether diabetes is a predictor of
more rapid decline of renal function, in patients with moderate to severe chronic renal
disease. During this period, baseline and follow up data were collected for N = 407
patients. After exclusion criteria, n = 333 patients who had more than three serum
creatinine tests sufficient to calculate the rate of decline in kidney function were included
in the study. Patient characteristics were collected from electronic medical records,
including anthropometric values, demographics, BMI, comorbidities, and smoking status.
Patients were followed until dialysis initiation, death, or loss to follow up. Baseline
laboratory tests included creatinine ratios, serum albumin, and hemoglobin. Statistical
analyses included, univariate analyses, the Chi Square test, t tests, Kaplan-Meier, and
Cox proportional hazard regression. Confirmed using a time-dependent Cox model, of
the 333 patients in the study, the results showed that at comparable levels of albuminuria,
chronic kidney disease development was similar in patients with and without diabetes
(Lorenzo et al., 2009), in stark contrast to Yokoyama et al. (2011) study outcomes and
counter to what might be reasonably expected from the research hypothesis proposed by
this study. Unlike Yokoyama et al. (2011), who’s study outcomes showed that a Type II
diabetes significantly influenced albuminuria because of decline in glomerular filtration
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rate, Lorenzo et al. (2009) found conflicting results. For their study, the results showed
that in both the diabetic and nondiabetic groups, chronic kidney disease evolved in a
similar manner. The results, however, reveal a literature chasm that this research aimed to
narrow.
The study design employed by Lorenzo et al. (2009) aligns with the proposed
study design for this research inquiry. The authors retrospectively analyzed medical
records for their population. This proposed study extends the research protocol used by
Lorenzo et al. (2009), using the same retrospective approach, the same diabetic and
nondiabetic groups, but with a different and larger sample population. The author’s
comparison of both diabetic and nondiabetic groups reflects the methodology that was
employed for this study. Data collection and analysis also reflected study protocols
employed by Lorenzo et al. (2009). For their study, serum albumin levels were examined
both at baseline and through the follow up period. Similarly, this study examined serum
albumin levels at 3 and 6 months post baseline to identify possible albumin level
differences in the study’s sample population.
Albumin and chronic kidney disease.
The relationship between albumin levels and chronic kidney disease (CKD) is
remarkable. Equally remarkable is the importance of monitoring and maintaining
normoalbuminemic levels in these patients with this chronic disease. CKD describes
abnormal kidney function and/or morphology. The definition of CKD is based on the
presence of kidney damage manifested by albuminuria or decreased kidney function
based on glomerular filtration rates. Therefore, serum albumin levels in dialysis patients
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are strong predictors of CKD and risk of mortality (Iseki, Kawazoe, & Fukiyama, 1993).
Numerous studies have studied the relationship between albumin and CKD. The
following section presents selected studies investigating this association.
Goldwasser, Kaldas and Barth (1999) investigated albumin and creatinine as
mortality predictors of survival in dialysis patients. The authors recruited 195 patients
undergoing maintenance hemodialysis. The cohort was comprised of African American,
Caucasian, and Hispanic patients all of whom had a Type II diabetes mellitus diagnosis.
The authors found that the first half-year on hemodialysis showed a 13% increase in
serum albumin levels, but showed a slow, progressive decline in albumin levels in longterm patients, correlating with patient mortality. The authors found that newly diagnosed
patients that initiated hemodialysis showed some albumin improvements within months
1-6, but long-term dialysis patients showed a progressive serum albumin level decline
(Goldwasser et al., 1999).
Leavey, Strawderman, Young, Saran, Roys, Agodoa, Wolfe and Port (2000) also
demonstrated that low serum albumin concentrations predict increased mortality in
hemodialysis patients. For this study, the authors measured cross-sectional and
longitudinal predictors of serum albumin and found that among the various predictors
serum albumin levels were significantly lower in patients with diabetes. The authors
found that various predictors such as a diabetes diagnosis were associated with serum
albumin. The Goldwasser et al. (1999) and Leavey et al. (2000) studies support the
assertion that serum albumin levels are strong predictors of mortality and are closely
associated with several exposures and chronic disease diagnoses such as diabetes. This
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underscores the reason why serum albumin should be frequently and aggressively
monitored in order to make necessary adjustments to dialysis dose, diabetic hemodialysis
diet, as well as for other therapeutic strategies. The Goldwasser and Leavey studies were
particularly informative to this investigation because the recruited populations were Type
II diabetes mellitus patients on hemodialysis and because the studies examined albumin
levels over time.
Considering the known vital functions of albumin previously discussed and the
importance of maintaining adequate levels in the blood, there are differences in serum
albumin levels amongst various ethnicities. Noori et al. (2011) assert that higher serum
albumin and creatinine and various other indices are seen in African Americans versus
Caucasians. N = 1300 patients on maintenance hemodialysis were recruited for their
prospective cohort study. Inclusion criteria included outpatients on hemodialysis from
eight Davita clinics in Los Angeles. Of these, 893 signed the IRB consent form. After,
exclusion of Asians, Indians, and those of unknown racial/ethnic background, the authors
compiled 799 total participants. Among these were n = 520 whites, of which n = 457
were Hispanics and 279 African Americans. The authors followed these patients for 6
years and found the African American group had leaner muscle mass indices, but had
higher BMI, lean body mass and mid-arm muscle circumference when compared to their
white counterparts of mostly Hispanic descent. Furthermore, this group showed higher
albumin, prealbumin, creatinine and homocysteine levels. Intriguingly, and perhaps
paradoxically, despite having poor survival indicators, the results also showed a 2.4 and
4.1 death risk in African Americans and Whites respectively, suggesting that albumin as
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well as interleukin-6 may have a protective, mitigating role in the patient’s survival in
African Americans (Noori et al. 2011).
Choi, Karter, Liu, Young, Go, and Schillinger (2011) disagree with Noori et al.
(2011). In their prospective survey study, the authors recruited diabetic patients from a
health care system in Northern California from the DISTANCE study. A large sample of
N = 20,030 subjects responded to the survey of which 3,629 individuals were excluded.
Ethnic minorities were well represented, with a larger proportion of Hispanics, Filipinos,
Asians, and African Americans. The authors found that there were 981 confirmed
incident albuminuria events in three years, with Hispanics and Asians only showing 8%
albuminuria incidence and hence a higher mortality risk. In comparison, African
Americans, Filipinos, and Asians, showed an albuminuria incidence of 11%, 10%, and
9%, respectively (Choi et al., 2011), contradicting the death risk outcomes from the Noori
et al. (2011) research findings. Both studies, although contradictory in the result
outcomes, do reflect possible differences in albumin levels across various ethnicities.
Chronic dialysis patients show significantly lower levels of serum albumin. This
is especially formidable in hemodialysis patients with a Type II diabetes mellitus
diagnosis (Iseki, Kawazoe, & Kukiyama, 1993). Iseki et al. (1993) assert that serum
albumin is a strong predictor of death in dialysis patients. In their prospective study, the
authors recruited N = 1,982 patients that had survived at least 1 year of maintenance
hemodialysis. Those that did not satisfy the inclusion criteria were removed. A cohort of
1,243 participants were recruited. Of these, 104 had died, 16 underwent renal
transplantation and 5 had been transferred. The remaining 1,222 patients were used for
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analysis. The authors reviewed the medical records and compiled a treatment profile for
each participant, including serum albumin laboratory values. In both the deceased group
and the participant group serum albumin levels were significantly lower and therefore a
strong predictor of death in maintenance hemodialysis (Iseki et al., 1993).
Similarly, Liu, Peng, Liu, Xiao, Chen, Huang, and Liu (2008) conducted a clinical
study by analyzing the clinical records of N = 514 end-state renal disease Chinese
patients. The authors sought to ascertain the level of renal function and the relationship of
renal function and serum albumin at the start of maintenance hemodialysis. The authors
retrospectively examined these records from 2001 to 2007 and found that a wide
variation existed in renal function at the initiation of hemodialysis in this population (Liu
et al., 2008). Comparably, Sridhar and Josyula (2013) also retrospectively analyzed 57
end-state renal disease hemodialysis patients. For their study, serum albumin levels were
analyzed against several independent variables. Demographic and other clinical data were
reviewed. The authors found that serum albumin had a significant correlation with serum
albumin levels. Additionally, patients with Type II diabetes also showed significant
correlations with the plasma protein. The authors confirmed that serum albumin is an
effective marker of nutrition and inflammation and can consistently predict patient
mortality. A serum albumin level of less that 3.8 g/dL confers a greater mortality risk in
end-stage renal disease hemodialysis patients and is therefore an adequate indicator of
patient prognosis and patient death (Sridhar et al., 2013).
Both the Iseki et al. (1993) and the Liu et al. (2008) studies were particularly
informative to this study. In both, the authors reviewed clinical medical records, which
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was the methodological approach used in this study. The Sridhar et al. (2013) study
demonstrates a retrospective analysis of medical records, which aligns with the type of
design used in this research study. The Iseki et al., (1993) and Liu et al., (2008) studies
demonstrate the significance of analyzing serum albumin levels in hemodialysis patients
and the impact albumin level fluctuations have, not only on subsequent hemodialysis
treatments in terms of treatment dose, duration, and frequency, but also on patient
hemodynamics and blood pressure maintenance, and muscle composition, tone and
strength. For patients with diabetes, the serum albumin levels were especially affected in
these studies and consequently the albumin clinical targets were not adequately achieved
(Sridhar, et al. 2013).
To further establish correlations and potential differences between albumin levels
among hemodialysis patients, Peacock et al. (2008) recruited N = 307 diabetic
participants of whom 258 were on maintenance hemodialysis and 49 of whom did not
have renal disease, which served as the control group. Blood samples were collected and
serum albumin levels were analyzed for all participants. Among the diabetic group with
renal disease, glycated albumin concentrations were significantly higher than those
without renal disease. The author’s prospective cohort study found that serum albumin,
compared to other measurements, more accurately reflected glycemic control in diabetic
hemodialysis patients (Peacock et al., 2008). This provides further evidence for the
association between serum albumin concentration, CKD, and Type II diabetes in
hemodialysis patients, and provided further justification for this research inquiry.
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Type II Diabetes and Chronic Renal Failure
Mahbub et al. (2013) assert that diabetes is the most common cause of kidney
failure. Approximately 180,000 people suffer from kidney failure as a consequence of
diabetes. Renal failure cases resulting from diabetes account for nearly 44% of new
cases. And, even when diabetes is controlled, the disease can lead to chronic kidney
disease and kidney dysfunction. In the U.S., about 24 million people have diabetes and
each year more than 100,000 people are diagnosed with renal failure (Mahbub, 2013).
Several studies have found an association between Type II diabetes mellitus and chronic
hemodialysis patients. The following are salient studies in the literature describing those
relationships.
Marimoto et al. (2010) reveals a relationship between Type II diabetes and
chronic hemodialysis. In their study, the authors investigated the characteristics of 43
hemodialysis patients that had survived more than 20 years of maintenance hemodialysis
in terms of their blood chemistry, chronic disease, complications, blood pressure, body
mass index, and the existence of chronic diseases such as diabetes. The participant’s
hemodialysis start dates were between 1974 and 1985 and they were followed
prospectively until they died or were still alive as of 2005. The patients were divided into
the survivor group and the deceased group. The results showed that long-term survivors
shared five common characteristics: (a) initiating hemodialysis at a young age; (b) being
diabetes mellitus free; (c) controlled cardiothoracic ratio; (d) a small decrease in weight
during the long course of treatment; and (e) being hypercholesterolemia and
hypertryglyceridemia free (Morimoto et al., 2010). Furthermore, the authors found that

70
serum albumin levels were lower in the deceased group with higher incidence of diabetes
mellitus compared to the survivor group. The study demonstrated the strong relationship
between diabetes mellitus and chronic hemodialysis. Additionally, the study also showed
a slight correlation between diabetes and albumin level decreases. This provides some
evidence that, at least in this Japanese population, a Type II diabetes mellitus diagnosis
might adversely influence albumin levels, potentially affecting patient prognosis and
mortality risk compared to their nondiabetic, hemodialysis patient counterparts.
Mahbub et al. (2013) recruited 118 patients to participate in cross sectional study
that would determine the primary etiology of their renal disease. For 9 months, the
patients were monitored and the authors found that 44.1% of the patients suffering from
renal failure was due to a Type II diabetes diagnosis. The authors concluded, even though
they had a relatively small population and was limited to a single center dialysis unit, that
diabetes is the leading cause of renal failure in hemodialysis patients (Mahbub et al.,
2013). Sattar et al. (2012) conducted a similar study, expanding on the population size
and dialysis centers used by Mahbub et al. (2013). In their HEMO Study, N = 883
diabetic patients were recruited to ascertain risk of death of these patients. The authors
found the hazard ratio for diabetes increased with each year, suggesting that risk of death
associated with diabetes in ESRD increases over time and this relationship is
underappreciated using statistical survival methods. The studies by Mahybub et al. (2013)
and Sattar et al. (2012) establish a positive correlation between renal disease and Type II
diabetes mellitus.
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Girman, Brodovics, Alexander, O’Neill, Engel, Williams-Herman, and Katz
(2011) further examined studies on patients with Type II diabetes. The authors reviewed
the Full Feature General Practitioner Research Database. This database contains current
electronic health records collected from 590 general medicine practices. A cohort of Type
II diabetes patients (n = 119, 966) and those without the disease (n = 1, 794, 516) were
sampled from the large database. The authors found, that from 2003 to 2007, acute renal
failure was 198 per 100,000 person-years in patients with Type II diabetes and only 27
per 100,000 person-years among patients without the disease. The authors concluded that
patients with a Type II diabetes diagnosis were at higher risk for renal failure compared
with patients without diabetes. This study, in particular investigated a cohort of patients
with and without a Type II diabetes diagnosis in a large population, similar to the design
that was employed in this study. To achieve statistical power, Girman et al. (2011)
established a significant relationship between Type II diabetes, renal disease, and
hemodialysis patients but with a larger population size than that employed by Mahbub et
al. (2013) and Sattar et al. (2012). The Girman et al. (2011) study, in particular informed
this proposed study about an appropriate population sample size.
The relationship between Type II diabetes and renal failure is well described in
the literature (Mihaescu et al., 2012). Renal disease is one of the most serious
complications of Type II diabetes mellitus and is the leading cause of end-stage renal
disease in the United States, requiring renal replacement therapy via various modalities
including hemodialysis. As the population of patients with a Type II diabetes diagnosis
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continues to grow, the diabetic nephropathy burden increases correspondingly (Mihaescu
et al., 2012), providing the impetus to further investigate these relationships.
Hispanic Population Dimensions
Hispanic Biological Dimensions
Biological variations are those diverse, phenotypic manifestations that exist
between people with respect to physical appearance such as skin and hair color and other
visible physical characteristics, enzymatic and genotypic variations, electrocardiographic
patterns, susceptibility to disease, nutritional preferences and deficiencies, and
psychological characteristics (Tienda & Mitchell, 2006). While it is accepted that
individuals may differ culturally, the biological differences evident among people in
various ethnic groups are rarely considered, especially for the administration of medical
care.
Comprehensive efforts to provide a description of the health and health behaviors
of Hispanics are complicated by numerous factors (Tienda & Mitchell, 2006). Hispanics
living in the United States represent an increasing diversity of national origin subgroups.
Newer groups, such as Dominicans, Salvadorans, Guatemalans, and Colombians, have
grown rapidly, adding their numbers to well-established populations of Mexican, Puerto
Rican, and Cuban origin groups. The information that is available about origin subgroups
suggests that health status differs across these subgroups. Additionally, the health of U.S.
Hispanics differs by generational status. On numerous dimensions, foreign-born
Hispanics have better health indicators than their U.S.-born counterparts. Moreover,
among the foreign-born, health status and health behaviors may differ by degree of
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American acculturation.
From this perspective, the gaps in the available data on the health and health
behaviors of Hispanics impose significant limitations. One frequent and noteworthy issue
is the lack of specific data for subgroups of Hispanics defined by national origin and
generation in the United States. Most studies categorized Hispanics into a single group or
they focus solely on Hispanics of Mexican decent, who are by far the most numerous.
The relative lack of detailed epidemiological data on the incidence and prevalence of
common and important diseases such as cardiovascular disease or Type II diabetes is yet
another important problem. Moreover, for many such conditions, data are unavailable to
assess incidence or prevalence according to immigrant status or, among the foreign-born,
by length of residence in the United States and degree of acculturation (Tienda &
Mitchell, 2006). These biological factors that exist among Hispanic subgroups are
important considerations for the diabetic and renal health statuses in patients receiving
maintenance hemodialysis.
Hispanic Behavioral Dimensions
Although a genetic etiology has been established, for some Hispanics eating
behaviors is known to trigger Type II diabetes (Tuomilehto, 2001). Poor nutritional
choices by this population exacerbate diabetes and are also linked to other related
conditions such as hypertension and renal failure. There is also strong evidence
supporting the fact that risk factors such as obesity and a sedentary lifestyle are primary,
nongenetic factors of this disease. Other behavioral risk factors include cigarette smoking
and excessive alcohol consumption (Schneiderman, 2004).
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Evidence shows that a diet high in saturated fats and low fiber content may
increase the risk of Type II diabetes (Bazzano, Serdula, & Liu, 2005). Typical Hispanic
cuisine is high in saturated fats and low in fiber content, especially those residing in
communities bordering Mexico (Ritchie, Calloway, Murphy, Receveur, Lamp, & Ikeda,
1995). Monounsaturated or polyunsaturated fats, however, appear to have a beneficial
effect on insulin activity by increasing insulin sensitivity. Another dietary factor in
developing Type II diabetes is whole grain consumption. According to Bazzano et al.
(2005), whole grain consumption provided a protective quality towards significantly
lowering the risk of developing Type II diabetes. The author showed that there was a
27% decrease risk of developing diabetes when 33 servings of whole grain foods were
consumed per week.
A sedentary lifestyle is a known risk factor for Type II diabetes (Bazzano et al.,
2005; Tuomilehto et al., 2001). The protective effects of physical activity, even if
infrequent, for the diabetic cannot be overemphasized. This physical inactivity is
especially pervasive in the Hispanic community. Increased physical activity amplifies
tissue sensitivity to insulin. Improvements in cardiorespiratory fitness and muscle
strength by engaging in at least four hours of exercise per week was found to have a
significant reduction in the risk of developing Type II diabetes (Tuomilehto et al., 2001),
and this included any type of sports, household work, gardening, or work-related physical
activity which showed similar reduction in risk. Hispanics that participated in diabetic
studies involving increased physical activity reported that having a disability, back pain,
or ankle or foot injuries limited their ability to engage in or maximize physical activity.
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Others reported that inclement weather, unsafe neighborhoods, and insufficient time were
also factors that influenced their opportunities to engage in exercise (Castillo et al.,
2010). Nevertheless, any amount of modified physical activity confirmatively showed a
reduction in both diabetic risk and Type II diabetes complications.
In the Hispanic community behavioral expression is based on customs and Latin
traditions. Young men are influenced to drink and smoke at an early age (Ritchie et al.,
1995). According to Bazzano et al. (2005), smoking may increase risk of diabetes by
causing elevated blood glucose levels, increased insulin resistance, and higher levels of
glycosylated hemoglobin than do non-smokers (Bazzano et al., 2005). Additionally,
excessive alcohol consumption contributes to excess energy intake and obesity,
disturbance of carbohydrate and glucose metabolism, and liver dysfunction. Hispanic diet
is influenced by deep-rooted customs and traditions and may often be inadequate and
deleterious to health. This is an important consideration for this study; examining
hematology profiles for this population, might identify differences in albumin levels
based on Type II diabetes.
Not only does the traditional Hispanic diet consist primarily of high fat content
and low fiber food dishes (Bazzano et al., 2005), Hispanic desserts are largely influenced
by traditional Mexican sweat bread, which largely is high in sugar content that may
potentially elevate blood glucose levels. “Panaderias,” or Mexican sweet bread
businesses, abound in Hispanic communities, making it difficult for diabetics to resist
temptation and make healthier food choices. Additionally, dietary fiber has been shown
to delay absorption of carbohydrates after a meal and thereby decreases the response to
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other dietary carbohydrates. Coupled with a low fiber diet, a diet high in sugar content
exacerbates Type II diabetes mellitus. Studies show that people who have diabetes tend to
lack enough fiber in their diet (Chaufan, Davis & Constantino, 2011). Because dietary
fiber helps slow down the rate of glucose that enters the bloodstream, it is considered a
protective agent that helps prevent diabetes. Hispanics, however, albeit erroneous,
perceive fiber consumption as mostly used for medicinal reasons, such as impaction or
other digestive complications. Access to healthy foods in Hispanic communities, as well
as access to recreational areas such as gyms or parks is limited in these communities
which makes reducing or preventing diabetes incidence in this community a challenging
endeavor (Chaufan et al., 2011).
Hispanics express their eating habits based on traditional Mexican customs
(Noble, 1991). Alimentation for Hispanics consists largely of the following regimen.
First, a light “desayuno,” or breaksfast, is served. This is followed by a lunch, or “el
almuerzo,” consisting of traditional staple foods like eggs, beans, and tortillas, which is
usually the main meal of the day. According to Mexican tradition, it is customary for
adult family members and children to come home from work or school for about two
hours to be together for this meal. “La siesta,” which is a rest period taken after lunch, is
known to be a common practice among adult Hispanics. In the early evening, “la
merienda,” a light snack of coffee and rolls or sandwiches is served. This meal is often
informal. Finally, in the evening, often as late as 9:00 p.m., “la cena,” a small supper,
concludes the day's meals (Noble, 1991). This eating regimen is not conducive of a
healthy lifestyle and reflects some of the primary risk factors that trigger Type II
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diabetes. First, the number of meals is more than the typical three-meal system adopted
by non-Hispanic individuals. Also, “la siesta” contributes to the sedentary lifestyle that
studies show leads to increased risk of diabetes (Bazzano et al., 2005; Tuomilehto et al.,
2001). Lastly, eating supper at such a late hour allows for dietary fats to be stored
viscerally while sleeping (Yurugi et al., 2012). Hispanic dietary behaviors must therefore
be considered as potentially influential when investigating this chronic disease in this
population.
Behavioral social determinants of health are largely centered on dietary issues.
Dietary behaviors are closely aligned with culture and customs in this community.
Studies show that a diabetics’ primary barrier to trying to maintain and adhere to a proper
diet is being in the presence of friends or relatives that are non-supportive; when they
indulge in foods with little or no nutritional value in the presence of the diabetic, this can
be deconstructive in their efforts to prevent weight gain (Wen, Parchman, & Shepherd,
2004). Other important dietary behaviors, influencing the health of this population are
access to healthy foods and recreational areas. The accessibility of farmers markets,
healthy food stores, parks and other recreational areas are scarce, which only exacerbates
the health issue in this population (Chaufan et al., 2011).
Hispanic Cultural and Religious Dimensions
Barriers that exist to address the health issue among Hispanics are not restricted to
behavioral dietary factors. Cultural and religious barriers also exist. For example,
Hatcher and Whittemore (2007) address the concept of “susto” as a cultural cause of
diabetes. Occurring during a specific startling event, “susto” literally means ‘‘fright of
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surprise.” Hispanic adults believe that diabetes already exists in their body, and the strong
emotional response to a startling event triggers the body’s susceptibility to diabetes.
Erroneously, to them, being overweight is protective against “susto.” In terms of religious
aspects, Hispanics’ strong affiliation and dedication to the Catholic Church and their
dutiful connection to God through prayer influences their daily life in a significant way.
Hispanics strongly believe that their priest or prayer could help with their diabetes and
therefore removes the need for subsequent doctor consultations. They believe that prayer
and religious guidance prevents stress and anxiety and allows them to adhere to their
initial treatment regimens. This, in turn, helps better cope with “susto,” which may lead
to improved diabetes outcomes (Zaldivar & Smolowitz, 1994).
Hispanic Psychosocial Dimensions
Depression is two times more prevalent among Hispanics with Type II diabetes
(Fortmann, Gallo, Walker, & Philis-Tsimikas, 2010). It is an important factor to consider
when investigating and addressing diabetes health disparities in this population.
Hispanics express the highest incidence of depression than any other ethnicity. Diabetes
and depression only intensifies adverse effects and complications such as poorer
compliance with treatment recommendations, worse glycemic control, increased diabetes
complications, and higher overall mortality rates (Fortmann et al., 2010). According to
Fortmann et al., participants in her study who reported greater self and neighborhood
support expressed less depressive episodes than those that did not have similar support
systems. Furthermore, of those that reported less depression, improved diabetes selfmanagement was seen. The authors further assert, that individuals with Type II diabetes
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who experience comorbid depression manage their diabetes less effectively, are less
socially and physically active, and are more likely to express feelings of hopelessness and
despair. These individuals report an overall dismal perception of life and their future than
their non-depressed counterparts. The impact that depression has on glycemic control and
health outcomes and the impact support systems have on disease management and
depression in this population is significant because it represents a possible direction by
which depression and health outcomes can be prevented, reduced or eliminated
(Fortmann et al., 2010).
A diabetes diagnosis provokes a grieving process with characteristic rejection or
anger responses that are typically seen in chronic illnesses. The progressive nature of the
disorder compounded by secondary complications, may add further psychological stress
(Zambanini, McIntosh, Mitchell, & Catalan, 1999). Stress hormones are released in
respond to daily work or living working conditions. Cortisol and the catecholamines
epinephrine and norepinephrine are secreted in response to these stressors. Although
these hormones provide protective effects, including maximizing muscular exertions,
sustained long term secretion of these hormones because of persistent stress can lead to a
chronic health condition such as Type II diabetes. Increased and prolonged levels of these
hormones have been correlated with increased risk of developing diabetes
(Schneiderman, 2004). Increased levels of cortisol causes adipocyte deposition deep in
the abdomen and in the coronary arteries. Visceral fat accumulation is correlated with
increase diabetes risk and fat deposition in the coronary arteries may lead to
atherosclerosis (Yurugi et al., 2012). In the Hispanic population, abdominal fat
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accumulation is expressed with larger, pear-shaped physiques. The magnitude of this
expression is evidenced by increases in angioplasty and stent procedures and other heart
related complications requiring drug interventions or surgery (Schneiderman, 2004).
Hispanic External Dimensions
The socioeconomic status of Hispanics is comparable to that of African
Americans and significantly lower than that of non-Hispanic Whites (Morales, Lara,
Kingston, Valdez, & Escarce, 2002). This is reflected in most measures of socioeconomic
status, including personal and family income, poverty rates, educational attainment, and
occupation. In 1997, for example, 26% of Hispanic and African American families lived
in poverty, compared with 7% of White families. While the median family income for all
Americans was $42,299, the median income for Hispanic families was $26,178. Among
Hispanic subgroups, socioeconomic status varies significantly. Generally, Mexicans and
Puerto Ricans are the worst off, while Cubans and South and Central Americans are the
best off. In 1997, the median family income was highest for Cubans, followed by
Mexicans and Puerto Ricans; the poverty rate was greatest among Puerto Rican families
(33%), followed by Mexican families (28%), South and Central American families
(19%), and Cuban families (13%). Educational attainment, as the proportion of the
population to go beyond high school, was greatest among Cubans (65%), followed by
South and Central Americans (63%), Puerto Ricans (61%), and Mexican Americans
(49%). Rates of occupation in high-risk/low-status occupations were highest among
Mexicans (77%), Puerto Ricans (68%), and South and Central Americans (68%), and
lowest among Cubans (53%) (Morales et al., 2002). The socioeconomic status of this

81
population may influence the ability of patients to adequately manage their diabetes and
may therefore influence albumin levels.
Summary
The ubiquity of albumin provides the body with the protein needed for growth
maintenance and tissue repair and supports the oncotic blood pressure and hemodynamics
(Brin & Christensen, 2006). For patients undergoing maintenance hemodialysis, albumin
found in the blood aids with fluid removal by drawing extra fluid from edematous tissues
back into the blood, where it can then be removed by a dialyzer (Fresenius Medical Care,
2013). Seminal research conducted by Dutrochet and Nollet laid the foundation for
filtration system dialyzers currently used for hemodialysis patients. Furthermore, Pfeffer
and van’t Hoff elucidated osmotic pressure principles that not only frame physiological
chemical and biological processes, but also govern the way dialyzers and kidney dialysis
machines filter a dialysis patient’s blood from toxins and waste products that accumulate
during the interdialytic period. As a consequence of their disease, patients with Type II
diabetes suffer renal dysfunctions ranging from renal insufficiencies to chronic kidney
disease due to the kidney’s compromised ability to filter albumin. The greater the severity
of the renal disease, the greater the decreases in albumin levels found in the blood plasma
and hence the greater the degree of albuminuria (Stoian et al., 2012). The decreased
serum albumin levels are most extraordinary in Hispanic American hemodialysis patients
with diabetes. Type II diabetes prevalence is 14% in the Hispanic population (Black,
2002). This group suffers a higher risk of mortality and microvascular complications
including renal disease. Because of the hyperglycemic filtration strain imposed on the
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kidneys and eventual glomerular destruction, albuminuria is often seen in Hispanic
patients with Type II diabetes (Choi, Karter, Liu, Young, Go, & Schillinger, 2011). As
presented in this literature review, numerous studies confirm these clinical indices and
disease trends in the Hispanic population.
This literature review has elucidated information about albumin levels in the
Hispanic population on maintenance hemodialysis. Albumin levels are lower in this
group since the incidence of diabetes is higher in this population. The higher occurrence
of renal failure and hence improper renal filtration lowers albumin levels markedly in
Hispanic, hemodialysis patients (Black, 2002). The number of Hispanics requiring
hemodialysis has consequently risen by 70% between 1996 and 2001 (Lash, Vijil,
Gerber, & Go, 2005), correlating with observations that this population is the fastest
growing demographic in the U.S. (Kanna, Fersobe, Soni, & Michelen, 2007). There
exists a paucity of literature on differences in albumin levels of Hispanic patients with
and without a Type II diabetes mellitus undergoing maintenance hemodialysis. The
differences in diabetes incidence in the Hispanic population suggest albumin levels may
also be different in this population. This literature review reveals a clear literature gap,
which this research study aimed to fill. Furthermore, not only does the identification of
potentially modifiable factors associated with albumin levels have the potential for
translational therapeutic implications, the outcomes from this study can be useful for
clinical risk stratification. Hence, this provides the opportunity to make an impactful
contribution to positive social change.
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This quantitative, cohort study employed a retrospective approach, analyzing
medical records collected and compiled at seven dialysis clinics in San Antonio, Texas.
The study evaluated possible differences in serum albumin levels in a population of
Hispanic patients receiving maintenance hemodialysis with and without a Type II
diabetes diagnosis for comparative analysis. Data were extracted and analyzed from
CMS-2728 forms on the health status and renal measures from medical records of
Hispanic patients on hemodialysis treated at Fresenius Medical Care-NA’s designated
renal dialysis clinics. The study examined associations between the outcome variable
albumin and the independent variable Type II diabetes. Chapter 3 will discuss the
methodology of this research study.
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Chapter 3: Research Method
Introduction
It is well understood that hypoalbuminemia manifests in a plethora of different
diseases and disorders (Haller, 2006; Kaysen et al., 1995). It is therefore a reliable blood
chemistry value used in a variety of settings to help diagnose disease, to monitor changes
in health status with treatment or with disease progression, and as a screen that may
indicate the need for subsequent laboratory testing. Hence, low albumin levels can reflect
diseases in which the kidneys cannot prevent a depletion in albumin in the blood due to
its leakage from the bloodstream into the urine (Girman et al., 2011).
One of the earliest signs of kidney damage is albuminuria. Albumin’s utility in
fluid dynamic maintenance in the body is well established in the literature (Haller, 2006;
Stoian, Stoica, & Radulian, 2012). Through fundamental osmotic principles and pressure
theories, the kidneys filter toxins from the blood, while glomerular membranes disallow
proteins from permeating through in order to maintain normal fluid dynamics and
homeostatic oncotic blood pressure. Physiologically, proteins should be reabsorbed in the
blood and not be allowed to escape into the urine. However, if the kidneys are damaged
or diseased, renal filtration capacity is compromised and albumin may seep into the urine
(Haller, 2006; Stoian et al., 2012).
Type II diabetes is a chronic disease that exposes the kidneys to an inordinate
amount of glucose that can damage the filtration system of the kidneys (Fukuoka et al.,
2007). The hyperglycemia exhausts the glomerular membranes, allowing albumin to seep
into the urine and thus lowering albumin levels in the blood. The disease is characterized
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by increased plasma glucose levels, which modify blood plasma proteins by a nonenzymatic reaction referred to as glycation. Protein glycation leads to formation of toxic
molecules. In diabetes, the accumulation of these toxic end products is accelerated and
contributes to pathogenesis of diabetic sequelea (Fukuoka et al., 2007).
Blood plasma proteins are the first to get modified as they are directly exposed to
higher glucose concentrations (Peakcock et al., 2008). A number of plasma proteins have
been identified. Human serum albumin, as one of most abundant plasma proteins, is
heavily glycated in diabetes. Since albumin constitutes more than 50% of plasma
proteins, any variation in levels of albumin may change the stoichiometry of glycation of
other plasma proteins’ glycation. In patients with a Type II diabetes diagnosis, albumin
synthesis and secretion is therefore decreased due to insulin deficiency. Consequently, it
can be reasonably expected that albumin levels decrease in diabetes and may affect
plasma protein glycation.
I investigated if a difference in serum albumin levels exists between adult
Hispanic patients undergoing hemodialysis treatments due to renal disease associated
with and without Type II diabetes. To test the hypothesis of possible albumin level
differences, a review of the medical records of this cohort of patients to quantify pre,
post, and peritreatment serum albumin levels was conducted. Furthermore, the study
aimed to ascertain if albumin levels continue to follow any patterns observed from
hemodialysis treatment onset to 3 and 6 months post onset.
This chapter includes an outline of the selection of study design for this
investigation, the study population and sampling decisions, data collection procedures
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and methods, and the statistical analysis planned to test the hypothesis concerning the
potential albumin level differences in adult, Hispanic patients with and without a Type II
diabetes diagnosis, undergoing maintenance hemodialysis, possible albumin level
differences that may exist within these groups, and to determine if there is an association
between serum albumin, Type II diabetes, and known predictors that may modulate
albumin levels in this sample population.
Research Design
The intent of this investigation was to ascertain potential albumin level
differences and patterns in a population of Hispanic patients undergoing maintenance
hemodialysis with and without a Type II diabetes diagnosis, and to determine if an
association between albumin levels, Type II diabetes, and known predictors exists. The
conceptual framework that underpins this study was elucidated in Chapter 1, and the
literature review presented in Chapter 2 provides further substantiation to the merit of this
study. The quantitative design of this study undertook a deductive, systematic approach,
employing statistical and computational methods of measurement to test the hypothesis
that may reveal and quantify possible differences in albumin levels (dependent variable)
in hemodialysis patients with and without a Type II diabetes diagnosis (independent
variable) (Creswell, 2009). This study was observational in nature in that there were no
interventions or manipulations of the conditions under study. The selected population was
merely observed and exposures or interventions occurred based upon their own choice
(Aschengrau & Seage, 2008).
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A cohort study is one of the most common observational and epidemiological
research designs (Thiese, 2014). Cohort studies are used to evaluate two groups from
within a defined population, one with a known exposure and the other without. These
groups are then followed prospectively for an established time period to ascertain
whether a disease occurs at a greater frequency and/or magnitude when compared to the
non-exposed group. For this study, the exposure is Type II diabetes mellitus. Cohort
studies, although common and powerful, however, cannot determine causality, but can
suggest an association or correlation (Thiese, 2014).
The research questions for this proposed research are:
Research Question 1. Is there a difference in serum albumin levels between
Hispanics with and without Type II diabetes initiating hemodialysis treatment?
HO1: There is no difference in serum albumin levels between Hispanics with and
without Type II diabetes initiating hemodialysis treatment.
HA1: Differences in serum albumin levels are observed between Hispanics with
and without Type II diabetes initiating hemodialysis treatment, (HO is false).
Research Question 2. Is there a difference in serum albumin levels over time
(baseline, 3 months, and 6 months post baseline) between Hispanics with and
without Type II diabetes following hemodialysis treatment?
HO2: No albumin level differences are observed over time (baseline, 3 months,
and 6 months post baseline) between Hispanics with and without Type II diabetes
following hemodialysis treatment.
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HA2: Albumin level differences are observed over time (baseline, 3 months, and 6
months) between Hispanics with and without Type II diabetes following hemodialysis
treatment.
Research Question 3. Is there a relationship between serum albumin, Type II
diabetes and known predictors (e.g., hypertension, peripheral vascular disease,
and infection/inflammation) that may modulate albumin levels in Hispanic
dialysis patients?
HO3: There is no relationship between serum albumin, Type II diabetes and
known predictors (e.g., hypertension, peripheral vascular disease, and
infection/inflammation) that may modulate albumin levels in Hispanic dialysis patients.
HA3: There is a relationship between serum albumin, Type II diabetes and known
predictors (e.g., hypertension, peripheral vascular disease, and infection/inflammation)
that may modulate albumin levels in Hispanic dialysis patients.
A historical, retrospective analysis of Center for Medicare and Medicaid Services
(CMS)-2728 forms and treatment records of hemodialysis patients was conducted to
address the research questions for this study. The design is consistent with the state of
knowledge in this field, as numerous studies employ a similar design and analysis model
(Dalrymple et al., 2013; Jolly et al., 2011; Lukowsky et al., 2012; Murthy et al., 2005;
Ricks et al., 2011; Ricks et al., 2012; Yan et al., 2013). Since all relevant events have
already occurred, retrospective cohort designs are generally conducted within a small
time frame at a minimal cost (Thiese, 2014). They are powerful to study rare exposures
and offer the most unambiguous determination of a temporal sequence. However, for
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historical designs, although time and cost efficient, data reliability may be compromised
since they were recorded in the past. Information about confounders may be unavailable
because they were not considered when the study was initiated. Although these factors
may pose some research challenges, the nature of a retrospective cohort design minimizes
time and resource constraints (Thiese, 2014).
Population Setting and Sample
Fresenius Medical Care-North America (FMC-NA) is the world's largest
integrated provider of products and services for individuals undergoing dialysis due to
chronic kidney failure, a condition that affects more than 2.1 million individuals globally
(Fresenius Medical Care, 2013). FMC-NA provides renal services to people throughout
the United States, Mexico, and Canada through an expansive network of more than 2,100
dialysis facilities in North America. Vascular access centers, laboratory, pharmacy and
affiliated hospitals, and nephrology practices provide individualized renal
supplementation therapies for patients. FMC-NA is also the continent's leading producer
of dialysis equipment, dialyzers and related disposable products, and is a major supplier
of renal pharmaceuticals (Fresenius Medical Care, 2013).
With appropriate permission from FMC-NA’s research department (Frenova
Renal Research) and Walden’s Internal Review Board, a request was submitted for
permission to access patient medical records at Village Oaks Dialysis Center (#8856),
Southeast Dialysis Center (#1664), Northwest Bexar County Dialysis Center (#1648),
Alamo City Dialysis Center (#8861), Central San Antonio Dialysis Center (#8855), West
Bexar Dialysis Center (#6618), and Ingram Dialysis Center (#8868) in San Antonio,
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Texas, to review the medical records of patients attending these facilities. The numbers in
parentheses are the official clinic facility numbers that will be used for identification and
reference in this study. These seven facilities are FMC-NA’s largest dialysis centers in
the San Antonio region. Patients attend these facilities triweekly for dialysis treatments.
To gain access to patient records, Frenova Renal Research required an application to be
completed. These forms included the Clinical Research Approval application and the
Governing Body Memorandum (Appendices B and C).
There are n = 125, n = 159, n =140, n = 106, n = 104, n = 97, and n = 106 patients
attending #8856, #1664, #1648, #8861, #8855, #6618, and #8868, respectively. Between
the seven facilities, there are approximately 837 cumulative patients, undergoing weekly
dialysis therapies. Of these patients, Hispanics account for approximately 65%, 75%,
75%, 95%, 95%, 98%, 85% attending #8856, #1664, #1648, #8861, #8855, #6618, and
#8868, respectively. Approximately, 75% of the Hispanic, hemodialysis facilities
receiving treatments at these facilities have a Type II diabetes diagnosis. Clinic #8856
currently has 70 diabetic patients (56%). #1664 has 115 (72%), #1648 has 92 diabetic
patients (66%), #8861 has 74 diabetic patients (70%), #8855 has 66 (63%), #6618 has 65
(67%) and #8868 has 70 (66%) diabetic patients currently on the clinics’ dialysis
schedules. While the number of diabetic patients at each facility does fluctuate slightly
over the years, overall the large Hispanic, diabetic and nondiabetic population in these
facilities at any given year provided a suitable number of medical records to access for
review.
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The study population consisted of a cohort of adult, hemodialysis patients
attending seven local dialysis facilities in San Antonio, Texas. Each facility follows the
exact dialysis treatment protocols and utilizes the same documentation system and
instrumentation provided by the clinical services department. Protocols implemented by
the clinical services department follow the National Kidney Foundation Kidney Disease
Outcomes Quality Initiative (NKF KDOQI) guidelines, which are recognized throughout
the world for improving diagnosis and treatment of kidney disease (National Kidney
Foundation, 2013).
The same data for both diabetic and nondiabetic patients were collected for each
patient from CMS-2728 forms at treatment onset and subsequently from medical records
based on their treatment schedules. For older patient records, those prior to 2012, data
were extracted from paper records. After 2012, the data were collected and amassed from
electronic medical records; the same data were extracted from both paper and electronic
records and information about how the transition between paper and electronic records
was implemented and whether there were any differences in data uniformity in terms of
the type of data collected, data documentation and entry, data compilation, and data
storage was also be presented. To ensure data collection quality control, duplicate entry
or spot checks of a small population sample (10%) at each clinic was conducted. The
sample population was randomly selected and then divided into two groups, those with a
Type II diabetes diagnosis and those without one. Stratified random sampling was
considered in this study. Statistical stratification of the data was conducted to identify
possible serum albumin patterns per individual clinic to assess possible regional
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differences in albumin levels and by gender to identify possible differences in albumin
levels between diabetic and nondiabetic men and women on maintenance hemodialysis.
Random samples are commonly used in population sampling situations when
reviewing historical data (Stat Trek, 2014). For this study, the samples that were selected
for review were assigned random sequential numbers to keep records organized and more
importantly to maintain patient confidentiality. These numbers were used solely to keep
an accurate count of records being amassed per clinic and for categorization of diabetic
and nondiabetic groups. The key feature to a random sampling strategy is that each unit
in the population has an equal probability of being selected in the sample. Random
sampling minimizes selection bias, and hence ensures obtaining a valid representative
sample (Stat Trek, 2014). A stratified random sampling will help increase the study’s
validity and veracity. By isolating strata with shared attributes or characteristics, key
population characteristics in the sample can be captured (Stat Trek, 2014). Stratified
random sampling, therefore, was a suitable strategy for obtaining and amassing samples
for this study.
As this was a retrospective analysis of data, the sampling frame consisted of a
complete case analysis for all patients that were attending the dialysis facilities. This
included those patients currently on the dialysis schedules and those that passed away,
transferred, received a transplant, and for other reasons with complete data. A listwise
deletion of patients that did not meet inclusion criteria was conducted. Inclusion criteria
consisted of hemodialysis patients with and without a Type II diabetes diagnosis that
remained in the dialysis facilities for at least six months and who had their albumin levels
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documented on CMS-2728 forms at treatment onset and subsequently in medical records.
Patients who moved away, received a transplant, changed dialysis modalities,
discontinued treatment, were transients, had an allograft rejection, or passed away before
the 6-month period were excluded from the proposed study.
The estimated sample size for this study was determined by G*Power 3.1
software. G*Power is a free, downloadable statistical analysis program commonly used
in social, behavioral and biomedical research (Faul, Erdfelder, Lang, & Buchner, 2007).
The software runs on most computer platforms, covering a wide variety of statistical
tests, power analyses, effect size calculations, and graphic options. Because this is a
quantitative, epidemiological study, G*Power 3.1 was appropriate to determine an
adequate sample size.
A small effect size of 0.2 was selected based, in part, on personal interviews with
clinical managers of each facility, which through their numerous years of experience
assert that patients with a Type II diabetes diagnosis exhibit remarkable differences in
achieving hemodialysis albumin goals compared to their nondiabetic counterparts.
Additionally, the selected effect size corresponds to KDOQI guidelines, which report
both normal and abnormal albumin clinical values. KDOQI guidelines suggest an
albumin value goal of ≥4.0 mg/dL. Furthermore, the guidelines report that a mere 0.2%
drop in albumin levels warrants albumin supplementation therapies. Additionally,
KDOQI guidelines caution that a 0.5% drop from standard normoalbuminemic values
hinders the patients from achieving prescribed hemodialysis goals and renders
unfavorable patient prognoses and overt, deleterious signs and disease sequelea
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(American Journal of Kidney Disease, 2007; National Kidney Foundation, 2002;
National Kidney Foundation, 2013a; National Kidney Foundation, 2013b), further
justifying the selected effect size. A 0.2 effect size was the most conservative estimate
that lead to larger sample size requirement.
To quantify albumin levels at two different time intervals, the absolute and
relative change was computed to compare potential albumin level changes among
patients in both groups. The intervals used to quantify albumin levels were baseline CMS
to 0 months, 0 to 3 months, 3 to 6 months, and 0 to 6 months. To compute the absolute
change in albumin levels, the albumin level value at time Interval 1 was subtracted from
the albumin level value at time Interval 2 to obtain the difference. For example, if a
patient initiated hemodialysis with an albumin level of 2.3mg/dL and after 3 months the
albumin level rose to 3.7mg/dL, then the absolute change was computed as 3.7mg/dL –
2.3mg//dL = 1.4mg/dL. The relative change was then the absolute change divided by the
albumin level value at time Interval 1 times 100. Therefore, the relative change would be
1.4mg/dL ÷ 2.3mg/dL X 100% = 60.9%. For this quantitative study, an average was
taken for all interval values and then plugged into the formulae to quantify the absolute
and relative changes for the entire sample population used for this proposed study.
By convention, an alpha level of .05, power of .80, and small effect size of 0.2
was entered in the G*Power 3.1 software. Since an ANOVA was the planned statistical
test to address Research Question 1, drop down menu settings on G*Power included the
test family, which was set to t test, the statistical test, which was set to difference between
two independent means (two groups), and type of power analysis, which was set to a
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priori computation of required sample size given α, power, and effect size. The generated
sample size for each group according to G*Power was 394, which yielded a cumulative
cohort of 788 patient records. In accordance with the G*Power results, a cohort of 788
CMS-2728 forms and treatment records was the projected sample size to address
Research Question 1. The longitudinal power analysis, which addressed Research
Question 2, was also conducted using G*Power 3.1. To address Research Question 2, the
same alpha, effect size, and power values will be inputted into G*Power. Since a repeated
measures t-test was the planned statistical test to address Research Question 2, drop down
menu settings on G*Power included the test family, which was set to t test, the statistical
test, which was set to difference between two independent means (two groups), and type
of power analysis, which was set to a priori computation of required sample size given α,
power, and effect size. The generated sample size for each group according to G*Power
was 394, which yielded a cumulative cohort of 788 patient records. In accordance with
the G*Power results, a cohort of 788 CMS-2728 forms and treatment records was
amassed to address Research Question 2. The summative cohorts, estimated by G*Power
3.1 yielded 788 cohorts to address both research questions. These calculated cohorts
provided adequate sample sizes for this study.
The intent of this research was to ascertain possible albumin level differences or
patterns in a cohort of Hispanic patients on maintenance hemodialysis. Given the rapid
growth in minority populations in the United States, particularly the Hispanic population
(Lopez, 2008), the selection of the study population was justified (Lopez, 2008). In 2002,
Hispanics became the largest minority group in this country, accounting for 14.5% of the
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U.S. population by 2005. According to the United States Census Bureau, Hispanics in
Bexar County accounted for 63.2% of the total population in 2010 (United States Census
Bureau, 2014). Furthermore, in the same year, 137,009, or 11.8% of the population, were
diagnosed with diabetes, correlating with epidemiological evidence that it is the fourth
leading cause of mortality in Bexar County (Texas Diabetes Institute, 2014). The diabetes
health disparity in this region of Texas is a grave, widespread, and omnipresent public
health issue.
The demand for health care among this population parallels its rapid growth.
Lopez et al. (2008) asserts that Hispanics in the U.S. show a higher prevalence of Type II
diabetes mellitus. The chronic nature of this disease increases the risk for developing
renal disease. As a known risk factor for renal disease, Type II diabetes incurs a higher
risk of Stage 5 chronic kidney disease on the Hispanic population, which often requires
dialysis therapy (Table 2). For this quantitative research, a retrospective examination of
CMS-2728 forms and the treatment records of a cohort of Hispanic patients on
hemodialysis that received treatments at local dialysis clinics in San Antonio, Texas was
conducted. Both diabetic and nondiabetic patients on maintenance hemodialysis that
received treatments at these clinics were reviewed to test the hypothesis that potential
albumin level differences or patterns exist between hemodialysis patients with a Type II
diabetes mellitus diagnosis and those without one. Additionally, known predictors,
albumin levels, and Type II diabetes were compared to identify possible associations that
may reveal if serum albumin is modulated by these covariables.
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Instrumentation
Upon receiving official permission from Frenova Renal Research, data were
collected from Centers of Medicare and Medicaid Services (CMS)-2728 forms
(Appendix A). The CMS-2728 government form is a validated data collection instrument
that is completed for all new patients who are initiated on dialysis. Data arising from this
form have been published in numerous studies (Dalrymple et al., 2013; Lukowsky et al.,
2012; Murthy et al., 2005; Ricks et al., 2011; Ricks et al., 2012; Yan et al., 2013). The
form captures data on sociodemographic characteristics, anthropometric measurements,
as well as comorbidities, hematology, and clinical indicators (Murthy et al., 2005).
For this study, IBM Statistical Package for the Social Sciences (SPSS) was used
for data collection and analysis. SPSS is a widely used and powerful statistical analysis
software suite that facilitates data collection and analysis (Faul et al., 2007). It is used
extensively in the social sciences for quantitative, epidemiological studies. The software
contains several modules, which provide the researcher the ability to create databases for
analysis. SPSS creates a database from which statistical treatments can be conducted
using simple drop down menu options. The analysis module capabilities include reading
and analyzing the entered data using statistical treatments such as descriptive statistics,
including cross tabulation and frequencies, and bivariate statistics, including means, ttest, ANOVA, correlation, and nonparametric tests. Additionally, SPSS generates linear
regression, multiple regression, and factor and cluster analyses. The generated data
analyses are represented via tabular and/or graphical forms (Faul et al., 2007).
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Data Collection and Management
The data for this study were extracted from both electronic and paper patient
medical records located securely at each dialysis facility. The clinical data and patient
treatment records are collected and documented by nursing personnel and patient care
technicians (PCT), including anthropometric measurements of age, weight, and height, as
well as renal indices such as BUN-serum creatinine ratios, hemoglobin A1C, lipid
profiles, and serum albumin documented at the onset of treatment. Peritreatment, in
addition to monitoring blood pressures, PCT’s draw blood to conduct complete blood
counts. Subsequent blood draws are conducted weekly by nursing personnel for
hemoglobin A1C and pre and post BUN-creatinine ratios and potassium if deemed
necessary by the nephrologist. Calcium, phosphorus, and albumin levels are collected
monthly, peritreatment. Both weekly and monthly lab tests are documented in the
patient’s medical records. Routine lab testing and reporting of monthly albumin levels
through Spectra Laboratories were reviewed from the patient’s medical records.
The primary cause of renal failure and ICD-9 codes for associated comorbidities
are documented on CMS-2728 forms and the patient’s medical records. ICD-9 codes for
the primary chronic disease and associated comorbidities (covariables) were collected to
streamline data collection and analysis. Table 1 lists the ICD-9 codes that were used for
this study. In addition to ICD-9 codes and comorbidities, this study collected data on
therapeutic management of diabetes; the data included whether the patients were on
insulin, oral medications, or both.
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Table 1
ICD-9 Codes For Independent Variable and Covariables (Comorbidities)
ICD-9 Code Ranges

Covariable (Comorbidity)

Description

250.40
250.42
25000A

Type II Diabetes

Type II Diabetes with Renal Manifestations
Type II Diabetes or unspecified type,
uncontrolled

401-405

Hypertension

440-449

Peripheral Vascular Disease

Codes with root 686,
038, 040-041,
996.62, 999.31

Infection/Inflammation

Essential Hypertension, Hypertensive heart
disease, Hypertensive chronic kidney
disease, Hypertensive heart and chronic
kidney disease, and Secondary hypertension
Atherosclerosis, aortic aneurysm and
destruction, peripheral vascular disease,
arteriole embolism and thrombosis,
atheroembolism, polyarteritis nodosa allied
conditions, disorders of arteries and
arterioles, disease of capillaries, septic
arteriole embolism
Unspecified local infection skin and
subcutaneous tissue; wound infection,
septicemia, bacterial diseases, bacterial
infection, infection and inflammatory
reaction due to internal prosthetic device and
graft, central venous catheter infection

During data collection, each CMS-2728 form was screened to ensure that all data
were complete. CMS-2728 forms with missing data such as gender, age, albumin levels,
cause of renal failure, and associated comorbidities were excluded from the data analysis
sample. Hence, a listwise deletion of the data minimized data cleaning prior to the data
analysis phase. Additionally, an Excel spreadsheet was used to compile the data extracted
from CMS-2827 forms and patient treatment records. The spreadsheet employed a
formula whereby it would flag inaccurate or erroneous data that were keyed incorrectly
during data entry. For example, normoalbuminemic range, according to KDOQI
guidlines, is 3.4 - 5.4 mg/dL (American Journal of Kidney Disease, 2007; National
Kidney Foundation, 2002; National Kidney Foundation, 2013). When an albumin value
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was keyed into the spreadsheet that was not within these parameters and therefore
incompatible with life, the value box on the spreadsheet would automatically flag the
entry in red for immediate correction. This strategy prevented the inclusion of corrupt,
truncated, or inaccurate data that were erroneous or incompatible with life. The same
procedure was applied to other variables such as gender, age, Type II diabetes diagnosis,
hypertension, peripheral vascular disease, and infection/inflammation, thus minimizing
data cleaning during data analysis. Furthermore, for quality assurance, duplicate entries
or spot checks were randomly collected on a separate spreadsheet from electronic records
for 10% of the population sample from each clinic and then further verified on treatment
record hard copies.
In order to compile comparable amounts of follow-up data for both groups,
hospital labs or clinic labs were used from CMS-2728 forms to qualify patients as End
State Renal Disease (ESRD) patients (Table 2), depending if the patient initiated
treatment at the hospital or the dialysis clinic. These labs include hemoglobin A1c,
creatinine clearances, and serum albumin levels. These documented labs were used as
baseline values to which subsequent labs were compared. Comorbidities documented on
these records were also used as baseline data. The retrospective review of medical
records captured all patient data currently attending the facilities. Patients were followed
prospectively from their treatment initiation date to 6 months into their treatment.
Between 7 clinics, approximately 15 patients are admitted each month as new
hemodialysis patients. Therefore, an approximate pool of 900 CMS-2728 forms and
treatment records were available for review. This available pool estimation amply

101
satisfied the proposed cohort of 788 records (394 per group) to address Research
Questions 1 and 2 generated by G*Power.
Data collection also captured mortality rates as well as anthropometric
information (e.g. age and height) on those records that were excluded from the sample
population. For example, patient records with missing data entries either because they
passed away, moved away, withdrew from dialysis, or that simply had no documented
reasons for treatment discontinuation, were also collected to create a comprehensive
profile of the exclusion criteria used to compile the final sample population.
Table 2
KDOQI – Chronic Kidney Disease Stages
Stage

Glomerular Filtration Rate (GFR)
mL/min/1.73m2

Description

1

≥90

Kidney damage with normal or
↑GFR

2

60-89

Kidney damage with mild ↓GFR

3

30-59

Moderate Kidney damage with
↓GFR

4

15-29

Severe Kidney damage with
↓GFR

5

<15 or on dialysis

Very severe damage; End Stage
Renal Disease

Source: National Kidney Foundation

Study Variables
Dependent Variable
The dependent variable in this study is albumin levels for each patient as
documented on CMS-2728 forms at treatment onset and subsequently in their treatment
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records. Albumin levels are documented at treatment onset and monitored peri and post
treatment as deemed necessary by the clinic nephrologists. Decreased albumin levels may
cause numerous symptoms that can affect hemodialysis treatment goals and overall
patient prognosis. Furthermore, a chronic disease process, such as Type II diabetes, may
influence albumin levels. Acutely, a drop in normoalbuminemic levels produces a
plethora of maladies including ascites or bloating in abdominal area, cramps, fatigue, loss
of appetite, pleural effusions, localized swelling, muscle weakness, and weight loss. As
the hypoalbuminemia worsens, chronic symptoms include liver problems, heart
conditions, digestive ailments, respiratory infections, and kidney dysfunction. Therefore,
measured albumin levels for each patient is the outcome variable for this study (Davita,
2014; Fresenius Medical Care, 2013). The level of measurement for this variable was
operationalized on SPSS as 0 for albumin levels <4.0 mg/dL and 1 for albumin levels
≥4.0mg/dL (Table 3).
Independent Variable
The independent variable in this study is a Type II diabetes mellitus diagnosis
with ICD-9 code 25040 and 25000A in patients undergoing maintenance hemodialysis.
Individuals with this disease can synthesize the hormone insulin normally (Campbell,
2000; Mahler & Adler, 1999). Their pancreas, however, either does not secrete enough
insulin or the body’s cells are incapable of recognizing the insulin receptor. For the latter,
the insulin resistance prevents glucose endocytosis into the body’s cells. This endocytotic
failure allows the sugar to accumulate in the bloodstream, which over time causes cellular
dysfunctions, damaging nerves and small blood vessels of the kidneys (Figure 1).
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Additionally, the hyperglycemia can cause polyuria, which can lead to severe
dehydration (Campbell, 2000; Mahler & Adler, 1999). For this study, a person with Type
II diabetes was defined as someone with a fasting blood sugar of 140 mg/dL or higher
(Mahler & Adler, 1999) and identified from the record review and final diagnosis of the
case as being Type II diabetes with renal manifestations per ICD-9 code 25040 and
25000A, documented on CMS-2728 forms (Table 1). The level of measurement was
operationalized on SPSS as Yes or No (Table 3).
Potential Confounders
There were potential confounders that were considered in this study that may have
influenced study outcomes. First, hypertension may be a potential confounder in
hemodialysis patients with Type II diabetes. Malliara (2007) asserts that the prevalence
of hypertension in hemodialysis patients is about 86%. Isolating possible differences in
albumin levels in hemodialysis patients with and without a Type II diabetes diagnosis
may be challenging in terms of determining whether the differences are due to serum
albumin differences, hypertension, or both. This extraneous variable may have influenced
study outcomes, either positively or negatively, and therefore may have resulted in
erroneous study conclusions. Hypertension was defined using ICD-9 root codes 401-405
(Table 1). These codes included: Essential hypertension (401), Hypertensive heart disease
(402), Hypertensive chronic kidney disease (403), Hypertensive heart and chronic kidney
disease (404), and Secondary hypertension (405). As this is a chronic condition, this
covariable was defined as physician diagnosed at time of initiation of hemodialysis. It
was operationalized on SPSS as, Yes = 1 and No = 0.
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A second potential confounder is peripheral vascular disease (PVD). PVD is
common in the US population. Recent prevalence estimates show 4%-12%, depending on
age and diabetes status. PVD prevalence in the dialysis population is significantly higher.
According to Plantinga et al. (2009), global and US prevalence estimates in this
population account for 25% and 28%, respectively. Consequently, PVD is a known
predictor that can influence albumin levels in patients receiving maintenance
hemodialysis. O’Hare, et al. (2002) found a negative association between serum albumin
and PVD. It is reasonable to expect that serum albumin levels may be lower as a
consequence of PVD and not because of a Type II diabetes diagnosis. Furthermore, PVD
may also lower serum albumin levels in the non-diabetic hemodialysis group, which may
skew result outcomes towards the null. PVD was defined using ICD-9 codes 440-449
(Table 1). These codes include: Atherosclerosis, aortic aneurysm and destruction,
peripheral vascular disease, arteriole embolism and thrombosis, atheroembolism,
polyarteritis nodosa allied conditions, disorders of arteries and arterioles, disease of
capillaries, and septic arteriole. This chronic disease was also defined as physician
diagnosed. It was documented as present at hemodialysis initiation and operationalized
on SPSS as, Yes = 1 and No = 0.
Another potential confounder to consider in this study is inflammation due to
infection. Inflammation is the body's response to either physical injury and/or the
invasion of foreign bodies such as bacteria or viruses (Don & Kaysen, 2004). The
inflammatory response occurs when the immune system activates white blood cells and
other immune chemicals, which sends them to the invasion or injury site. In some cases,
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the response may be acute, which manifests rapidly and may last for minutes or days.
Chronic inflammation, however, persists long-term. Because it is continually reinforced
by the release of immune system chemicals, this type of inflammation is often
omnipresent.
Inflammation is known to lower albumin levels by forcing the liver to divert
albumin synthesis towards making proteins that are necessary for the immune response
(Don et al., 2004). Furthermore, when the fractional catabolic rate is extreme, the transfer
of albumin out of the vascular compartment is increased leading to hypoalbuminemia.
Abnormally low serum albumin levels develop during an acute or chronic inflammatory
response. Acute sources of low serum albumin include bladder and gingival infections.
Potential chronic sources leading to hypoalbuminemia include lupus, inflammatory bowel
disease, arthritis, MRSA, and chronic kidney disease (Don et al., 2004).
Acutely, the study identified when and if a patient was diagnosed with an
infection. These infections were primarily skin and subcutaneous tissue infections. Other
infections included, wound infection, septicemia, bacterial diseases, bacterial infection,
infection and inflammatory reaction due to internal prosthetic device and graft, and
central venous catheter infection (Table 1). These infections may be present at
hemodialysis initiation or may manifest subsequently peritreatment and were documented
accordingly. Chronically, the infections were defined as physician diagnosed, present at
time of hemodialysis initiation, and documented on CMS-2728 forms and or treatment
records. On treatment records, this covariable was identified based on hematology results
showing a white blood cell count greater than 10.80mg/dL confirming the infection and
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with a physician diagnosis.
The “Healthy Migrant Effect” may confound the study population used for this
study. According to Fennelly (2005), first generation immigrants are often healthier than
U.S.-born residents who share similar ethnic or racial backgrounds. Over time, however,
the migrant health advantage drastically dwindles. This “paradoxical assimilation”
phenomenon has to do with the length of time that an immigrant spends in the U.S. and
correlates with increases in low birth weight infants, adolescent risk behaviors, cancer,
anxiety and depression, and general mortality (Fennelly, 2005).
Intriguingly, though, the Hispanic paradox may confound the results in an entirely
different way. For the past twenty years there has been widespread evidence of a
Hispanic paradox in the United States, in which most Hispanic groups are characterized
by low socioeconomic status, but better than expected health and mortality outcomes.
Franzini, Ribble, & Keddie (2001) assert that the paradox may be due to possible
underreporting of Hispanic deaths, the “healthy migrant effect,” and/or unique risk
profiles in this population group, including the “reverse epidemiology” phenomenon.
These factors, according to the authors, may contribute to, but do not explain, this
paradox. The reasons for this paradox, although speculative, are likely multifactorial and
social in origin (Franzini et al., 2001).
The term “reverse epidemiology” refers to associations between traditional and
nontraditional risk factors and clinical outcomes that are the opposite of those expected
from studies in the general population (Balakrishnan & Rao, 2007). A reversal in the
association is often encountered in patients with chronic illness, including those with
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advanced chronic kidney disease on maintenance hemodialysis. For this study, there is a
reasonable expectation that this phenomenon may confound study outcomes, considering
the ethnicity of the sample population and associated comorbidities. Table 3 summarizes
the variable types, variable names, potential responses, and corresponding level of
measurements for this study.
Table 3
Variables – Potential Responses and Level of Measurements
Variable Type

Variable Name

Potential Responses

Level of Measurement

Dependent

Albumin

Independent

Type II Diabetes

<4.0mg/dL = 0
≥4.0mg/dL = 1
Yes/No

Nominal with a
dichotomous response
Dichotomous

Covariable

Hypertension

Yes/No

Dichotomous

Covariable

Peripheral Vascular
Disease
Infection/Inflammation

Yes/No

Dichotomous

Yes/No

Dichotomous

Covariable

Study Limitations
The proposed study may have some potential limitations that warrant explication.
First, the data analyzed were secondary data. Although the medical records reviewed
were compiled, stored and maintained by medical professionals, the data may be
incomplete due to patient hospitalizations, patient referrals, and/or patient treatment
absenteeism. Secondary data analysis, however, can be quite advantageous in that it saves
time and money and provides access to large quantities of data at once. The data,
however, are collected by third party entities and may have been collected for reasons not
directly related to the specific study aims or research hypothesis. With permission from
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Frenova Renal Research and with Internal Review Board approval, access to patient
medical records was attained, and data were extracted and amassed to address the specific
research questions for this study.
Generalizability to other ethnic populations may also limit this study. The study
population consists of adult, Hispanics undergoing maintenance hemodialysis with and
without a Type II diabetes diagnosis. The study outcomes, therefore, may not be
generalizable to other ethnic populations. Additionally, the population is restricted to
patients attending weekly dialysis treatments at local dialysis clinics, and so excludes
patients undergoing home hemodialysis, in-patient hospital hemodialysis, or those
electing a dialysis modality not available at these clinics such as peritoneal dialysis. In
addition to this population restriction, a population sample limitation may also limit the
proposed study. To ensure internal validity, a complete data analysis at all seven clinics
was conducted with strict exclusion criteria. To ensure external generalizability, basic
anthropometric information, mortality, and hematology on patient medical records that
were excluded from the study were collected. Generalizability and sample population
restrictions are two important factors that may limit the study.
Other important considerations that may limit this study include patient phobias
and demographics. Patients lacking health insurance or that simply refuse dialysis
treatment either because of disease denial or because of doctor, needle or blood phobias
may not be included in the sample population. Therefore, the population sample may be
capturing only those that are sick that are actually attending the dialysis clinics and
excluding those that are sick and not receiving necessary treatments. Additionally, the
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clinics from which the data are collected may represent a demographic limitation in that
the community in which the clinic is located may have a higher or lower Hispanic
representation than do other similar clinics in other regions of the city. Both of these
potential limitations are considerations for this investigation.
Review of the Study Design
Research in the field of nephrology and hemodialysis primarily employs
experimental and observational study designs. This study employed an observational
approach to address the research questions. Observational studies in general can be used
to investigate the effects of a wide range of exposures, including preventions, treatments,
and possible causes of disease. This study is a cohort study, which is one of the most
common types of observational and epidemiological research models. Advantages of
observational studies such as a cohort study include providing information that explains
the causes of disease incidence and the determinants of disease progression, to predict the
future health care needs of a population, and to control disease by studying ways to
prevent disease and prolong life with disease. A strong limitation to observational studies
is the inability of the investigators to have complete control over disturbing influences or
extraneous factors. This is because a key feature of observational cohort studies is that
the investigator is disconnected from direct patient contact and instead passively collects
data without patient contact (Aschengrau & Seage, 2008), as was the case in this study.
Another important characteristic of cohort observational research designs is that they
cannot determine causality but can suggest variable associations and/or correlations; this
study aimed to show potential associations between serum albumin and Type II diabetes,
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but did not aim to show that Type II diabetes causes serum albumin differences between
diabetics and nondiabetics.
Well-designed cohort studies can provide powerful outcomes (Song & Chung,
2010). In a cohort study, an outcome or disease-free population is initially identified by
the exposure or event of interest and followed until the disease or outcome of interest
occurs. This design has the potential to provide the strongest scientific evidence because
exposure is identified before the outcome. This temporal framework, consequently, can
assess causality (Song & Chung, 2010). Cohort study designs have advantages and
disadvantages. Cohort studies are particularly advantageous for examining rare exposures
since subjects are chosen based on their exposure status. Additionally, the researcher can
examine multiple outcomes simultaneously. The need for a large sample size, the
potentially long follow-up duration, and the cost to conduct the study, are all definite
disadvantages of this design model (Song & Chung, 2010).
Cohort study frameworks can be either prospective or retrospective (Song &
Chung, 2010). Whereas prospective studies are carried out from the present time into the
future retrospective or historical studies are carried out at the present time and examine
past events. Often times this study design examines medical events or past outcomes, as
was the case for this study. For this design approach, a cohort of subjects selected based
on exposure status is chosen at the present time, and outcome data, which was measured
in the past, are reconstructed for examination. Researchers have limited control over data
collection, since the data were previously collected. Therefore, existing data may be
incomplete, inaccurate, or inconsistently measured between subjects. However, because
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the data is immediately available, this study design is comparatively less costly and
shorter in duration than prospective cohort designs (Song & Chung, 2010). A
retrospective, cohort design is therefore the most appropriate approach to answer the
research questions of this study and to test the hypotheses of potential differences in
albumin levels in hemodialysis patients with and without Type II diabetes.
A retrospective cohort study was an adequate design model to investigate the
hypothesis of whether albumin levels in two homogeneous populations of Hispanic
patients receiving hemodialysis show differences or are influenced by a Type II diabetes
diagnosis. This design type would allow the selection of a Hispanic population of
hemodialysis patients from a specific treatment start date and then examined 3 and 6
months into the course of their treatment. The patient population can therefore be
carefully selected from those that remained on maintenance hemodialysis for the full
study period in order to control missing data due to loss to follow up, transplant, death or
other inevitable reasons. Additionally, the study population size can be controlled, and
patient confidentiality can be maintained by randomly listing each patient record in
sequential order. This numbering system would be different from the 6-digit medical
records identification numbers (MRI) assigned by the clinics.
Data Analysis
After collecting the necessary data from the dialysis facilities, the compiled data
spreadsheet was uploaded into SPSS to conduct a comparison of means for all patients in
both groups. The collected data included anthropometric measurements of age, gender,
and ethnicity, associated comorbidities, including diabetes, hypertension, PVD, and
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presence of infections/inflammation, and hematology profiles, including creatinine values
and albumin levels. Descriptive univariate analysis included frequency tables for all
variables. Mean values for albumin levels at diagnosis, treatment onset, and 3 and 6
months post onset were also presented.
Research Question 1 aimed to investigate if albumin level differences existed in
Hispanics patients with and without a Type II diabetes diagnosis that are initiated on
hemodialysis. The null hypothesis (NO) is that there will be no difference in albumin
levels between both groups. The alternative hypothesis (HA) is that there will be a
difference in albumin levels between both groups. Depending on the data a simple linear
regression analysis or an ANOVA was proposed to address Research Question 1. If the
data fit the simple linear regression model, then the days that each patient came in for
dialysis treatment and had their blood drawn for albumin analysis would be the
independent variable (X-axis), and the dependent variable would be albumin level values
(Y-axis). Data permitting, linear regression analysis would allow a comparison of slopes
between both groups to determine if a difference in albumin levels exists between both
groups within a period of 6 months. The data, however, did not fit the linear regression
model; therefore, an ANOVA was conducted instead. The data met the assumptions for
the ANOVA and therefore qualified as a suitable model to test for significant differences
in means. For this study, the ANOVA was used to determine if a difference exists in
mean albumin levels between the diabetic and nondiabetic group. An alpha level of .05,
power of .80, and a small effect size of 0.1 was entered into G*Power 3.1 software. Drop
down menu settings on G*Power included the test family, which was set to t test, the
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statistical test, which was set to difference between two independent means (two groups),
and type of power analysis, which was set to a priori computation of required sample size
given α, power, and effect size. The generated sample size for each group according to
G*Power was 394, which yielded a cumulative cohort of 788 patient records. This was
the projected sample size to address Research Question 1.
For Research Question 2, the data were analyzed at 3 and 6 months post baseline;
repeated measures t tests were conducted to determine if potential differences existed in
albumin levels at these time intervals in both the diabetic and nondiabetic, hemodialysis
groups. Repeated measures designs allow the detection of within-person change over
time and typically exhibit higher statistical power (Guo et al., 2013). Repeated measures
designs are advantageous; for this study, collection of repeated measurements of key
variables can provide a more definitive evaluation of changes in albumin levels over
time. Furthermore, collecting repeated measurements can simultaneously increase
statistical power for detecting albumin level changes while minimizing the costs of
conducting the study. Research Question 2 aimed to determine if Hispanic patients on
hemodialysis, both with and without a Type II diabetes diagnosis, showed differences in
albumin levels at 3 and 6 months post initiation of hemodialysis. The null hypothesis
(HO) is that there will be no albumin level differences observed between both groups at
these intervals. The alternative hypothesis (HA) is that albumin level differences are
observed between both groups at these intervals. A repeated measures t test was a
suitable test to compare means between four time intervals in this sample population. The
intervals will be baseline CMS-0 months, 0-3 months, 3-6 months, 0-6 months. G*Power
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determined that a cumulative cohort of 788 (394 per group) medical records was required
to achieve statistical power. This statistical test and corresponding power analysis was
repeated for the nondiabetic group during the same intervals for comparative analysis.
Research Question 3 aimed to determine if there is a relationship between known
predictors hypertension, peripheral vascular disease, and infection/inflammation, serum
albumin levels, and Type II diabetes in Hispanic, hemodialysis patients that might
modulate albumin levels. The null hypothesis (HO) is that there will be no relationship
between these predictors, serum albumin, and Type II diabetes in these patients. The
alternative hypothesis (HA) is that there is a relationship between known predictors,
serum albumin levels, and Type II diabetes in both groups. In this study, co-variables
such as hypertension, PVD, and inflammation/infection are known to influence albumin
levels and were dealt with during the analysis phase. To address this research question, a
Pearson’s correlation test was selected to establish an association between the known
predictors and serum albumin levels. This decision assumed the data met the strict linear
assumption of this test. Since the data did not meet this linear assumption for this
parametric test, a nonparametric Spearman correlation was conducted instead. For this
test, the variables must be ordinal, interval, or ratio. A Pearson correlation on interval or
ratio data would be the preferred parametric test to conduct; however a Spearman
correlation can be used when the assumptions of the Pearson correlation are markedly
violated. A second assumption of the Spearman Correlation is that there is a monotonic
relationship between the variables. A monotonic relationship is an important underlying
assumption of the Spearman correlation, which is less restrictive than a linear
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relationship. All variables were modeled together using logistic regression analysis to
determine the relative contribution of each covariable in addition to the study’s
independent variable and to identify their individual relationship to the dependent
variable of albumin levels. Multiple logistic regression is the appropriate multivariate
statistical test to address this research question since the independent variable, the
covariables, and the dependent variable are all dichotomous.
Seven hundred and eighty eight medical records (394 records for each group)
were randomly selected and amassed until the final cohort was completed. The data were
extracted from the same CMS-2728 forms and patient medical records at each facility.
Data from these records included anthropometric measurements of age, weight, gender
and ethnicity, cause of renal failure, albumin levels, a Type II diabetes diagnosis, and the
presence of associated comorbidities. The collected data were transformed into
dichotomous responses for each variable of interest. Albumin levels were operationalized
as <4.0 mg/dL = 0 and ≥40 mg/dL = 1. For covariables it was Yes = 1 and No = 0, and
for Type II diabetes it was Yes = 0 and No = 1. The transformed data were uploaded into
SPSS for analysis. Univariate, bivariate and multivariate analysis were used to address
each research question.
Threats to Study Validity
There are several potential threats to validity that can impact the veracity of this
study. First, selection bias poses a serious problem in retrospective cohort studies
(Aschengrau & Seage, 2008). This occurs when the method by which subjects are chosen
is erroneous, leading to a distortion of the statistical analyses, resulting from the method
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by which samples were collected. This distortion may either underrepresent or
overrepresent an association, incorrectly favoring the null or alternative hypothesis. This
may lead to inaccurate study conclusions. The patient records selected for this study came
from a large cohort of hemodialysis patients from whom samples were randomly selected
and then grouped according to the presence or absence of a Type II diabetes diagnosis.
The selection process for this study, therefore, minimized internal validity.
Second, information bias also constitutes a threat to validity to this study
(Aschengrau & Seage, 2008). Nondifferential misclassification bias resulting from a lack
of documented information in the patient records can pose a data collection and analysis
challenge. For example, if there are missing albumin values on CMS-2728 forms or on
patient medical records either because they were missed or because they were
inaccurately recorded, then this would reflect an under representation of those data
favoring the null hypothesis. Missing data may occur if patients are hospitalized for an
extended period of time or if they are transients, in which case their travel schedules
would necessitate them attending facilities outside the regional scope of this study.
Unfortunately, this bias may not be entirely resolved except by increasing the sample size
so as to minimize the effect. The proposed sample size for this study should likely reduce
the impact of nondifferential misclassification bias.
Aschengrau & Seage (2008) assert that confounding by extraneous variables may
influence study outcomes. Covariates, such as hypertension, peripheral vascular disease,
or inflammation/infection, may lower albumin levels in hemodialysis patients in a similar
manner as would Type II diabetes mellitus. These variables cannot be excluded from
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analysis and must be dealt with to prevent erroneous statistical outcomes such as Type 1
or Type 2 errors. When comparing two means, concluding that the means were different
when in reality they were not different would constitute a Type 1 error; concluding the
means were not different when in reality they were different would constitute a Type 2
error (Banerjee et al., 2009). An effective way to deal with these covariates is through
multiple logistic regression, which will identify contributions to the outcome and
relationship to the dependent variable albumin.
Protection of Participants Rights
Data were collected from confidential patient treatment records. According to
FMC-NA’s clinical services department, new patient admissions are offered the
opportunity to permit the use of their personal health information in any future research
studies, having been informed that no personal identifiers will be included in the research
and that the nature of such research would report aggregate data outcomes only.
Additionally, the clinical services department follows HIPPA rules to ensure patient
rights. The Health Insurance Portability and Accountability Act of 1996 (HIPAA)
Privacy Rule aims to protect individually identifiable health information from uses and
disclosures that may compromise patient privacy. The HIPAA Privacy Rule provides
federal protections for personal health information that is stored by health care entities.
The rule does, however, permit the disclosure of personal health information needed for
patient care and for research purposes upon a special approval process (Fresenius
Medical Care, 2013b). The patients sign a consent form upon admission to the facility.
The patients are given the option to accept or decline the offer upon admission and are
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advised that should they decline the offer, they may at any point during their clinic tenure
reverse their declination. These forms are stored in the patient’s treatment records. For
newer patients, the medical records are in electronic form. For older patients, the records
are in paper form. In addition to being stored on one laptop that was password protected,
the data extracted from these records were compiled and stored on a flash drive and
external drive, both of which were password protected and encrypted. The laptop flash
drive and external drive containing the data were kept in a locked cabinet with restricted
access. The data will be retained and securely stored for a minimum of five years from
the end of the study, after which the data will be permanently deleted.
Summary
The purpose of the study was to explore the possibility that albumin levels in
hemodialysis patients may be mediated by a Type II diabetes diagnosis. The null
hypotheses are that there will be no differences in albumin levels between Hispanic
patients with and without a Type II diagnosis on hemodialysis, that there will be no
significant disparate differences post treatment onset, and that known predictors do not
significantly modulate serum albumin in both groups. The study design was a
retrospective cohort study conducted on a sampling of a large cohort drawn from
hemodialysis patient medical records that attended local dialysis clinics for renal therapy
in seven of FMC-NA’s largest dialysis facilities in San Antonio, Texas. A sample size of
788 patient records (394 diabetics and 394 nondiabetics) was generated by G*Power.
These records were selected randomly until a complete cohort was amassed. Data
collected from each record included anthropometric measurements, hematology profiles
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(including serum albumin levels), predictors, and whether a Type II diabetes mellitus
diagnosis was present. These data were uploaded into SPSS for analysis.
This study aimed to fill a literature gap on possible differences and patterns in
albumin levels between patients with and without a Type II diabetes diagnosis.
Hemodialysis patients are treated as a homogenous group from a clinical perspective. All
hemodialysis patients currently receive standardized hemodialysis treatments. Hispanic
patients, however, are unique in terms of behavioral, psychosocial, cultural and religious
dimensions. Neither the literature nor the clinical operating procedures implemented at
the dialysis facilities consider these nuances, so specific strategies to improve and
maintain albumin levels are nonexistent for this population. This is the gap this research
attempted to fill.
The positive social change from this endeavor is significant. In addition to
contributing knowledge and understanding to the discipline, examinations and
comparisons of albumin levels in Hispanic patients with and without a Type II diabetes
diagnosis may reveal information about specific serum albumin level patterns that may
exist in one group and not the other. These examinations may help elucidate possible
albumin improvement trends that might inform healthcare professionals about ethnicspecific nutritional supplementation or therapeutic interventions. These supplementations
and/or interventions may inform and assist dialysis healthcare professionals in improving
albumin levels to achieve dialysis goals and overall health. Chapter 4 will present the
results of this research study.
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Chapter 4: Results
Introduction
The purpose of this quantitative, retrospective cohort study was to investigate if
differences existed between albumin levels in a cohort of patients, both with and without
Type II diabetes receiving maintenance hemodialysis. The null hypotheses for this study
are that there are no differences in albumin levels in both groups and albumin patterns
will not show similar improvement clinical trends towards normoalbuminemic restoration
through the course of their hemodialysis treatments. Known predictors such as a history
of hypertension, peripheral vascular disease, and the occurrence of an infection or
inflammatory immunological response were also examined to ascertain what effect, if
any, these covariables might have towards modifying albumin levels in this population.
This chapter includes the results of this investigation.
Eight hundred and twenty-seven CMS-2728 forms and patient treatment records
of patients evaluated and treated at Fresenius Medical Care – North America were
reviewed to amass the final cohort. Records that were incomplete were excluded from
this sample. This left N = 582 records (males = 299 and females = 283) with complete
data over 6 months. Of these, the final Hispanic cohort of N = 405 patient records, (n =
281 diabetic and n = 124 nondiabetic) met the inclusion criteria for this study. A
summary of all records amassed by clinic and key variables collected for this study is
shown on Table 4.
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Table 4
Summary of Participant Characteristics by Clinic Based on Medical Records Review
1648
N = 113
M=65.3
SD=13.4

1664
N = 125
M=63.8
SD=12.6

6618
N = 61
M=64.1
SD=12.2

8855
N = 79
M=63.7
SD=12.9

8856
N = 139
M=66.9
SD=12.3

8861
N = 79
M=64.2
SD=12.5

8868
	
  
N = 80
M=64.8
SD=12.3

Weight (Kg)

(n=48)
53.9%
(n=41)
46.1%
89

(n=53)
45.3%
(n=64)
54.7%
86.3

(n=36)
60.0%
(n=24)
40.0%
76.8

(n=36)
48.0%
(n=39)
52.0%
77.1

(n=54)
54.5%
(n=45)
45.5%
85.5

(n=40)
55.6%
(n=32)
44.4%
84.7

(n=32)
45.7%
(n=38)
54.3%
88.5

Height (cm)

162.0

164.5

163.5

161.5

163.7

164.9

161.0

	
   (n=56)

	
   (n=72)

	
   (n=52)

	
   (n=68)

	
   (n=41)

	
   (n=59)

	
   (n=57)

Clinic #
Age
Gender
Male
Female

Ethnicity
Hispanic or Latino
NonHispanic or Latino

62.9%
(n=33)
37.1%

61.5%
(n=45)
38.5%

86.7%
(n=8)
13.3%

90.7%
(n=7)
9.3%

41.4%
(n=58)
58.6%

81.9%
(n=13)
18.1%

81.4%
(n=13)
18.6%

Race

	
   (n=94) 	
   (n=56) 	
   (n=72) 	
   (n=79) 	
   (n=65) 	
   (n=62)
96.6%
80.3%
93.3%
96.0%
79.8%
90.3%
88.6%
(n=1)
(n=23)
(n=3)
(n=3)
(n=19)
(n=7)
(n=8)
Black/African American
1.1%
19.7%
5.0%
4.0%
19.2%
9.7%
11.4%
(n=2)
(n=0)
(n=1)
(n=0)
(n=0)
(n=0)
(n=0)
Asian
2.2%
0.0%
1.7%
0.0%
0.0%
0.0%
0.0%
(n=0)
(n=0)
(n=0)
(n=0)
(n=1)
(n=0)
(n=0)
Native Hawaiian or Other
0.0%
0.0%
0.0%
0.0%
1.0%
0.0%
0.0%
Pacific Islander
M=3.1
M=3.0
M=2.8
M=3.2
M=3.3
M=3.0
M=3.2
CMS Baseline Albumin
SD=.69
SD=.70
SD=.73
SD=.70
SD=.66
SD=.73
SD=.79
(n=54)
(n=75)
(n=43)
(n=50)
(n=66)
(n=42)
(n=51)
Diabetic
60.7%
64.1%
71.7%
66.7%
66.7%
58.3%
72.9%
(n=35)
(n=42)
(n=17)
(n=25)
(n=33)
(n=30)
(n=19)
Nondiabetic
39.3%
35.9%
28.3%
33.3%
33.3%
41.7%
27.1%
(n=77)
(n=113)
(n=45)
(n=71)
(n=91)
(n=68)
(n=63)
Hypertension
86.5%
96.6%
75.0%
94.7%
91.9%
94.4%
90.0%
(n=8)
(n=17)
(n=7)
(n=8)
(n=8)
(n=7)
(n=6)
Peripheral Vascular Disease
9.0%
14.5%
11.7%
10.7%
8.1%
9.7%
8.6%
(n=18)
(n=26)
(n=0)
(n=15)
(n=19)
(n=11)
(n=18)
Infection/Inflammation
20.2 %
22.2%
0.0%
20.0%
19.2%
15.3%
25.7%
Note. Table reflects all records that met inclusion criteria over six months. N= 582 (males n = 299, females n = 283);
CMS is Centers for Medicare and Medicaid Services
White

	
   (n=86)
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The study population was drawn from a large cohort of records, which were
amassed from all patients (N = 827) currently attending seven dialysis clinics in San
Antonio, TX. Prior to 2014, the electronic data were collected from Proton; this was the
computer software used to collect, monitor, and store patient treatment records at these
facilities. Beginning in 2014, the electronic records were collected from eCube Clinicals.
This is the newest web-based data collection and storage software currently used by
Fresenius Medical Care – North America. All data from CMS-2728 forms were extracted
from paper treatment records. Patient data that were collected and stored prior to Proton
and eCube Clinicals integration were extracted from paper treatment records. All records
were randomly selected from each clinic by shift without replacement and then
operationalized according to age, sex, diabetic status, comorbidities, and clinic locale
until both groups were identified. The diabetic group was defined as those hemodialysis
patients with a nephrologist diagnosis on record of Type II diabetes, with a blood glucose
level at or exceeding 140mg/dL (Mahler & Adler, 1999) and with ICD-9 codes 250.40,
250.42, and 25000A (Table 1). Patients identified for the nondiabetic group were
attending hemodialysis treatments for alternative diagnoses.
Selected data elements were extracted from each record. These included
anthropometric measurements of age, race, gender, height, body weight, hematology
levels, including hemoglobin, white blood cell count, transferrin saturation, ferritin, and
serum albumin, and renal parameters, including creatinine, potassium, phosphorus, and
calcium. Data collection also included medications, comorbidities such as peripheral
vascular disease, hypertension, and infection, as well as other relevant data that would

123
help address the research questions, meet study inclusion criteria, satisfy statistical
power, and allow for future research expansion opportunities.
Power Analysis
The original proposed sample size for this study was determined using G*Power
3.1 analysis software using an alpha of .05, a power of .80, and a small effect size of .20.
This was a two-sided test and these values were based upon previous study estimates and
KDOQI guidelines (National Kidney Foundation, 2002; National Kidney Foundation,
2013a; National Kidney Foundation, 2013b). These guidelines are followed by each
dialysis facility and are the standard operating guidelines that each facility uses to
properly and uniformly dialyze patients on their treatment schedules. After the data
collection and analysis phases were complete, the proposed cohort of N = 788 (394 per
group) was not met for two reasons. First, the hemodialysis clinics are required to “thin
out” patient treatment records as the compilation of treatment records prevents the
binders from closing. These older records are sent to Iron Mountain, an off-site data
storage location, where they are stored for a negotiated period of time. Access to Iron
Mountain records is restricted to clinical managers and medical directors seeking to
verify historic patient records that exceed those stored at the facilities. Iron Mountain
charges a per record fee to the dialysis facilities interested in acquiring historic patient
treatment records stored at their facility.
Frenova Renal Research stipulated in their Research Project Approval
Application (Appendix B) that the principle investigator should not incur any additional
research-related costs to the facility because of this study. Second, continually fluctuating
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censuses at each dialysis facility, due to patients lost to follow up (n = 4), patient
transfers/transient status (n = 110), hospitalizations (n = 6), allograft rejection (n = 16),
transplantation (n = 6), or patient withdrawal/death (n = 4), placed a limitation as to
amassing the originally proposed population sample. The population sample was,
therefore, restricted to all current patients on the treatment schedule at each facility, all
deceased patients who currently had treatment records stored in the dialysis facilities, all
patients that had not received a cadaver kidney, had an allograft rejection or that had not
previously transferred in from or out to another facility beyond the scope of this research
study.
To verify power on the final population sample, a post-hoc power analysis was
conducted using G*Power software to achieve statistical power with the final cohort of N
= 405 (281 diabetics and 124 nondiabetics). On the G*Power main menu, t tests was
selected from the drop down menu under test family. The statistical test was set at Means:
Difference between two independent means (two groups). Since this was a power
analysis conducted after the analysis phase, the type of power analysis selected from the
drop down menu was Post hoc: Compute achieved power – given ∝, sample size, and
effect size. Under input parameters, a two-tailed test with a medium effect size of 0.5, ∝
= 0.05 and sample size groups of 281 and 124 were inputted, which was more suitable for
the collected data. The achieved statistical power, generated by G*Power software, was
greater than 0.99, amply satisfying the power for a medium effect size for this study
cohort.
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As outlined in Table 4, the variables were transformed into dichotomous or binary
variables. The variable gender was categorized as Male = 0 and Female = 1. Race was
operationalized as White = 1, Black/African American = 2, American Indian/Alaskan
Native = 3, Asian = 4, and Native Hawaiian or other Pacific Islander = 5. Ethnicity was
further operationalized as Hispanic = 0 and NonHispanic = 1. Patients with ICD-9 codes
25040 and 25000A, Type II diabetes mellitus with renal manifestations as their cause of
renal failure were operationalized as Yes = 0 and No = 1. Comorbidities documented on
CMS-2728 forms were operationalized as HBP_Comorbidity_Num and
PVD_Comorbidity_Num; if present at treatment initiation, then Yes = 1 and No = 0. The
comorbidity of Infection/Inflammation was defined as exceeding normal white blood cell
hematology counts of >10.80mg/dL, according to CMS-2728 forms; this comorbidity
was then operationalized as Yes = 1 and No = 0. Quantitative analysis of the absolute and
relative albumin level changes at four different intervals was operationalized as
Abs_change and Rel_change, respectively, for each of the four intervals (Table 5).
Following these conversions, the transformed data were entered into SPSS Version 21 for
analysis.
Table 5
Variables and Covariables – SPSS Measurement Level
Variable

Operationalized

Sex

Sex_Num

Ethnicity

Ethnicity_Num

Measurement
Male 0 Female 1
Hispanic or Latino 0
NonHispanic or Latino 1
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Race

Race_Num

White 1
Black/African American 2
American Indian/Alaskan Native 3
Asian 4
Native Hawaiian or other Pacific Islander 5

Renal Failure ICD-9

Diabetic_Num

Diabetes Y/N: Yes 0 No 1

Hypertension

HBP_Comorbidity_Num

Hypertension Y/N: Yes 1 No 0

Peripheral Vascular Disease

PVD_Comorbidity_Num

PVD Y/N: Yes 1 No 0

Infection/Inflammation

Infect_Num

Albumin (CMS)

Alb_CMS_Num

Albumin (0 months)

Alb_0mos_Num

Albumin (3 months)

Alb_3mos_Num

Albumin (6 months)

Alb_3mos_Num

Infection /Inflammation Y/N: Yes 1 No 0
<4.0mg/dL = 0
≥4.0mg/dL = 1
<4.0mg/dL = 0
≥4.0mg/dL = 1
<4.0mg/dL = 0
≥4.0mg/dL = 1
<4.0mg/dL = 0
≥4.0mg/dL = 1

Albumin Absolute Change

Abs_change (3mos-CMS) Interval: CMS - 0 months

Albumin Absolute Change

Abs_change (3mos-0mos) Interval: 0 months - 3 months

Albumin Absolute Change

Abs_change (6mos-3mos) Interval: 3 months - 6 months

Albumin Absolute Change

Abs_change (6mos-0mos) Interval: 0 months - 6 months

Albumin Relative Change

Rel_change (3mos-CMS)

Interval: CMS - 0 months

Albumin Relative Change

Rel_change (3mos-0mos)

Interval: 0 months - 3 months

Albumin Relative Change

Rel_change (6mos-3mos)

Interval: 3 months - 6 months

Albumin Relative Change
Rel_change (6mos-0mos) Interval: 0 months - 6 months
Note. Num was used as a categorical variable on SPSS; CMS is Centers for Medicare and Medicaid
Services; HBP is high blood pressure; PVD is peripheral vascular disease; Infect is infection/inflammation

127
Analysis
Descriptive Univariate Analysis
For the entire study cohort, the ages ranged from 22 to 96 years with a mean age
of 62.4 years and a mode of 67 years. There were 301 (53.5%) males and 262 (46.5%)
females. The vast majority of the population, 706 (85.4%) were White and of those 562
(68.0%) were of Hispanic or Latino ethnicity. Anthropometric measurements included
weight and height mean values of 82.0 Kg and 162.1 cm, mode values of 83.0 Kg and
160.0 cm, and median values of 80.1 Kg and 163.0 cm, respectively. The final study
population that met inclusion criteria was comprised of n = 281 (69.4%) diabetic patients
and n = 124 (30.6%) nondiabetic patients. Of those, n = 366 (90.4%) patients had a
history of hypertension and n = 43 (10.6%) patients were diagnosed with peripheral
vascular disease as comorbidities. Additionally, n = 74 patients (17.8%) were diagnosed
with an infection or inflammatory condition present at treatment initiation. Amongst the
Hispanics with diabetes, n = 256 (91.1%) had a history of hypertension, n = 38 (13.5%)
had PVD, and n = 45 (16.0%) developed an infection or inflammatory condition preand/or peritreatment. These findings are summarized on Figure 2. Descriptive statistics
for albumin levels at four different time intervals are listed in Table 6.

Hispanic Diabetics

Hispanic Non-Diabetic

All Hispanic

No Comorbidity
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450

405
366

400

362
331

Frequency

350
300

281

256

250
200
124

150

110

100

39

50
0

45

43

38
5

All Comorbidities

Hypertension

Peripheral
Vascular
Disease

74
29

Infection

Figure 2. Frequency of Comorbidities in Hispanic Population
Table 6
Descriptive Statistics of Albumin Levels Over Time
Time Interval

N

Albumin Level
Minimum (mg/dL)

Albumin Level
Maximum (mg/dL)

Mean

Std. Error

Std.
Deviation

Variance

CMS baseline

405

1.1

4.9

3.0243

0.03743

0.75334

0.568

0 months

405

1.7

4.5

3.4149

0.02677

0.53884

0.290

3 months

405

1.5

4.7

3.7017

0.02107

0.42406

0.180

6 months

405

2.0

4.8

3.8121

0.01981

0.39861

0.159

Note. CMS is Centers for Medicare and Medicaid Services

One-Way ANOVA
Research Question 1 seeks to determine if a difference exists in albumin levels
between diabetic and nondiabetic, hemodialysis patients. To address this research
question, a one-way ANOVA statistical test was selected to compare means between four
albumin levels at four different time intervals. An ANOVA puts all the data into one
number (F) and gives one p value for the null hypothesis. This test has several important
assumptions that must be met, two of which were used to assess the suitability to address
Research Question 1. First, there is an assumption of normality. The groups must be
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normally distributed on the dependent variable. To assess a deviation from normality, a
histogram was generated on SPSS after data collection was complete and cleaned; the
generated results did not indicate evidence of skewness, or light or heavy-tailedness
(Data not shown). Second, the inequality of the population variances was assessed by
examination of the relative size of the sample variances using a robust Levene’s test
(Data not shown). Since both the normal distribution and equal population variances
assumptions were met, the ANOVA was suitable to address Research Question 1. The
generated results between both groups are presented in Table 7.
Table 7
Statistical Analysis of Variance of Albumin Levels Between Diabetic and Nondiabetic
Patients

CMS baseline

0 months

3 months

6 months

Sum of
Squares

df

Mean
Square

F

Sig.

Between Groups

1.292

1

1.292

2.283

0.032

Within Groups

227.984

403

0.566

Total

229.276

404

Between Groups

0.469

1

0.469

1.619

0.004

Within Groups

116.83

403

0.29

Total

117.299

404

Between Groups

0.029

1

0.029

0.162

0.687

Within Groups

72.62

403

0.18

Total

72.649

404

Between Groups

0.034

1

0.034

0.211

0.646

Within Groups

64.157

403

0.159

Total

64.191

404

Note. CMS is Centers for Medicare and Medicaid Services; Underline indicates significance (p < .05)

The analysis of the data shows that the albumin levels at CMS baseline and 0
month intervals were statistically significant, 95% CI [2.9, 3.1], p < .032 and 95% CI
[3.3, 3.5], p < .004, respectively. The F statistic for the CMS baseline and 0 month
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intervals were statistically significant (CMS baseline: F = 2.283 and, 0 month: F =
1.619). The intervals at 3 and 6 months, however, were not statistically significant as
each have p values greater than 0.05 at 0.69 and 0.65 and F statistics of .162 and .211,
respectively. Hence, the albumin level mean differences at 3 and 6 months are most likely
due to chance. This demonstrates that peritreatment hemodialysis patients with and
without Type II diabetes showed a significant difference in albumin levels at time
interval CMS and 0 months. However, the patients did not continue to show similar
albumin patterns through the course of their treatment. Confirmation of the statistical
insignificance of these intervals is seen in Table 8. The upper and lower bounds 95% CI
[2.90, 3.07 and 2.96, 3.26] and 95% CI [3.33, 3.45 and 3.36, 3.57] in the CMS and 0
month intervals between both diabetic and nondiabetic groups do not overlap, thus
confirming this conclusion.
Table 8
Between Group Differences of Albumin Levels According to Diabetes Status Over Time
Minimum

Maximum

3.0714

1.30

4.60

2.9637

3.2550

1.10

4.90

2.9508

3.0979

1.10

4.90

3.3923

3.3318

3.4528

1.90

4.50

124

3.4661

3.3616

3.5706

1.70

4.40

405

3.4149

3.3623

3.4675

1.70

4.50

Diabetic

281

3.6961

3.6508

3.7414

1.70

4.70

Nondiabetic

124

3.7145

3.6254

3.8036

1.50

4.50

Total

405

3.7017

3.6603

3.7432

1.50

4.70

Diabetic

281

3.8060

3.7619

3.8502

2.00

4.80

Nondiabetic

124

3.8258

3.7463

3.9053

2.00

4.50

Total
405
3.8121 3.7732
Note. CMS is Centers for Medicare and Medicaid Services

3.8510

2.00

4.80

CMS baseline

0 months

3 months

6 months

N

Mean

95% Confidence Interval for Mean
Lower Bound

Upper Bound

Diabetic

281

2.9868

2.9022

Nondiabetic

124

3.1094

Total

405

3.0243

Diabetic

281

Nondiabetic
Total

131
Absolute and Relative Change
Research Question 2 seeks to ascertain if a difference in serum albumin levels
exists at four different time intervals between Hispanics with and without Type II
diabetes post treatment initiation. To address this question, the absolute and relative
changes in albumin levels were computed and a Spearman’s Correlation of albumin
levels at these time intervals and Type II diabetes was conducted. A repeated measures t
test was also conducted to further assess differences in albumin levels over time. The
repeated t test was selected over a repeated ANOVA in order to clearly see effects across
all four intervals (CMS baseline, 0, 3, and 6 months). Additionally, the repeated t test was
used to generate information for future larger studies; for these larger studies a repeated
ANOVA test would be ideal, as it would account for more information in variance over
all time points and would control error rate. The absolute and relative albumin level
computations for both the diabetic and nondiabetic groups and the entire Hispanic sample
population are shown in Table 9. Figures 3 and 4 illustrate these findings.
Table 9
Average Absolute and Relative Albumin Level Changes at Four Time Intervals of
Hispanic Cohort
Groups

Absolute Change Relative Change (%)

Diabetic (CMS – 0 months)

0.40

18

Diabetic (0 – 3 months)

0.29

10

Diabetic (3 – 6 months)

0.11

4

Diabetic (0 – 6 months)

0.40

14

Nondiabetic (CMS – 0 months)

0.37

17

Nondiabetic (0 – 3 months)

0.25

9

Nondiabetic (3 – 6 months)

0.10

3

Nondiabetic (0 – 6 months)

0.35

12

All Hispanic Population (CMS – 0 months)

0.39

17
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All Hispanic Population (0 – 3 months)

0.28

10

All Hispanic Population (3 – 6 months)

0.11

3

All Hispanic Population (0 – 6 months)
0.39
Note. CMS is Centers for Medicare and Medicaid Services
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0.45

Absolute Change

0.4

0.40
0.37

0.40

0.39

0.39
0.35

0.35
0.29

0.3

0.28
0.25

0.25
0.2
0.15

0.11 0.10 0.11

0.1
0.05
0

CMS

0 Months
Diabetic

Non-Diabetic

3 Months

6 Months

All Hispanics

Figure 3. Albumin Absolute Change Among Hispanics With and Without Type II
Diabetes. CMS is Centers for Medicare and Medicaid Services
20%

Relative Change (%)

18%

18%

17% 17%

16%

14%

14%

12%

12%

10%

10%

9%

13%

10%

8%
6%

4%

4%

3%

3%

2%
0%

CMS

0 Months
Diabetic

Non-Diabetic

3 Months

6 Months

All Hispanics

Figure 4. Albumin Relative Change Among Hispanics With and Without Type II
Diabetes. CMS is Centers for Medicare and Medicaid Services
Compared to the entire Hispanic cohort, the results show a greater albumin level
absolute and relative change at time interval CMS to 0 months in the diabetic group than
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any other time interval (0.40mg/dL and 18%). At the 3 to 6 month interval, the least
amount of change occurred, (0.11mg/dL and 4%). This was also true for the entire
Hispanic sample population, which showed a 0.11mg/dL and 3% absolute and relative
change, respectively.
Spearman’s Correlation
Spearman's rank-order correlation was conducted to determine if a correlation
exists between albumin levels and Type II diabetes over time. This nonparametric test
was selected because the data violated the required assumptions for the Pearson’s
Correlation test and therefore it was not a suitable model. Upon scatterplot analysis, the
data points were not normally distributed and the data showed monotonicity between the
variables at each time interval, satisfying the requirement for the Spearman Correlation
(Data not shown). A monotonic relationship exists when either the variables increase in
value together, or as one variable value increases, the other variable value decreases. The
results showed a strong, positive correlation between albumin levels at all four intervals
and Type II diabetes. In terms of the direction of the correlation, a Type II diabetes
diagnosis influenced albumin levels over time. In terms of the magnitude of the
correlation, both the CMS baseline and the 0 month intervals showed the highest
correlation value (r = .723), followed by the 3 and 6 month intervals (r = .629). A more
moderate correlation was noted between the 0 and 6 month interval (r = .441). All
intervals were statistically significant as denoted by the asterisks and a p < .000 (Table
10).
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Table 10
Spearman Correlation for Albumin Levels at Four Intervals
Diabetic Status
Diabetic Status

CMS baseline

0 months

3 months

6 months

CMS baseline 0 months

3 months 6 months

Correlation
Coefficient

1

0.082

0.08

0.072

0.063

Sig. (2-tailed)

.

0.098

0.11

0.149

0.209

N
Correlation
Coefficient

405

405

405

405

405

0.082

1

.723**

.447**

.297**

Sig. (2-tailed)

0.098

.

0.000

0.000

0.000

N
Correlation
Coefficient

405

405

405

405

405

0.08

.723**

1

.629**

.441**

Sig. (2-tailed)

0.110

0.000

.

0.000

0.000

N
Correlation
Coefficient

405

405

405

405

405

0.072

.447**

.629**

1

.689**

Sig. (2-tailed)

0.149

0.000

0.000

.

0.000

N
Correlation
Coefficient

405

405

405

405

405

0.063

.297**

.441**

.689**

1

Sig. (2-tailed)

0.209

0.000

0.000

0.000

.

N
405
405
405
405
405
** Correlation is significant at the 0.01 level (2-tailed); Note. CMS is Centers for Medicare and
Medicaid Services

Repeated Measures t test for Albumin Levels
Repeated measures analysis can be used to assess and serially measure changes
over time in an outcome variable. This test is also used to test for differences in one or
more treatments based on repeated assessments in the same subjects. To address
Research Question 2, a repeated measures t test was conducted to determine if albumin
level differences exist over time in hemodialysis patients with and without Type II
diabetes. Because albumin levels were examined over four different intervals and
because the examination was conducted on a cohort of subjects who’s serum albumin
were serially measured and compared, this statistical test fits the model to address
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Research Question 2. A regression analysis with the variable time integrated into the
model, although quicker, would not show specific potential albumin level decreases in
patients. Furthermore, a regression model assumes a linear relationship between the
outcome variable and the independent variable. Albumin level changes over time differ
among patients; in some patients, albumin levels may initially increase and then decrease
over time, and in some patients the opposite effect is observed. Furthermore, in some
patients albumin levels remain relatively constant from dialysis onset over the course of
their treatment therefore albumin levels do not follow a linear trend. The repeated
measures t test was used to generate information for future larger cohort studies for which
a regression model would be ideal, as it would account for more information in variance
over all time points. For this study, repeated measure t tests provide very specific albumin
level data points over time and therefore, although a bit more time consuming, were ideal
for this study. These values serve as useful clinical indicators vital for patient care. The
results of the repeated measures t tests of albumin levels at four different time intervals,
CMS – 0 months, 0 – 3 months, 3 – 6 months, and 0 – 6 months are shown in Tables 1118.
The patients in the diabetic group had a Type II diabetes diagnosis (ICD-9 code
25040 and 25000A) as either cause of renal failure or as an associated comorbidity. For
the diabetic group (n = 281) CMS to 0 month interval, the difference in albumin means
was -0.41, 95% CI [-0.46, -0.35], suggesting that the albumin levels decreased from the
time the patients were hospitalized and diagnosed with renal failure to when they initiated
treatment at the dialysis treatment centers. The correlation was significant, (p < .000) at

136
0.730. Table 11 shows a significant 2-tailed paired samples t test at (p < .000) and an
upper and lower 95% confidence interval of the difference that does not include the value
of 0, confirming the significance.
Table 11
Repeated Measures t test: CMS – 0 Months (Diabetic Group)

Std.
Deviation

Mean

Paired Differences
Std. Error
95% Confidence Interval of
Mean
the Difference

Lower
CMS baseline
0 months
-0.40544
0.49253
0.02938
-0.46328
Note. CMS is Centers for Medicare and Medicaid Services

t

df

Sig. (2tailed)

280

0.000

Upper
-0.34761

-13.799

For the 0 to 3 month interval, the diabetic population (n = 281), the difference
between both means was significant (p < .000) at -0.3, 95% CI [-0.35, -.026], suggesting
that peritreatment the albumin levels were improving through the course of their dialysis.
The correlation was significant (p < .000) at 0.615. The upper and lower bounds of the
95% confidence interval of the difference did not include the value of 0, thus confirming
this result (Table 12).
Table 12
Repeated Measures t test: 0 Months – 3 Months (Diabetic Group)

0 months
3 months

Mean

Std.
Deviation

Paired Differences
Std. Error
95% Confidence Interval of the
Mean
Difference
Lower
Upper

-0.30381

0.40840

0.02436

-0.35177

-0.25585

t

-12.470

df

Sig. (2tailed)

280

0.000

For the 3 to 6 month interval, the diabetic population (n = 281), the difference
between both means was significant (p < .000) at -0.11, 95% CI [-0.15, -0.07], suggesting
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that peritreatment the albumin levels continued to improve, albeit not as markedly as the
0 to 3 month interval, through the course of their dialysis. Comparing the two mean
differences (-0.30 and -0.11) at the 0 to 3 month and the 3 to 6 month intervals,
respectively, although significant, suggests the albumin level changes were not as
pronounced through the course of their treatment and therefore improvement trends
decreased slightly during that time interval. The correlation at the 3 to 6 month interval
was significant (p < .000) at 0.598. Additionally, the upper and lower bounds of the 95%
confidence interval of the difference did not include the value of 0, thus confirming this
result (Table 13).
Table 13
Repeated Measures t test: 3 Months – 6 Months (Diabetic Group)

3 months
6 months

Mean

Std.
Deviation

Paired Differences
Std. Error
95% Confidence Interval of the
Mean
Difference
Lower
Upper

-0.10996

0.34159

0.02038

-0.15008

-0.06985

t

-5.396

df

Sig. (2tailed)

280

0.000

To achieve a more comprehensive albumin profile, the 0 to 6 month interval was
also tested. For the diabetic group at this interval (n = 281), the difference between both
means was significant (p < .000) at -0.41, 95% CI [-0.47, -0.35], suggesting that
peritreatment the albumin levels showed an improvement trend. This trend reflected the
improvement trend of the CMS to 0 interval. The computed mean difference between
these two intervals was a mere -.01, 95% CI [-0.47, -0.35], suggesting that at this larger
interval albumin trends demonstrated similar improvement patterns as when they were
first initiated on dialysis. The overall trend at this larger interval suggests that
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improvement patterns throughout the entire 6-month course of their treatment were
increasing. The slight acceleration noted between the CMS to 0 and the 0 to 3 month
interval may be due to the newly prescribed, vigorous and effectual dialysis treatments,
which would begin to effectively remove the excess fluid collected in their body because
of their renal failure. At the 0 to 6 month interval, the correlation was significant (p <
.000) at .399. Furthermore, as shown in Table 14, the upper and lower bounds of the 95%
confidence interval of the difference did not include the value of 0, thus confirming this
result.
Table 14
Repeated Measures t test: 3 Months – 6 Months (Diabetic Group)

Mean
0 months
6 months

-0.41377

Std.
Deviation

0.50197

Paired Differences
Std. Error
95% Confidence Interval of the
Mean
Difference

0.02994

Lower

Upper

-0.47272

-0.35483

t

-13.818

df

Sig. (2tailed)

280

0.000

The repeated measures statistical treatment was also applied to the nondiabetic
group for comparative analysis. First, the CMS to 0 interval was conducted on the
nondiabetic subpopulation (n = 124). The results showed a significant (p < .000)
correlation value of 0.764. The mean difference was -0.36 with a lower and upper bound
values that did not include the value of 0, 95% CI [-0.45, -0.26]. The 2-tailed test was
significant at p < .000 (Table 15).
Table 15
Repeated Measures t test: CMS – 0 Months (Nondiabetic Group)
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Mean

Std.
Deviation

Paired Differences
Std. Error 95% Confidence Interval of the
Mean
Difference

CMS baseline
0 months
-0.35677 0.53009
0.0476
Note. CMS is Centers for Medicare and Medicaid Services

Lower

Upper

-0.451

-0.26255

t

-7.495

df

Sig. (2tailed)

123

0.000

The results of the repeated measures t test at the 0 to 3 month interval are shown
on Table 16. The mean difference was -0.25, which was lower than the CMS to 0
interval. This smaller difference suggests that, although significant at p < .000, albumin
level changes were not as marked as the previous interval. The correlation value of 0.738
was significant at p < .000. The 95% confidence interval of the difference did not include
the value of 0, CI [0.32, -0.18], thus confirming the statistical significance.
Table 16
Repeated Measures t test: 0 Months – 3 Months (Nondiabetic Group)

Mean
0 months
3 months

-0.24839

Std.
Deviation

0.40233

Paired Differences
Std. Error 95% Confidence Interval of the
Mean
Difference

0.03613

Lower

Upper

-0.3199

-0.17687

t

-6.875

Sig. (2tailed)

df

123

0.000

The mean difference at the 3 to 6 month interval (n = 124) dropped to -0.11, 95%
CI [-0.16, -0.06]. A similar drop in mean differences was noted in the diabetic group (0.11). This slightly lower value noted in the diabetic group, suggests that for these data a
diabetes diagnosis might be, at least in part, slightly lowering albumin levels compared to
the nondiabetic group. The correlation value at this interval was significant (p < .000) at
0.853. Correspondingly, the 95% confidence interval of the difference, CI [-0.16, -0.06]
did not include the value of 0, thus confirming the results (Table 17).
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Table 17
Repeated Measures t test: 3 Months – 6 Months (Nondiabetic Group)

Mean
3 months
6 months

-0.11129

Std.
Deviation

0.26264

Paired Differences
Std. Error
95% Confidence Interval of the
Mean
Difference

0.02359

Lower

Upper

-0.15798

-0.0646

t

-4.719

df

Sig. (2tailed)

123

0.000

Lastly, the 0 to 6 month time interval (n = 124) provided an expanded timeline to
analyze albumin levels. The data generated from this test in the nondiabetic group served
as the comparison group for the diabetic group. The difference in mean values between
the diabetic group and the nondiabetic group were -0.41 and -0.36, 95% CI [0.45, -0.27],
respectively. The slightly higher value in the diabetic cohort suggests albumin levels
differences were slightly more pronounced than those in the nondiabetic cohort. It’s
reasonable to suggest that this higher value may be due to some degree to having Type II
diabetes. The correlation at this larger interval was significant (p < .000) at 0.544. The
95% confidence interval of the difference was CI [-0.45, -0.27] and did not include the
value of 0, confirming the significance of the statistical treatment (Table 18).
Table 18
Repeated Measures t test: 0 Months – 6 Months (Nondiabetic Group)

Mean
0 months
6 months

-0.35968

Std.
Deviation

0.50973

Paired Differences
Std. Error
95% Confidence Interval of the
Mean
Difference

0.04578

Lower

Upper

-0.45029

-0.26907

t

-7.857

df

Sig. (2tailed)

123

0.000
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Strong, positive correlation values in both groups coupled with p values less than
.05, suggests that in this population a Type II diabetes diagnosis may modulate albumin
levels in hemodialysis patients. The slightly higher mean differences at the larger time
interval in the diabetic group suggests that albumin level changes are slightly more
pronounced, revealing that albumin level patterns, albeit nuanced, are different between
both groups. The albumin level patterns seen at three different intervals are summarized
in Figure 5. The separation between the diabetic group (blue) and the nondiabetic group
(red) at the CMS and 0 month interval confirms the results of the repeated measures t
tests. Also in alignment with the repeated measures t test, the latter intervals of 3 and 6
months show trend lines demonstrating similar improvement trends. Both trend lines
gradually approach each other and plateau at the 6-month time interval, suggesting that
improvement trends in the diabetic group were normalizing faster in order to reach

Albumin Level (mg/dL)

normoalbuminemic levels similar to the nondiabetic group.
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Figure 5. Albumin Level Differences Between Diabetic and Nondiabetics. CMS is
Centers for Medicare and Medicaid Services
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Stratified Analysis of Albumin Levels
The sample data were stratified to investigate whether any interaction occurred
within specific strata that may not be appreciable in the entire cohort. First, the data were
“split” on SPSS according to gender and the previous statistical tests were conducted to
determine if albumin level differences mirrored or deviated from those of the whole
Hispanic cohort. A new post-hoc power analysis was generated using G*Power software
to determine power with the new strata. Each post-hoc power analysis amply satisfied
statistical power for the study. Generated descriptive statistics showed 215 males and 190
females total in each strata. In the male stratum, there were n = 147 and n = 68 patient
records in the diabetic and nondiabetic group, respectively. Post-hoc power analysis for
the male stratum was (Power > 0.99, effect size = 0.5, alpha = 0.05). The female stratum
had n = 134 and n = 56 diabetic and nondiabetic records, respectively. Post-hoc analysis
for the female stratum was (Power > 0.99, effect size = 0.5, alpha = 0.05). The stratified
ANOVA revealed there was no difference in the mean albumin values between males and
females. p values for males were .522, .666, .685, and .475 and .137, 171, .916 and .846
for females, all of which fall above the standard p < .05 demarcation, which confirmed
this conclusion. Furthermore, the results did not reflect the outcome from the entire
Hispanic cohort since both the CMS to 0 months and 0 to 3 month intervals were
statistically significant in that test.
A Spearman correlation was run to determine if a significant correlation exists
within strata. The results reflected that of the entire cohort. Albumin levels at each time
interval showed significant 2-tailed correlation at .01. Whereas the p values in the
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original unstratified Spearman Correlation showed a strong correlation value of p < .000,
within these strata, a slight increment (p = .002) in the correlation between the CMS
baseline and 6 month interval was observed in the male stratum.
For the repeated measures t test, the strata were comprised of n = 147 male
diabetics and n = 134 female diabetics. These strata generated sufficient power for
analysis (Power = .99). The significance values at each time interval were essentially
identical to the original test in the diabetic group at p < .000. All other intervals showed
significant values of p < .000; the only remarkable interval was the 0 to 6 month interval
in the male stratum, which showed a p value of .001.
When the test was repeated for the nondiabetic group, the results were similar.
The n value to qualify for this group decreased within each stratum (n = 68 males and n =
56 females). The post-hoc power analysis generated a value of 0.78, which is sufficient
power with medium effect size of .50 to warrant further analysis. Overall, the tests were
identical to the original repeated measures t test, except for the 3 to 6 month time interval
in the female stratum, which revealed a significant .014 p value.
After running a post-hoc power analysis for the stratified multiple logistic
regression analysis, there was insufficient power between both groups and associated
comorbidities (Power = 0.47). Since G*Power generated insufficient power, further
analysis was not conducted.
Next, the data were split by clinic locale to determine if albumin levels differed
within clinics. Since each clinic is located in a different region and represents a different
demographic of San Antonio, the same statistical tests were conducted to identify
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potential albumin level differences in each San Antonio region. For four consecutive
weeks, the medical records at seven dialysis clinics were accessed with prior IRB and
Frenova Renal Research approval. Data were extracted from each record and amassed on
spreadsheets. The seven dialysis clinics are no more than 20-30 minutes away from each
other; their proximity facilitated access and minimized driving time between clinics in
order to easily verify data that were incomplete, inaccurate, missing, or pending. The four
weeks entailed diligently analyzing medical records and amassing the necessary data to
conduct the study. The data were collected daily for 6-16 hours a day including weekends
until all electronic and paper medical records in each facility were reviewed and
necessary data extracted for analysis. The one-way ANOVA test showed that of the seven
clinics, only clinic 8861 showed significance at the 3 and 6 month interval (p < .005),
with insufficient power generated by G*Power (Power = 0.45). This clinic is located in
downtown San Antonio, so is a centralized location with a predominately Hispanic and
Black population and a mean age of 63.2 years, which is the second lowest among the
seven clinics. This was the only remarkable difference from the ANOVA run for the
unstratified cohort.
The repeated measures t tests for the original cohort revealed strong correlation (p
< .05) for each interval for both groups. In the stratified analysis repeated measures t tests
there were some remarkable differences from the original unstratified analysis. First, in
the diabetic group the CMS to 0 month interval showed identical significant correlation
and significant 2-tailed values except in clinic 6618 which showed a correlation value of
.002. This clinic is located on the west side of San Antonio, which is predominately a
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Mexican population and Hispanic Americans of Mexican decent. Second, in the 0 to 3
month interval, only clinic number 8855 (n = 46) showed a 2-tailed p value for the paired
samples test of .018 that was different from the unstratified cohort. This significant value
was generated with sufficient power (Power = .66). Third, both the 3 to 6 month and the
0 to 6 month intervals showed differences in significant values for both correlation and
paired samples t tests. Clinics 1664 (stratum = 53), 8855 (stratum = 46), and 8868
(stratum = 42 showed significant 2-tailed p values of .033, .003, and .025, respectively,
with sufficient power (1664 power = 0.72, 8855 power = 0.66, and 8868 power = 0.63)
for a medium effect size. Clinics 1648, 8856, and 8861 were not significant (p > .05) at
this time interval (p value = .232, .942 and .186), respectively. Although the sample size
for both strata were smaller than the original unstratified cohort, (n = 147 for males and n
= 134 for females), the generated power for this analysis was amply achieved by
G*Power.
Lastly, at the larger time interval 0 to 6 months, clinics showed significant 2tailed paired test p < .000. Clinics 1648, 1664, 1618, 8855, 8856, 8861, and 8868 showed
significant correlation values of .001, .001, .004, .060, .002, .073, and .004, respectively;
these values were all significant except clinics 8855 and 8861. The pair samples t test
values at a 95% confidence interval, stratified by seven clinics overall showed statistical
significance (p < .000). Amongst the groups, the smallest stratum (n = 28) did not satisfy
statistical power (Power = .45) and therefore further stratified analysis on this clinic was
not further investigated.
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Next, SPSS was used to filter the nondiabetics and the cases were again split to
report on individual clinics. None of the clinics generated sufficient power on G*Power
to warrant stratification analysis. Since clinic 8861 had the largest strata from this group
(n = 23), it was used as the threshold to determine power. G*Power generated 0.32 as the
statistical power, which meant none of the other clinics would generate sufficient power
to warrant further stratification analysis.
After running a post-hoc power analysis for the Spearman correlation, only clinic
8856 (strata = 28) did not retain sufficient power for analysis (Power = 0.45). The six
remaining clinics qualified with sufficient power to warrant further analysis. Clinics
1648, 8855, 8856, 8861 had significant correlation values of p < .000, which was
comparable to the original Spearman Correlation test run for the unstratified cohort.
Three clinics showed correlation values that were not statistically significant and this
result was not seen in the unstratified test; clinic 1664, 6618, and 8868 had p values of
.246, .772, and .183 at the CMS to 6 month interval. Clinics 6618 also had correlation
values at the CMS to 3-month interval that were not significant (p = .276.). Similarly,
clinic 8868 had a correlation value of .234 that was not significant at the 0 to 6 month
interval. The six clinics that qualified for stratified analysis showed strong, positive
correlations between albumin levels and Type II diabetes at each time interval.
In the nondiabetic group, the minimum stratum size was n = 23. After running a
post-hoc power analysis for the Spearman Correlation analysis for the nondiabetic group
stratified by clinic locale, there was insufficient power generated by G*Power (Power =
.38), so further analysis was not pursued.
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Multiple Logistic Regression
Logistic regression was carried out to assess the interrelationships and the relative
contributing strengths and probabilities for each of the covariables (predictors) that could
potentially modify albumin levels over time in this study population. Research Question
3 aims to investigate if patients with and without a Type II diabetes diagnosis and
associated comorbidities such as hypertension, peripheral vascular disease, and
infection/inflammation, might modulate albumin levels in hemodialysis patients. As
presented in the stratified analyses, gender was a demographic consideration, but was not
controlled for in the regression analysis because G*Power generated insufficient power
(Power = .74) after introducing it into the model. Additionally, age was not controlled in
this analysis for similar reasons. The mean age was nearly identical (Average M = 64.7
years) across the board for each clinic, as was educational level and employment for each
clinic and therefore were not included in the model. For this analysis, the independent
variables were operationalized and uploaded onto SPSS for analysis and retained in all
iterations to assess the relative contribution at each time interval. Diabetic patient records
with one or more of these covariables were transformed into dichotomous variables, yes
or no. The dependent variable albumin was transformed into binary variables of 0 if the
values were <4.0mg/dL and 1 for albumin values ≥4.0mg/dL. These cut off values were
based upon KDOQI clinical guidelines, which recommend a target albumin level of
≥4.0mg/dL, which is consistent with optimal cardiovascular and renal function. Tables 19
-22 illustrate the final results of this test at each time interval.
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Each regression analysis model had 405 total records. For the CMS baseline time
interval, n = 359 (88.6%) patients had an albumin level value <4.0mg/dL. For the 0, 3,
and 6-month intervals, the values were n = 333 (82.2%), n = 289 (71.4%), and n = 252
(62.2%), respectively. The post-hoc analysis for CMS baseline, 0, 3, 6 month intervals
was greater than 0.99. The declination of participants with albumin levels <4.0mg/dL
over time suggests that improvement trends were observed in this population. There were
n = 366 patients with hypertension, n = 43 with PVD, and n = 74 with
infection/inflammation according the case processing summary. The parameter estimates
table showed p values of .447, .935, and .173 for hypertension, PVD, and
infection/inflammation, respectively, for the three comorbidities. The medium effect size
of 0.5 was appropriate for this analysis. The p values for each comorbidity suggest that
the relative contribution by each predictor variables to patients with Type II diabetes is
not significant and hence the inclusion of these covariables did not significantly
contribute to influencing albumin levels in this population. The confidence interval for
each predictor included 1, 95% CI [.47, 5.5], 95% CI [.36, 2.6], 95% CI [.19, 1.3], thus
confirming this result (Table 19).
Table 19
Parameter Estimates – CMS Baseline Interval
CMS Baseline
Albumina

B

Std. Error

Wald

df

Sig.

Intercept

2.627

0.668

15.448

1

0.000

[HBP = 0]

0.474

0.624

0.578

1

0.447

1.607

0.473

5.457

[HBP = 1]

0b

.

.

0

.

.

.

.

[PVD = 0]

-0.041

0.506

0.007

1

0.935

0.959

0.356

2.588

[PVD = 1]

0b

.

.

0

.

.

.

.

Exp(B)

95% Confidence Interval for Exp(B)
Lower Bound

Upper Bound
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[Infect = 0]

-0.673

0.494

1.857

1

0.173

0.51

0.194

1.343

[Infect = 1]

0b

.

.

0

.

.

.

.

a The reference category is: Albumin =>4.0
b This parameter is set to zero because it is redundant
Note. CMS is Centers for Medicare and Medicaid Services; HBP is high blood pressure; PVD is peripheral vascular
disease; Infect is infection/inflammation
	
  

The 0 month interval showed similar results. For this interval there were n = 366
patients with hypertension, n = 43 with PVD, and n = 74 with infection/inflammation,
according to the case processing summary. Although the results showed lower p values
for hypertension and PVD than the CMS time interval (p = .389, .700, and .278) for each
predictor, respectively, overall the results were not significant at this interval. This
suggests that there is no significant difference in albumin levels in diabetic patients with
one or more of these associated comorbidities in this population. Decrements in albumin
levels, therefore, may have been due to other factors. Once again, the lower and upper
bounds of the 95% confidence interval included 1, CI [.58, 4.1], CI [.36, 2.0], CI [.33,
1.4], thus confirming this outcome (Table 20).
Table 20
Parameter Estimates – 0 Month Interval
0 Month
Albumina

B

Std. Error

Wald

df

Sig.

1

0.000

Exp(B)

95% Confidence Interval for Exp(B)
Lower Bound

Upper Bound

Intercept

1.981

0.539

13.52
8

[HBP = 0]

0.43

0.499

0.743

1

0.389

1.537

0.579

4.084

[HBP = 1]

0b
0.169

.

.

0

.

.

.

.

0.437

0.148

1

0.700

0.845

0.359

1.991

.

.

0

.

.

.

.

[Infect = 0]

0b
0.401

0.369

1.179

1

0.278

0.67

0.325

1.381

[Infect = 1]

0b

.

.

0

.

.

.

.

[PVD = 0]
[PVD = 1]

a The reference category is: Albumin => 4.0
b This parameter is set to zero because it is redundant
Note. HBP is high blood pressure; PVD is peripheral vascular disease; Infect is infection/inflammation
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The improvement in statistical significance is most notable in the 3 month time
interval. At this interval, there were n = 366 patients with hypertension, n = 43 with PVD,
and n = 74 with infection/inflammation. The generated p values and 95% confidence
intervals were p = .124, CI [.83, 4.5], p = .830, CI [.46, 1.9], and p = .519 CI [.47, 1.5].
Though not significant, hypertension showed a lower p value from the 3 month interval,
suggesting that when compared to the other two comorbidities included in the model, this
predictor contributed the most towards modulating albumin levels. Since albumin trends
showed improvement trends with the inclusion of these covariables in the analysis, it is
reasonable to conclude that the prescribed dialysis treatments along with other dietary,
educational, and lifestyle modifications may be improving albumin levels in this
population despite their comorbidities (Table 21).
Table 21
Parameter Estimates – 3 Month Interval
3 Month
Albumina

B

Std. Error

Wald

df

Sig.

Exp(B)

95% Confidence Interval for Exp(B)
Lower Bound

Upper Bound

Intercept

1.083

0.435

6.186

1

0.013

[HBP = 0]

0.666

0.433

2.366

1

0.124

1.947

0.833

4.548

[HBP = 1]

0b

.

.

0

.

.

.

.

[PVD = 0]

-0.078

0.362

0.046

1

0.830

0.925

0.455

1.880

[PVD = 1]

0b

.

.

0

.

.

.

.

[Infect = 0]

-0.19

0.294

0.417

1

0.519

0.827

0.465

1.472

[Infect = 1]

0b

.

.

0

.

.

.

.

a The reference category is: 1
b This parameter is set to zero because it is redundant
Note. HBP is high blood pressure; PVD is peripheral vascular disease; Infect is infection/inflammation

Lastly, the 6 month interval regression analysis was also not significant. The p
values and 95% confidence intervals were p = .541, CI [.62, 2.5], p = .696, CI [.45, 1.7],
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and p = .612, CI [.68, 1.9] for the same predictors, respectively. There were n = 366
patients with hypertension, n = 43 with PVD, and n = 74 with infection/inflammation.
These data were also not significant and relative to the previous three intervals, the p
values were higher in most of the models in comparison (Table 22), suggesting that the
contribution of these covariables in modulating albumin levels was less than the three
previous intervals.
Table 22
Parameter Estimates – 6 Month Interval
6 Month
Albumina

B

Std. Error

Wald

df

Sig.

Exp(B)

95% Confidence Interval for Exp(B)
Lower Bound

Upper Bound

Intercept

0.488

0.4

1.491

1

0.222

[HBP = 0]

0.218

0.357

0.374

1

0.541

1.244

0.618

2.502

[HBP = 1]

0b

.

.

0

.

.

.

.

[PVD = 0]

-0.132

0.339

0.153

1

0.696

0.876

0.451

1.703

[PVD = 1]

0b

.

.

0

.

.

.

.

[Infect = 0]

0.134

0.264

0.257

1

0.612

1.143

0.682

1.916

[Infect = 1]

0b

.

.

0

.

.

.

.

a The reference category is: Albumin => 4.0
b This parameter is set to zero because it is redundant
Note. HBP is high blood pressure; PVD is peripheral vascular disease; Infect is infection/inflammation

Summary of Findings
This study was focused on investigating potential albumin level differences
between dialysis patients with and without Type II diabetes. This research study has three
research questions. The statistical tests conducted and presented in this chapter aimed to
address these questions to determine if the null hypotheses were to be rejected. Research
Question 1 aimed to determine if there was a difference in albumin levels between
dialysis patients with and without Type II diabetes. The quantitative computations of
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absolute and relative changes showed a difference in albumin levels between both
groups. The results of the ANOVA were significant at all CMS baseline and 0 month
time intervals. The 3 and 6 month intervals, however, were not significant. The Spearman
Correlation test showed a strong, positive correlation between albumin levels and a Type
II diabetes diagnosis at all four time intervals. This finding suggests that hemodialysis
patients with Type II diabetes have albumin levels that trend differently than nondiabetic
hemodialysis patients.
Research Question 2 aimed to investigate if albumin levels differed amongst both
groups over four time intervals during their treatment. The repeated measures t tests for
both groups showed strong, statistically positive correlations. These findings suggest that
there were significant differences in albumin levels within each time interval. When both
groups were compared, changes between each group followed dissimilar modulation
patterns. When mean differences were compared between both groups, the diabetic group
showed disproportionately larger mean differences at the CMS to 0 and 0 to 3 month
intervals, while plateauing at the 3 and 6 month time intervals (Figure 5). This suggests
that albumin level differences in the diabetic group deviated from those in the
nondiabetic group and it may be reasonably plausible that in this population Type II
diabetes may be lowering albumin levels when compared to patients without the disease.
Lastly, Research Question 3 aimed to determine if three known predictors
modulated albumin levels in patients with and without Type II diabetes undergoing
hemodialysis treatments. The multiple logistic regression analyses showed the three
predictor variables hypertension, peripheral vascular disease, and infection /inflammation
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did not significantly modulate albumin levels in this population, contrary to what was
hypothesized in Research Question 3. Previous literature confirms that these covariables
are known to influence albumin levels in dialysis patients in some manner and to some
magnitude. These findings were not confirmed with appreciable significance in this
sample population. Further discussion, elaboration, and interpretation of these findings
will be presented in Chapter 5.
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Chapter 5: Discussion, Conclusions, and Recommendations
As the most abundant plasma protein, albumin plays significant physiological
roles to maintain physiological homeostasis. As elucidated in Chapter 2, the protein’s
primary role in the body is colloid osmotic pressure maintenance, which is explicated
from and framed by osmosis and osmotic pressure principles that underpin this study. It
is by these fundamental principles that fluids are moved into various cellular
compartments pulling fluid into the circulatory system through the capillaries,
maintaining homeostatic blood pressure. A reduction of albumin in plasma, therefore, can
cause a decrease in colloid osmotic pressure and subsequently tissue edema (Ahren &
Burke, 2012).
Epidemiological information about renal disease, hypoalbuminemia, albuminuria,
and Type II diabetes reveals a significant public health concern. According to
Chukwueke and Cordero-MacIntyre (2010), an estimated 17.5 million people in the
United States were diagnosed with either Type I or Type II diabetes in 2007. In that year,
diabetes was the leading cause of blindness in people between the ages 20 and 74 years
and of end-stage renal disease (ESRD) in Hispanic Americans (Chukwueke & CorderoMacIntyre, 2010). Type II diabetes prevalence is 14% in the Hispanic population (Black,
2002). This group suffers a higher risk of mortality and microvascular complications
including renal disease. When kidney disease is strongly associated as a comorbidity, the
consequence is often albuminuria in patients with Type II diabetes (Choi et al., 2011;
Yokoyama et al., 2011; Zakerkish et al., 2013). Albuminuria is confirmation of the
consequences of glomerular destruction, compromised renal filtration (Mendez et al.,
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2005), and of the complete departure from fundamental osmotic pressure principles that
govern basic membrane function and physiological homeostasis. Albumin levels are
lower in Hispanics since the incidence of diabetes is higher in this population. The higher
occurrence of renal failure and subsequent improper renal filtration, the lower albumin
levels become in Hispanic patients receiving maintenance hemodialysis (Black, 2002;
Lorenzo et al., 2009; Yokoyama et al., 2011; Zakerkish et al., 2013). Consequently, the
number of Hispanics requiring hemodialysis rose by 70% between 1996 and 2001 (Lash
et al., 2005), correlating with observations that this population is the fastest growing
demographic in the U.S. (Kanna et al., 2007) and thus the most appropriate population for
this study.
The objective of this quantitative, retrospective study was to examine the
relationship between and potential differences of serum albumin levels in Hispanic
patients initiating hemodialysis treatment due to renal disease associated with a Type II
diabetes diagnosis and those without the disease after controlling for gender,
hypertension and other comorbidities. A retrospective examination of the medical records
of these patients was conducted to determine if albumin levels differ in a population of
adult Hispanic, hemodialysis patients with and without a Type II diabetes diagnosis.
Furthermore, the research aimed to ascertain if albumin levels followed improvement
trends observed from hemodialysis treatment onset and if known predictors influenced
normoalbuminemic levels. Patient medical records were analyzed at baseline (CMS), 0
months, 3 months, and 6 months post baseline to ascertain potential differences in
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albumin levels between patients with and without Type II diabetes during the course of
their dialysis treatments.
This was a historic, records-based cohort study of all N = 827 hemodialysis
patients, Hispanic diabetic group (n = 367) and Hispanic nondiabetic group (n = 186),
evaluated and treated at Fresenius Medical Center - North America clinics in San
Antonio. The cohort included all current patients on the treatment schedules at each
dialysis facility and patients that were deceased that had complete medical records stored
at these facilities. The overarching research question was: Is there a difference in serum
albumin levels between Hispanics with and without Type II diabetes initiating
hemodialysis treatment? The null hypothesis for this study was that there was no
difference in serum albumin levels between Hispanics with and without Type II diabetes
initiating hemodialysis treatment (Mean differences: CMS baseline interval = 3.1 mg/dL,
p = .032, 0 month interval = 3.4 mg/dL, p = .004, 3-month interval = 3.7 mg/dL, p =
.687, 6-month interval = 3.8 mg/dL, p = .646). The prescribed hemodialysis treatment
applied at the CMS baseline interval and the albumin level improvements that indirectly
occur are reflected in the 0 month interval. The rigorous hemodialysis treatments are
designed to remove fluid overload during the interdialytic period and remove uremic
toxins in the bloodstream. The 0 month interval specifically reflects these hemodynamic
improvements and hence greater improvements in albumin levels. Compared to the other
intervals, the 0 month interval reflects these greater albumin differences from CMS
baseline interval, with a statistically significant p value of .004. For Research Question 2
and Research Question 3, the research questions were: Is there a difference in albumin
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levels over the course of patient treatments? And, is there a relationship between known
predictors, albumin levels, and Type II Diabetes that may modulate albumin levels? Null
hypotheses were: there is no difference in albumin levels over time and no significant
relationship between the study covariables and the dependent variable.
In this study, albumin levels were compared in both groups. The comparison
group without diabetes showed baseline albumin levels from which the diabetic group
could be compared. The variables of interest were baseline (CMS) albumin levels,
albumin levels at, 0, 3 and 6 months, and a Type II diabetes diagnosis. Bivariate and
multivariate analyses were employed to evaluate these differences. In addition to the
variables of interest, the other well established covariables known to have significant
influence in modulating albumin levels such as hypertension, peripheral vascular disease,
and infection/inflammation needed to be included in the analyses and appropriately
controlled for analysis.
In contrast to the results of this study, other studies have reported a clear
association between the known predictors hypertension, serum albumin, and renal failure.
Reasons for this conflicting outcome might be due to the proposed sample size,
underreporting of the comorbidity on the CMS forms, differences of water consumption
during the interdialytic period, or any combination of these factors. Because the results of
this comorbidity contrasted with what is known in the literature, this warrants further
explanation. As explicated in Chapter 2, under normal physiological circumstances
albumin is excluded from being filtered through the glomeruli because of its relative size
and negative charge (Mendez et al., 2005). Essential hypertension changes glomerular
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hemodynamics, which leads to progressive glomerular damage (Yokoyama et al., 2011).
As renal damage progresses, glomerular perfusion pressure increases in the remaining
viable glomeruli in order to drive compensatory hyperfiltration. This glomerular capillary
hypertension is translated into increased mechanical stress affecting glomerular cells,
including podocytes, mesangial, and endothelial cells (Fogo, 2000). Hypertension
consequently destroys the glomeruli in the kidneys, compromising renal filtration and
thus allowing albumin to seep into the urinary system for eventual excretion. This
abnormal albuminuria affects albumin levels in patients with renal failure. Although not
demonstrative in this study, the literature does show an association between hypertension,
serum albumin, and renal failure.
The hypoalbuminemia observed in hypertensive hemodialysis patients is similarly
observed in patients with peripheral vascular disease (PVD). PVD is a common
circulatory problem in which narrowed arteries reduce blood flow to the extremities
(American Heart Association, 2015). The added pressure that is incurred on the
circulatory system affects the glomeruli in the kidneys, compromising the renal filtration
system, thus permitting albumin seepage into the urine. The literature elucidates that
PVD is a known predictor that can potentially affect albumin levels. This elucidation,
however, was not evidenced in this study.
A compromised immune system due to renal failure and/or associated
comorbidities, increases the risk of infections in patients on maintenance hemodialysis.
Patient susceptibility to infection increases with renal failure. Access to the vascular
system through arteriovenous graft implantation may exacerbate this risk (Nassar &
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Ayus, 2001). In the predialysis era, 60% of patients with chronic renal failure that
required hospitalization were infected and 39% died from infectious causes
(Antimicrobe, 2014). At that time, it was assumed that the debility caused by the uremic
state increased the risk of infection, and the reversal of uremia would therefore reduce
infection risk. The prescription of maintenance hemodialysis for the reduction of the
uremic state did not effectively minimize infection risk; it merely changed the paradigm.
Maintenance hemodialysis superimposes new issues onto patients already suffering
relentless renal deterioration. Infections pre or peritreatment exacerbate this problem. The
results of this study did not confirm this assertion; the study did not find with appreciable
confidence that the variable infection/inflammation contributed in modulating albumin
levels with statistical significance in Hispanic, hemodialysis patients with and without
Type II diabetes.
For population based studies such this one, demographic factors are an important
consideration. Covariates such as age, race, gender, economic status, educational level,
income level, and employment therefore must be considered in statistical analysis
models. This study is no exception. First, gender was an important covariable that was
considered during the stratified analyses. Although the entire cohort generated sufficient
power (Power = .99), after exclusion criteria was conducted G*Power did not generate
sufficient power within each clinic to conduct this analysis with a small effect size. A
medium effect size was chosen instead to satisfy statistical power for the stratified
analyses. As presented in Chapter 4, the regression analysis was not significant in the
potential of known predictors to modulate albumin levels in this cohort. When gender
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was introduced into the model, the data were not significant to pursue further analysis.
Age was not controlled in this analysis for similar reasons. The mean age was nearly
identical (Average M = 64.7 years) across the board for each clinic, as was educational
level (elementary or high school) and employment (unemployed, housewife) for each
clinic and therefore were not an analysis concern.
Interpretation of Results
The final study population of N = 405 was comprised 53.1% males and 46.9%
females. Two hundred and eighty-one of those were diabetic patients and 124 were
nondiabetic. This distribution of study subjects is consistent with the percentages of
dialysis patients across each of the seven dialysis clinics. No statistical differences were
identified during the analysis of these descriptive data for any of the variables based on
comparisons between both groups. Strong, positive correlations, however, were seen
between albumin levels and Type II diabetes at each time interval. Statistically significant
mean differences in albumin levels within each group were seen, (Repeated Measures t
test: p = .000 and ANOVA: F = 2.28, p = .032 and F = 1.62, p = .004 for CMS baseline
and 0 month intervals, respectively). The study design was a complete data analysis of
the treatment records of all patients attending seven dialysis clinics. The average age for
subjects in the diabetic group (n = 281) was nearly identical (M = 64.3 years SD = 10.9
and 62.6 years SD = 15.2) to that of the nondiabetic comparison group (n = 124), thus
there is no concern that age differences may have influenced the statistical outcomes of
this study.
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As detailed in Chapter 4, correlations exist between the independent variable
Type II diabetes and dependent variable albumin levels. This was confirmed within each
group independently through Spearman Correlation and repeated measured t test analysis.
Between both groups, differences or trends in albumin levels were equally significant.
The null hypothesis can be rejected in favor of the alternative. The results were similarly
confirmed with the one-way ANOVA, which showed p values below p = .05 and
significant F values (2.28 and 1.62) at the CMS baseline and 0 month time intervals,
which again suggests albumin levels are different between both groups. Surprisingly,
some findings of this study do not align with the published literature. The literature
shows that infections acquired during the course of the dialysis treatments would lower
albumin levels in these patients. Neither group, however, exhibited this tendency with
confirmatory statistical significance upon logistic regression analysis. This finding was
inconsistent with Kaysen et al, 1995, Kaysen et al., 2001, Kaysen, et al., 2002, for
example, which found significant associations between lower albumin levels with the
development of an infection. This inconsistency may be due to a reduced sample size
because of patients that were excluded from the final sample that did not meet inclusion
criteria due to underreporting of the comorbidity infection or inflammation on CMS-2728
forms. The exclusion criteria used for this study may have therefore influenced the final
outcomes of the regression analysis.
Severe infection and inflammation almost invariably leads to hemostatic
abnormalities. When a microorganism invasion occurs in the body, there is a biological
response to try to promptly destroy and remove it. The typical signs and symptoms of
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inflammation show that the body is actively trying to heal itself. The inflammatory
response does not necessarily indicate infection, even when an infection causes
inflammation. Infection is caused by a bacterial, viral, or fungal infiltration, while
inflammation is the body's response to the microorganism’s proliferation (Szymanski,
2001).
Infection and inflammation trigger an acute-phase response that can precipitate
the development of mild to severe hematological disorders (Szysmanksi, 2001). In many
cases, changes in hematological parameters such as reticulocytes may be the initial sign
of an occult infectious or inflammatory disorder. In dialysis patients, the decrease in
reticulocytes and hence a disruption in erythropoiesis can indicate an infection that may
affect the way the liver synthesizes albumin. Reticulocytes are immature erythrocytes,
typically comprising approximately 1% of the red cells in the human body (Tsuchiya et
al., 2003). Reticulocytes develop and mature in the bone marrow and then are introduced
into the systemic circulation where they then further develop into mature erythrocytes. A
low reticulocyte count may indicate various conditions, one of which is an infectious
disorder. In addition to a high white blood cell count, reticulocyte indices can serve as a
second indicator for the presence of an infection.
To verify the final sample size (n = 74) of patients with the comorbidity infection
and inflammation (Figure 2), ferritin levels were collected at 0, 3, and 6 month intervals.
Ferritin is a protein produced in mammalian metabolism that serves to store iron in body
tissues (Wish, 2006). Normal ferritin levels in males and females are 12-300 ng/mL and
12-150 ng/mL, respectively. Serum ferritin levels are directly related to the amount of
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iron stored in the body. Iron is necessary for erythropoiesis. Any inflammatory disorder
can raise ferritin levels and hence is a reliable hematological indicator of inflammation.
Patients with an infection or inflammation comorbidity with an elevated white blood cell
count (>10.8 mg/dL) and confirmed with elevated ferritin levels (>800 ng/mL) were
assigned to the infection/inflammation subgroup.
Transferrin saturation (TSAT) values were collected for this study to further
verify the presence of an infection or inflammatory process. TSAT is the ratio of serum
iron and total iron-binding capacity, multiplied by 100. Of the transferrin that is available
to bind iron, this value indicates how much serum iron is actually bound. Because serum
ferritin is an acute-phase reactant and because the inflammatory state may inhibit the
mobilization of iron from reticuloendothelial stores, the scenario of patients with serum
ferritin >800 ng/mL, suggesting iron overload, and transferrin saturation ≤20%,
suggesting iron deficiency was a reliable indicator of an inflammatory disorder for this
study (Koo et al., 2014).
For this study, both ferritin and TSAT were collected to verify the presence of an
infection or an inflammatory response. Reticulocyte counts were not available in patient
treatment records and were therefore not collected. Verification of and qualification for
inclusion for patients with infection/inflammation comorbidity relied on four factors: (a)
proper documentation by nursing staff of the comorbidity pre and peritreatment, (b) white
blood cell count at CMS baseline, 0, 3, and 6-month intervals, (c) pre and peritreatment
ferritin levels, and (d) TSAT ratios documented over 6 months.
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This study also showed another unexpected result. Although a specific
comorbidity can predispose an individual to a disease initially, this does not mean once
the disease is established that the association will be similar with disease progression. For
this study, hypertension can affect renal function by disrupting glomerular function, but
the effects in modulating albumin levels may be dissimilar as the renal disease
progresses. Hypertension influences albumin levels, as it puts an inordinate amount of
pressure on the glomeruli, but it is challenging to find a relative effect between diabetic
and nondiabetic groups with a relatively short time frame among a cohort of patients with
consistently higher baseline blood pressure levels. It was surprising that hypertension did
not contribute in modulating albumin levels as was found through logistic regression
analysis. Considering that essential hypertension exerts an inordinate amount of pressure
on the glomeruli on a chronic basis (Milojkovic, 2014), and considering the overly
compelling body of knowledge consistent with this information (Milojkovic et al., 2014,
Reddenna et al., 2014), the results from this study did not reflect this. Logistic regression
analysis for each time interval was not statistically significant. This study relied on the
comorbidity hypertension being physician-diagnosed. Actual hypertension assessments
documented on treatment flow sheets were not collected since these data were not
accessible on eCube Clinicals or Proton. Furthermore, a hypertensive episode is a
cardiovascular event that can only be assessed by a nephrologist. Blood pressure values
documented on flow sheets may represent predialysis (or interdialytic) fluid overload
and/or therapeutic noncompliance and not necessarily a cardiovascular event indicating
hypertension.
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With respect to the variable of interest, albumin levels, the results showed that at
time intervals 0 to 3 months and 3 – 6 months the mean differences in both groups
followed similar improvement trends not observed at the earlier intervals. This was
confirmed with the repeated measures t test, which was used to quantify albumin level
changes over time. These findings suggest two biological processes. First, in this latter
interval during treatments, albumin levels may be normalizing to adequate levels and so
the progressive deceleration may be due to homeostatic restoration. Second, as albumin
levels approach adequacy (≥4.0mg/dL), (Davita, 2015; National Kidney Foundation,
2002; National Kidney Foundation, 2013a; National Kidney Foundation, 2013b), the
slower increments and eventual plateauing may simply be due to the values reaching the
maximum albumin level of 5.2mg/dL that is consistent with compatibility of life.
Graphical comparisons between both groups showing a greater disparity between mean
differences at the CMS to 0 and 0 to 3 month interval are shown in Figure 5. The trend
lines between both groups confirm that a Type II diabetes diagnosis lowers albumin
levels compared to those without the disease. With regards to the repeated measures t
test, the findings showed a similar trend in all the other time intervals as well. It can be
concluded that the independent variable Type II diabetes in this study contributed to
lowering albumin levels in this study population based upon comparisons of repeated
measures t tests conducted in both groups.
The absolute and relative change computations between both groups confirmed
differences in albumin levels. The greatest differences in absolute and relative albumin
level changes were seen during the CMS to 0 month interval, 0.4 and 18%, respectively.
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Furthermore, the smallest change occurred, .11 and 3%, during the 3 to 6 month interval.
These results may be due to various factors, including patient noncompliance, dietary
changes, additional comorbidities, lifestyle changes, or any combination of these factors
acquired peritreatment. Additionally, it is possible that during the 3 to 6 month interval
patients grow accustomed to and accepting of their dialysis treatments, dietary
modifications, and lifestyle changes, becoming more lax with their dialysis regimen.
With this new outlook, patients may develop tendencies that challenge or test these limits
or restrictions, possibly contributing to the diminished absolute and relative changes in
albumin levels at this interval.
The conceptual foundation for conducting this study as laid out in Chapter 1 and
supported by the literature review presented in Chapter 2 is sound and predicated upon
good biological plausibility. Given the significance of the role albumin plays in the
vascular system in maintaining colloid osmotic pressure, and its implication with osmosis
in blood pressure maintenance, it was reasonable to conclude that albumin level
differences in patients with Type II diabetes may also consequently show greater
hypotensive disparities than do those without the disease, which is consistent with the
findings of Nakamoto, et al. (2006).
The findings in this sample population show a correlation between albumin levels
at four different time intervals and Type II diabetes. Both the ANOVA and the Spearman
correlation tests showed statistically significant results that confirm this assertion, with
the one exception at the latter intervals of the one-way ANOVA, which were not
statistically significant for reasons previously explicated. Because of these results, the
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null hypothesis, which states that there are no differences in albumin levels between
hemodialysis patients with and without Type II diabetes, can be rejected in favor of the
alternative. Logistic regression analysis, however, did not demonstrate with satisfactory
significance that the three predictors included in the analysis contributed to modulating
albumin levels in this sample. Therefore, the null hypothesis, which states that there is no
relationship between serum albumin, Type II diabetes, and known predictors that may
modulate albumin levels, cannot be rejected; any observed differences in albumin levels
may have occurred by chance. However, the differences in albumin levels at each interval
within and between groups were statistically significant. Therefore, in this case the null
hypothesis there are no differences between albumin levels over time can be rejected in
favor of the alternative.
Strength of Study
Quantitative research designs have key strengths that maximize the study’s
credibility, validity, and accuracy. A distinguishing feature of this design is the collection
of numerical data that, in turn, can be subjected to statistical analysis. This
groundbreaking study is no exception; study strengths include: (a) generating precise,
numerical data; (b) the ability to study large populations; (c) generalizable research
findings; (d) a relatively quick data collection phase; and (e) a swift data analysis phase.
First, quantitative designs provide precise, numerical data. For this study, ANOVA,
repeated measures t tests, and multiple regression analysis provided empirical,
statistically based data that addressed each research question with achieved power.
Second, quantitative study designs provide the opportunity to study large populations.
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Over 800 records were reviewed in this study from seven different hemodialysis clinics.
This large cohort of patients ensured statistical power as well as generalizability. Third,
the study findings are generalizable since medical records were selected randomly. For
this study, a complete data review was conducted of all current patients on the treatment
schedules and deceased patients with complete medical records on file. This minimized
potential biases, thus increasing the study’s generalizability. And, lastly, both data
collection and data analysis phases are less time consuming with quantitative designs.
Because this is a historic, retrospective design, very large cohorts were accessible at once
with appropriate permission. Since the data were previously collected, the time frame for
secondary data collection and analysis phases were reduced. Additionally, since each
dialysis facility has streamlined the way they collect, compile, store, and access medical
records, data extraction from each medical record was relatively simple and
straightforward.
The Hispanic population is the fastest growing demographic. This rapid growth
corresponds to higher incidences of Type II diabetes and renal failure, as this group is
genetically predisposed to Type II diabetes. This study focuses on the Hispanic
population in San Antonio, Texas and provides information on a rapidly emerging
population. The researcher is able to construct a situation that eliminates confounding
influence of many variables, allowing for more credibly established cause-and-effect
relationships. The study is therefore useful and attractive from a research perspective.
More importantly, hemodialysis patients exist worldwide and so the outcomes of this
quantitative research study are useful and applicable to patients across the globe. Because
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of the many strengths of this study, its usefulness, applicability, and educative features
are unparalleled, rendering significant contributions to academia, research, and medicine.
Limitations of the Study
There are limitations in this type of study design, which may have influenced the
study outcome. Principal among these is the fact that this was a records-based study.
Records-based studies are dependent upon the quality and thoroughness of the records
(Checkoway et al., 2004). This cohort was amassed over a time period of multiple years,
during which time there were multiple dialysis clinicians who documented their findings
in these records and the quality of the efforts to solicit all the patient information may not
have been uniformly comprehensive. As clinical policies and protocols change through
the years, this may also have been influenced by the nature of the clinical circumstances
at the time of presentation for treatment. A listwise deletion of patients that did not meet
strict inclusion criteria was conducted to minimize data cleaning and to avoid
overestimation during the analyses. Although very rare, it is possible that truncated
medical records or patients with essential missing data values were not properly
documented on patient records, which would favor the null hypothesis in this study. This
is an inherent problem in conducting records-based studies (Checkoway et al., 2004).
Fluid overload (edema), during the interdialytic period is a critical factor in
maintenance hemodialysis and therefore a study limitation consideration. Interdialytic
weight gain is considered a measurement of compliance because it may be dictated, at
least in part, by patient behavior. The volume of fluid weight gained is dependent on the
amount of fluid that is consumed, how often a dialysis patient receives the dialysis
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treatment, and whether kidney function is merely insufficient and therefore capable of
removing some fluid through normal urine excretion. Some dialysis patients are unable to
urinate (renal failure), while others retain some renal function and hence have some
residual urine output (renal insufficiency). Individual goals for weight gain during the
interdialytic period must be determined by the nephrologists, and may vary based on
small or large body frames and other considerations.
The goal for an average sized hemodialysis patient is to keep fluid weight gain
during this period at or below 1 kilogram (2.2 pounds) each day. This equates to 2 kg (4.4
pounds) fluid weight gain when there are 2 days between treatments and 3 kg (6.6
pounds) fluid weight gain when there are 3 days between treatments. Therefore, during
this period it is expected that patients with renal failure may accumulate anywhere
between 2-5 kilos of fluid. The more fluid they accumulate, be it because noncompliance,
magnitude of renal failure, or inherent physiological osmotic fluid movement variances,
could produce a diluted serum albumin concentration. Edematous manifestations of
diluted albumin concentrations at various concentrations due to excessive fluid build-up
may have posed an inherent study limitation and skewed outcomes towards the null.
There is a considerable body of evidence indicating that serum albumin is a
prognostic indicator of malnutrition (Sridhar & Josyula, 2013). In this condition a
disparity between the amount of food and other nutrients that the body requires for proper
growth and health and the amount that it absorbs deviates from physiological
homeostasis. This imbalance is most frequently associated with undernutrition (Friedman
& Fadem, 2010). Considering the mean age of the population (M = 62.4 years), and other
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anthropometric indices, it can be reasonably deduced that any observed albumin level
differences may be due to malnutrition rather than the proposed independent variable,
Type II diabetes, investigated in this study. It is also uncertain if a combination of these
factors, malnutrition plus Type II diabetes, may have contributed to differences in
albumin levels in this sample population.
Other important considerations that may have limited this study include patient
phobias and demographics, as were presented in Chapter 1. Patients that for lack of
insurance or that simply refused dialysis treatment either because of disease denial or
because of physician, needle, or blood phobias may not be included in the sample
population. The sample population may have captured only those that were sick that were
actually attending the dialysis clinics and excluding those that were sick and not
receiving necessary treatments. The clinics from which the data were collected may
represent a demographic limitation in that the community in which the clinic is located
may have a higher or lower Hispanic representation than do other similar clinics in other
regions of the city. Additional limitations include cohort size, especially over multiple
strata as was shown in the stratified analyses, uninsured patients that are unable to pay for
out-of-pocket dialysis services, and immigration status concerns.
Limitations can be overcome in related, subsequent research studies.
Modifications in methodology or design can help minimize inherent study limitations.
For instance, future studies conducted using other ethnic populations, and encompassing
a broader population of patients in home-health and in-patient hospital setting
hemodialysis venues may help expand the generalizability and reduce study limitations.
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Selecting clinics with similar demographics may provide data uniformity. The limitations
discussed in this section collectively confer shortcomings, conditions, or influences that
cannot be controlled and that may place methodological and study conclusion
restrictions.
Implications for Social Change
The positive social change from this research endeavor is extensive, distinctive,
and beneficial at the individual, community, and global levels. Numerous studies have
investigated large cohorts of diabetic hemodialysis patients (Choi et al, 2011; Goldwasser
et al., 1999; Noori et al., 2011). Some have examined specific ethnic populations
receiving maintenance hemodialysis treatments (Liu et al., 2008; Locatelli et al., 2011;
Yokoyama et al., 2011; Zakerish et al., 2013). Several have examined or compared
survival analysis, dialysis modalities, glycemic/A1C control, race/ethnicity and age, renal
disease risk, and prevalence of Type II diabetes mellitus in various populations (Hsu et al.
2011; Leavy et al., 2000; Lorenzo, et al., 2009; Marimoto et al., 2010). These studies,
although informative, instructive, and pedagogic to the discipline, may not provide the
magnitude of social change that this endeavor achieves. From the exhaustive literature
review presented in Chapter 2, studies have not investigated a direct association between
serum albumin, a Type II diabetes diagnosis, and related predictors in Hispanic patients
to date. Additionally, the literature does not show if and to what magnitude a Type II
diabetes diagnosis influences albumin levels or whether albumin level patterns exist from
treatment onset through the course of their hemodialysis treatments. This research effort
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was the first to do so, with a comprehensible and profound aim towards positive social
change.
This research study provides a platform to promote positive social change. The
efforts and subsequent results from this study contribute to the evolving public health
discipline. This study was conducted to identify disease-specific albumin trends that
could influence the course of diseases such as diabetes and renal disease so that ethnicspecific and disease-specific care can be developed for patients on maintenance
hemodialysis. At the individual level, Hispanic patients with Type II diabetes can benefit
from individualized albumin supplementation provided by the dieticians at each clinic.
Since each patient is unique in terms of the dietary preferences and the amount of food
consumed, individualized dietary recipes can be created to better suit the needs of each
patient. As a cohort, hemodialysis patients with Type II diabetes may benefit from this
research by its potential to inform and empower dialysis clinical care professionals to
devote concerted efforts towards raising albumin levels in these patients. Thusly, these
efforts may improve the quality of life of patients afflicted with Type II diabetes and
renal disease. The positive social change, therefore, extends to a vast community of
health care providers that devote their time and efforts to educate and facilitate
hemodialysis patients initiating treatments transition to a new life. Lastly, on a global
scale, the study’s research findings contribute to the paucity of literature in this field and
helps address diabetes health and renal disease to potentially improve diabetic and renal
health outcomes to the broader population. The social change implications from this
study are clear, definitive, broad, and long-term.
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There is a strong conceptual premise, clinical basis, and biological plausibility to
suggest that albumin levels are different in patients with and without Type II diabetes and
that albumin level restoration trends are different post treatment onset. The conventional
standards of care among dialysis clinicians were to provide standardized albumin level
care/supplementation for all patients as a homogenous group. However, there was no
empirical evidence to fully support this standardized albumin care. Currently, there is no
diversity in serum albumin management for patients with a Type II diabetes diagnosis,
despite the theoretical concerns. A unique aspect of this particular endeavor was that
whatever the outcome, assuming adequate study power, useful and immediately relevant
information would ensue that would elucidate a nuanced albumin level protocol for
Hispanic patients with a Type II diabetes diagnosis on maintenance hemodialysis. Should
no association be defined, dialysis clinicians should continue to use the same
standardized albumin level care protocols without concern that they may be in some way
deleterious to the health and well being of the patients. If, on the other hand, an
association was identified, dialysis clinicians could be advised to modify and tailor their
albumin level care guidelines that would reinforce the nuances associated with patients in
this specific population to dialysis clinicians, support better albumin level outcomes in
patients with Type II diabetes, and promote better overall clinical health outcomes for
hemodialysis patients. In all instances, dialysis clinical experts, diabetologists, as well as
clinical providers would be informed by data from an evidence-based study rather than
serendipity or gestalt, magnifying the positive social change potential of this
investigation.
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Recommendations for Action
This study represents a first step towards filling the information gap that presently
exists. Given the compelling nature of the theoretical bases, which underpin this study, it
was important to pursue the research questions that were asked. The results of this
particular effort, some of which were not statistically confirmatory, suggest that there
may be some merit to pursuing the questions further.
The lack of statistical significance specifically at two time intervals in the oneway ANOVA should not be interpreted to mean that albumin levels in the diabetic group
should not be addressed differently than those without a Type II diabetes diagnosis; it
only means that it was not entirely demonstrable in this specific study. Similarly, the lack
of statistical significance in the logistic regression analysis should not be dismissed as not
showing important associations between albumin and known predictors and their
potential to modulate albumin levels. This, too, only represents one sample population
that may not have demonstrated the expected results that align with the existing body of
knowledge. As was presented in Chapter 2, it is important to consider serum albumin
concentrations to regulate blood pressure in patients on maintenance hemodialysis.
Additionally, a Type II diabetes diagnosis, which may mediate and/or exacerbate albumin
levels can therefore influence not only blood pressure homeostasis and hemodynamics,
but hemodialysis outcomes and overall health. This study, although not statistically
significant for all research questions posed, provided some substantiation to this
assertion.
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The results of this study may be of significant interest to Nephrologists, certified
nephrology nurses, hemodialysis technicians, diabetologists, renal scientists, and
physiology experts in academia in hopes that it will spawn additional inquiry into not
only albumin level differences among Hispanic patients, but other populations as well;
such endeavor would expand the study’s generalizability. Additionally, albumin
supplementation strategies can be designed to be ethnic-specific for populations that are
deeply rooted in long-standing Latin customs and traditions like the one selected for this
research. Certainly, hemodialysis facilities in other regions of the world should be
advised as to the findings of this investigation with the caveat that these are preliminary
conclusions, which will require additional studies aimed at investigating the potential
associations of albumin levels, Type II diabetes, and associated covariables to verify the
outcome. These results should be presented at annual scientific meetings of the American
Nursing Nephrology Association with follow up on publication in peer-reviewed
journals. Lastly, this information should be disseminated to Nephrologists and
diabetologists through trade journals as American Diabetes Association, Journal of
Nephrology, American Society of Nephrology, Nephrology Nursing Journal and the like.
Recommendations for Further Study
This was the first study to investigate whether differences in albumin levels exist
in patients with and without a Type II diabetes diagnosis. This investigation has
demonstrated that an appreciable association exists between albumin levels and a Type II
diabetes diagnosis. Disparate albumin level differences, however, were not statistically
significant between both groups at the earlier stages of their treatment. The study also
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found that albumin level differences at each time interval showed statistically significant
changes; albeit slight, this was demonstrably notable in the diabetic group when
compared to the nondiabetic group. When the known comorbidities were introduced into
the model, the relationships and relative contribution by each variable were not
significant in this population.
The inherent limitations associated with records-based studies may have
underestimated this association in this study. It is important, therefore, that future
research be undertaken to help clarify this concern. The ideal approach would be to
conduct an experimental study in which all other covariables could be controlled for
through the study design so as to isolate the independent variable alone. This would be
best accomplished using a blinded clinical trial format with a carefully defined study
population.
A critical recommendation would include collecting data on the volume of fluid
accumulated during the interdialytic period. Streamlining data collection to patients that
are compliant and that consistently show similar fluid accumulation patterns during the
interdialytic period over time would be an ideal strategy to isolate the dependent variable
and reduce this study limitation.
Conclusions
This was a groundbreaking study designed to investigate the potential association
between albumin levels, Type II diabetes, and associated covariables. Furthermore, trends
seen from treatment onset through the course of patient dialysis treatments were also
investigated. The results showed that differences exist in albumin levels from treatment
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onset through the course of their treatment. Type II diabetes confirmatively showed
differences in albumin levels compared to the nondiabetic comparison group. Given the
sample size and power of this study, it is reasonable to conclude that in this study
albumin level differences are seen at four different time intervals within each group.
Furthermore, between both groups (diabetic and nondiabetic), albumin levels also
showed appreciable differences. From this study, it can also be concluded that Type II
diabetes was influential in modulating albumin levels in a statistically significant way.
And, when known predictors such as a history of hypertension, peripheral vascular
disease, and the development of an infection or inflammatory response were considered
during analysis, albumin levels followed similar improvement trends and were therefore
not significantly influenced in this sample population.
There were univariate, bivariate and multivariate statistical treatments used to
address the three research questions in this study. First, an ANOVA was conducted to
compare means between two groups, diabetic and nondiabetic hemodialysis patients. The
albumin levels in the diabetic group were lower at time intervals CMS baseline and 0
months and therefore revealed disparate trends towards normoalbuminemic restoration
over time. The Spearman Correlation showed significant associations between Type II
diabetes and albumin levels at all time intervals. The repeated measures t tests results
were significant at all intervals, suggesting that albumin levels were different between
both groups. Lastly, the results of the multiple regression analysis were not statistically
significant for the three known predictors, hypertension, peripheral vascular disease, and
infection/inflammation in this sample population.
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This investigation helps narrow the literature gap about human serum albumin in
hemodialysis patients with and without Type II diabetes. The study elucidates key
information that is both attractive and useful to the academic, scientific and medical
communities. Because of the many physiological functions albumin provides for the
body, it can be used therapeutically for a myriad of diseases and conditions. Amongst
these are hypovolemia to help restore blood volume in trauma, for burn and surgery
patients to treat and expedite the restoration of fluid loss, and even as a dietary
supplementation to treat malnourished patients (Mendez et al., 2005). From this study,
the expectation is that albumin-specific and ethnic-specific guidelines, clinical policies,
and treatment protocols be created for albumin management in patients. This study
provides a foundation for future albumin studies. The results from this study provide the
impetus to design subsequent albumin investigations with methodological modifications
that would elucidate further information about albumin levels in hemodialysis patients
with and without Type II diabetes. These modifications might include extending the
study time frame, investigating a different ethnic population, and/or examining other
dialysis clinics in different cities in Texas.
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